TLR7 agonists and combinations for cancer treatment

BNT411, a potent TLR7 agonist, addresses the limitations of existing cancer treatments by inducing effective immune responses with reduced side effects, enhancing therapeutic outcomes for SCLC and other cancers.

JP2024544518APending Publication Date: 2024-12-03BIONTECH SE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024527367
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-09
Filing Date
2022-11-09
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current cancer treatments, particularly for advanced small cell lung cancer (SCLC), suffer from unsatisfactory outcomes and significant adverse reactions due to systemic administration of TLR7 agonists like imiquimod, limiting their effectiveness and safety.

Method used

Development of BNT411, a highly potent and selective TLR7 agonist that induces higher levels of IFNα with minimal febrile pro-inflammatory cytokines, offering both monotherapy and combination therapy options with standard treatments, including platinum-based chemotherapeutics and checkpoint inhibitors.

Benefits of technology

BNT411 demonstrates robust antitumor activity with an improved safety profile, enhancing immune responses and providing therapeutic benefits with reduced adverse effects, making it suitable for treating various cancers, including SCLC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544518000020
    Figure 2024544518000020
  • Figure 2024544518000021
    Figure 2024544518000021
  • Figure 2024544518000022
    Figure 2024544518000022
Patent Text Reader

Abstract

The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as an immunotherapeutic agent in monotherapy and combination therapy for reducing or preventing the progression of tumors, particularly solid tumors, or for treating cancer, particularly solid cancers.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as an immunotherapeutic agent in monotherapy and combination therapy for reducing or preventing the progression of tumors, particularly solid tumors, or for treating cancer, particularly solid cancers. [Background technology]

[0002] Cancer immunotherapy offers an option for long-term disease control by activating the patient's own immune system and inducing T cell memory. Promising approaches include Toll-like receptors (TLRs), a group of receptors belonging to the innate immune system. TLR7, in particular, is known to contribute to robust antitumor responses. Stimulation of TLR7 triggers intracellular pathways that lead to the activation of the adaptive and innate immune systems, characterized by the induction of type I interferons (IFNs), proinflammatory cytokines, and chemokines, and the upregulation of costimulatory molecules. These TLR7-mediated effects can contribute to tip the balance towards robust cancer immunity by enhancing pre-existing immunity through multifaceted mechanisms, and by inducing de novo antitumor immune responses.

[0003] A variety of synthetic TLR7 agonists are being tested as immunotherapeutic agents, including the imidazoquinolines imiquimod (R837), resiquimod (R848) and 852A. [ka]

[0004] So far, only imiquimod has been approved for human use, and only as a topical cream for basal cell carcinoma. Clinical application of these compounds is severely restricted in part due to dose-limiting adverse reactions upon systemic administration. This safety concern is thought to be related to TLR8 coactivation leading to the induction of a wide range of proinflammatory cytokines.

[0005] Thus, there is a great need for improved therapies to prevent tumor progression or to treat cancer, especially those that have fewer adverse reactions when administered systemically.

[0006] Furthermore, there is a strong unmet medical need to develop new effective therapies for patients with advanced malignancies whose disease no longer responds to standard therapies, as well as for patients for whom current standard therapies provide minimal long-term disease-free survival (e.g., extensive small cell lung cancer (ES-SCLC)). Recent advances in immunotherapy, as well as refinements of traditional therapies such as chemotherapy, radiation therapy, surgery, and targeted therapy, have improved outcomes for patients with advanced cancer. However, many immunotherapy treatments have demonstrated efficacy only for a select group of cancers (Ventola, Cancer Immunotherapy, Part 3: Challenges and Future Trends. 2017; PT 42(8):514-21; Yang, J Clin Invest. 2015; 125(9):3335-7).

[0007] SCLC accounts for approximately 15% of bronchogenic carcinomas. At the time of diagnosis, approximately 30% of patients with SCLC have tumors confined to the ipsilateral hemithorax, thus limited-stage small cell lung cancer (LS-SCLC) (Murray et al., J. Clin Oncol. 1993;11(2):336-44). Patients with tumors extending beyond the ipsilateral hemithorax, including malignant pleural or pericardial effusions or hematogenous metastases, have ES-SCLC.

[0008] Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory, despite improvements in diagnosis and treatment that have been made over the past 25 years. Without treatment, SCLC has the most aggressive clinical course of any type of lung tumor, with a median survival from diagnosis of only 2-4 months. In patients with ES-SCLC, a median survival of 6-12 months has been reported with currently available treatments, but long-term disease-free survival is rare.

[0009] Currently, chemotherapy remains the mainstay of treatment for ES-SCLC. Chemotherapy is generally administered as a two-drug combination of platinum and etoposide at doses associated with at least moderate toxic effects (as in limited-stage small cell lung cancer (LS-SCLC)) (Okamoto et al., Br J Cancer. 2007; 97(2): 162-9). Cisplatin is associated with significant toxic effects and requires hydration, which can be problematic in patients with cardiovascular disease. Carboplatin is active in SCLC, is administered according to renal function, and has fewer associated non-hematological toxic effects. Doses and schedules used in current programs result in overall response rates of 50% to 80%, and complete response rates of 0% to 30% (Pujol et al., Br J Cancer. 2000; 83(1): 8-15; Roth et al., J Clin Oncol. 1992; 10(2): 282-91). Radiotherapy to sites of metastatic disease, especially brain, epidural and bone metastases, is a standard treatment option, as chemotherapy is unlikely to provide palliation. In addition, ES-SCLC patients who have been treated with chemotherapy and achieved a response are considered for thoracic radiotherapy. Recently, atezolizumab in combination with chemotherapy has been approved as a first-line (1L) treatment. Although this combination has proven effective, outcomes remain unsatisfactory compared to other malignancies (i.e., 2 months overall survival benefit, and 0.9 months progression-free survival benefit; NCT02763579.A Study of Carboplatin Plus Etoposide with or Without Atezolizumab in Participants with Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (IMpower133)). Almost all patients eventually succumb to the diagnosis at recurrence. Median survival times of 6 to 12 months have been reported with currently available treatments, but long-term disease-free survival is rarely achieved. Therefore, there is a significant unmet medical need to develop new treatments for ES-SCLC, especially innovative combination therapies to improve outcomes. [Prior art documents] [Non-patent literature]

[0010] [Non-Patent Document 1] Ventola,Cancer Immunotherapy,Part 3:Challenges and Future Trends.2017;PT 42(8):514-21 [Non-Patent Document 2] Yang,J Clin Invest.2015;125(9):3335-7 [Non-Patent Document 3] Murray et al.,J.Clin Oncol.1993;11(2):336-44 [Non-Patent Document 4] Okamoto et al.,Br J Cancer.2007;97(2):162-9 [Non-Patent Document 5] Pujol et al.,Br J Cancer.2000;83(1):8-15 [Non-Patent Document 6] Roth et al.,J Clin Oncol.1992;10(2):282-91 [Non-Patent Document 7] NCT02763579.A Study of Carboplatin Plus Etoposide with or Without Atezolizumab in Participants with Untreated Extensive-Stage(ES)Small Cell Lung Cancer(SCLC)(IMpower133) Summary of the Invention

[0011] The present inventors have developed BNT411, a highly potent TLR7 agonist of the imidazoquinoline family, having the following formula: [ka] BNT411 is a selective TLR7 agonist, shown in vitro to be comparable to the most active imidazoquinoline comparator resiquimod, primarily IFNα release. Moreover, the inventors surprisingly found that upon BNT411 exposure, much higher amounts of IFNα were induced at much lower concentrations than comparable imidazoquinolines imiquimod, resiquimod and 852A. See, e.g., FIG. 1. Up to two orders of magnitude higher concentrations of BNT411 are required to induce the secretion of pyrogenic proinflammatory cytokines (e.g., TNFα). See, e.g., FIG. 7. Taken together, this stronger activity and superior selectivity indicate a higher potency and wider therapeutic window of systemically administered BNT411. In vitro and in vivo studies with BNT411 in mouse models demonstrate the release of high levels of therapeutically relevant IFNα; see, e.g., FIG. 2. Furthermore, the present disclosure demonstrates that in mouse tumor models, BNT411 exhibits antitumor activity both as monotherapy and in combination with standard therapies (e.g., in combination with platinum-based chemotherapeutic agents or checkpoint inhibitors). See, e.g., Figures 4-6. Furthermore, the present inventors show for the first time that BNT411 (i) has an acceptable safety profile at several doses tested in human patients, (ii) induces a substantial cytokine response in human patients dominated by type I IFN, and (iii) does not result in a substantial increase in pyrogenic proinflammatory cytokines such as tumor necrosis factor alpha (TNFα), at least at some therapeutically important doses. See, e.g., Examples 6 and 7 and Figure 8 of the present application.

[0012] Thus, in a first aspect, the disclosure provides a compound having the formula: [ka] or a pharma- ceutically acceptable solvate or salt thereof (collectively referred to herein as "BNT411" unless otherwise indicated or inconsistent with the context herein), wherein the method comprises administering to the subject an appropriate amount of BNT411. In some embodiments of the first aspect, the appropriate amount of BNT411 is a therapeutically effective and safe amount. In some embodiments, the appropriate amount of BNT411 is about 0.1 μg / kg to about 50 μg / kg body weight, or about 8 μg to about 4000 μg in total, and / or about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18x10 in total -9 mol~about 9100x10 -9 In some embodiments, a suitable amount of BNT411 is about 0.5 μg / kg to about 20 μg / kg body weight, or about 40 μg to about 1600 μg in total, and / or about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight, or about 91x10 in total -9 mol~approx. 3640x10 -9 In some embodiments, a suitable amount of BNT411 is about 2 μg / kg to about 10 μg / kg body weight, or about 160 μg to about 800 μg in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9 In some embodiments, a suitable amount of BNT411 is about 2.4 μg / kg to about 9.6 μg / kg body weight (such as about 4.8 μg / kg to about 9.6 μg / kg body weight), or a total of about 192 μg to about 768 μg (such as about 384 μg to about 768 μg), and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight (approximately 10.9x10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, etc.), or a total of about 437x10 -9mol~about 1747x10 -9 mol(about 873x10 -9 mol~about 1747x10 -9 In some embodiments, a suitable amount of BNT411 is about 4.8 μg / kg body weight, or about 384 μg total, and / or about 10.9×10 -9 mol / kg body weight, or about 874x10 in total -9 mol.

[0013] In a second aspect, the disclosure provides BNT411, a compound having the formula [ka] or a pharma- ceutically acceptable solvate or salt thereof, wherein the amount of BNT411 in the composition is about 8 μg to 4000 μg, or about 18×10 -9 mol~about 9100x10 -9 In some embodiments of the second aspect, the composition comprises from about 40 μg to about 1600 μg, or about 91×10 -9 mol~approx. 3640x10 -9 In some embodiments of the second aspect, the composition comprises about 160 μg to about 800 μg, or about 364×10 -9 mol~approx. 1820x10 -9 In some embodiments of the second aspect, the composition comprises about 192 μg to about 768 μg (such as about 384 μg to about 768 μg), or about 437×10 -9 mol~about 1747x10 -9 mol(about 873x10 -9 mol~about 1747x10 -9 In some embodiments of the second aspect, the composition comprises about 384 μg, or about 874×10 -9 Contains mol of BNT411.

[0014] In a third aspect, the disclosure provides a composition of the second aspect for use in a method for reducing or preventing tumor progression or treating cancer in a subject. In some embodiments of the third aspect, the composition comprises about 0.1 μg / kg to about 50 μg / kg body weight of BNT411, or about 8 μg to about 4000 μg total of BNT411, and / or about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight of BNT411, or about 18x10 in total -9 mol~about 9100x10 -9 In some embodiments, the composition is administered to a subject in an amount to provide about 0.5 μg / kg to about 20 μg / kg of body weight of BNT411, or about 40 μg to about 1600 μg of BNT411 in total, and / or about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight of BNT411, or about 91x10 -9 mol~approx. 3640x10 -9 In some embodiments, the composition is administered to a subject in an amount to provide about 2 μg / kg to about 10 μg / kg body weight of BNT411, or about 160 μg to about 800 μg of BNT411 in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight of BNT411, or about 364x10 in total -9 mol~approx. 1820x10 -9 In some embodiments, the composition is administered to the subject in an amount to provide about 2.4 μg / kg to about 9.6 μg / kg body weight (e.g., about 4.8 μg / kg to about 9.6 μg / kg body weight) of BNT411, or about 192 μg to about 768 μg (e.g., about 384 μg to about 768 μg) of BNT411 in total, and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight (approximately 10.9x10 -9 mol / kg weight ~ approx. 21.8x10 -9mol / kg body weight, etc.) of BNT411, or a total of about 437x10 -9 mol~about 1747x10 -9 mol(about 873x10 -9 mol~about 1747x10 -9 In some embodiments, the composition is administered to a subject in an amount to provide about 4.8 μg / kg body weight of BNT411, or about 384 μg of BNT411 in total, and / or about 10.9×10 -9 mol / kg body weight of BNT411, or about 874x10 in total -9 The subject is administered an amount to provide 100 mol of BNT411.

[0015] In a fourth aspect, the disclosure provides (i) BNT411, a compound having the formula: [ka] or a pharma- ceutically acceptable solvate or salt thereof; and (ii) one or more additional therapeutic agents selected from the group consisting of a checkpoint inhibitor (CPI), a platinum-based chemotherapeutic agent, a topoisomerase inhibitor, and combinations thereof.

[0016] In a fifth aspect, the present disclosure provides a kit of the fourth aspect for use in a method for reducing or preventing tumor progression or treating cancer in a subject. In some embodiments of the fifth aspect, BNT411 is administered at about 0.1 μg / kg to about 50 μg / kg body weight, or at about 8 μg to about 4000 μg in total, and / or at about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18x10 in total -9 mol~about 9100x10 -9 In some embodiments, BNT411 is administered to a subject in an amount of about 0.5 μg / kg to about 20 μg / kg body weight, or a total of about 40 μg to about 1600 μg, and / or about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9mol / kg body weight, or about 91x10 in total -9 mol~approx. 3640x10 -9 In some embodiments, BNT411 is administered to a subject in an amount of about 2 μg / kg to about 10 μg / kg body weight, or a total of about 160 μg to about 800 μg, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9 In some embodiments, BNT411 is administered to a subject in an amount of about 2.4 μg / kg to about 9.6 μg / kg body weight (e.g., about 4.8 μg / kg to about 9.6 μg / kg body weight), or in a total amount of about 192 μg to about 768 μg (e.g., about 384 μg to about 768 μg), and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight (approximately 10.9x10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, etc.), or a total of about 437x10 -9 mol~about 1747x10 -9 mol(about 873x10 -9 mol~about 1747x10 -9 In some embodiments, BNT411 is administered to a subject in an amount of about 4.8 μg / kg body weight, or about 384 μg in total, and / or about 10.9×10 -9 mol / kg body weight, or about 874x10 in total -9 The compound is administered to the subject in mol amounts. [Brief description of the drawings]

[0017] [Figure 1]In vitro human PBMC stimulation assay. Stimulation of IFNa in human PBMC preparations from healthy donors by BNT411 (concentration range: 0.1 nM-10 μM) or comparable imidazoquinolines (Resiquimod (R848; concentration range: 0.6 nM-50 μM); 852A (concentration range: 0.6 nM-50 μM); or Imiquimod (R837; concentration range: 0.6 nM-50 μM)). Data shown as mean ± standard deviation (SD), n=5. [Diagram 2] In vivo cytokine release in BALB / c mice upon administration of BNT411. Female BALB / c mice were administered BNT411 retro-orbitally at doses of 3, 5, 10 and 15 mg / kg. Blood samples were taken 1 hour after compound application and analyzed by mouse IFNa ELISA. [Diagram 3] Scheme of the mode of action of BNT411. [Figure 4] Antitumor efficacy of BNT411 alone in tumor mouse models. Mice (n=12 or 13 / group) inoculated subcutaneously with 5x105 CT26 colon carcinoma cells were used as tumor mouse models. BNT411 was administered iv at a dose level of 3mg / kg 8 times at 4-5 day intervals (days 14, 19, 23, 28, 33, 37, 42 and 47). The control group (n=13) received vehicle only. Adaptive immunity was assessed by analyzing gp70 antigen-specific T cell populations in blood and splenocytes 3 and 5 weeks after the first test drug administration. (A) Administration schedule. (B) Graph showing tumor volume versus days post-inoculation. Group mean tumor volume of all surviving animals is shown. Additionally, tumor volumes of animals euthanized due to tumor burden were carried forward as long as they were greater than the group median tumor volume (SEM: standard error of the mean; LOCF: last observation carried forward). [Diagram 5]Antitumor efficacy of BNT411 alone and in combination with oxaliplatin in tumor mouse models. Mice (n=12 or 13 / group) inoculated subcutaneously with 2.5x105 CT26 colon carcinoma cells were used as tumor mouse models. Oxaliplatin was administered intraperitoneally (ip) (5mg / kg, 4 times with 4-5 days between injections). BNT411 was administered iv at a dose level of 3mg / kg 8 times at least 2 days after oxaliplatin therapy with an interval of 2-5 days between injections. Antitumor efficacy was evaluated by group mean tumor volumes of test groups vs. control groups (vehicle only) on days 33 and 42 (at least 50% of surviving test and control animals). IFNα levels in plasma were analyzed 1 hour after the first BNT411 administration, and gp70+ T cell populations in blood were analyzed on days 34 and 41. (A) Administration schedule. (B) Graph showing tumor volume versus days post-inoculation. Group mean tumor volume (± SEM (standard error of the mean)) of all surviving animals is shown. Treatment groups included 9-10 mice. Additionally, tumor volumes of animals euthanized due to tumor burden were carried forward as long as they were greater than the median tumor volume of the group (last observation carried forward (LOCF) values). Curves were interrupted for groups with less than 50% of animals surviving. (C) Graph showing IFNα serum levels 60 min after the first injection for the four groups (control (vehicle); BNT411 alone; oxaliplatin alone; BNT411 and oxaliplatin). IFNα levels in control and test groups are indicated by vertical bars (+ SEM) and statistical significance between groups is indicated by horizontal lines. P-value summary: ****=p≦0.0001; ***=p≦0.001; **=p≦0.01, *=p≦0.1. [Figure 6]Antitumor efficacy of BNT411 alone and in combination with anti-PD-L1 antibodies in tumor mouse models. Mice (n=10 / group) inoculated subcutaneously with 5x105 CT26 colon carcinoma cells were used as tumor mouse models. Anti-PD-L1 antibody anti-PD-L1-mIgG1e3 was administered intraperitoneally (ip) at a dose level of 200μg / animal. BNT411 was administered iv at a dose level of 3mg / kg. All treatments were administered once every 5 days for a total of 6 doses. Body weight change and tumor growth were evaluated on study day 21, when at least 9 animals in each group were alive. (A) Dosing schedule. (B) Graph showing tumor volume versus study day. Mean tumor volume ± SEM (mm3) is shown for each treatment. The final observation was carried forward to day 35, when only animals with tumors eliminated remained. (C) Graph showing the effect of BNT411 and anti-PD-L1 combination treatment on tumor volume in tumor mouse models (data from day 21). Individual animal values ​​and mean ± SEM are shown for each treatment (*p≦0.05, **p≦0.01-Tukey's multiple comparison test). [Figure 7] Release of specific cytokines upon treatment of whole blood from human donors with various concentrations of BNT411. Whole blood from healthy human volunteers was treated in vitro with BNT411 to investigate the induction of the following cytokines / chemokines: IFNα, IP-10, IL-6, and TNFα. BNT411 concentrations ranging from 0.1 nM (1x) to 7.5 μM (75000x). Fold increase over baseline is shown for each cytokine and BNT411 concentration tested. [Figure 8] Release of selected cytokines from preparations obtained from whole blood of human patients treated with various dose levels of BNT411. Mean maximum fold change (+SD) calculated from highest cytokine value observed on day 1 of treatment cycle 1 compared to baseline. IFNa and IL-6 peaked 4-8 hours after treatment, IP-10 and TNFa peaked 2.5-8 hours after treatment. No significant cytokine changes were observed in DL1A, DL2A or DL3A. IP-10+: upper limit of detection of the assay was reached in DL6A. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present disclosure will be described in more detail below, but it should be understood that the disclosure is not limited to the specific methods, protocols and reagents described herein, which may vary.It should also be understood that the terms used herein are only intended to describe specific embodiments, and are not intended to limit the scope of the present disclosure, which is limited only by the scope of the appended claims.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0019] In the following, the elements of the present disclosure are described in more detail. Although these elements are listed with specific embodiments, it should be understood that they may be combined in any manner and in any number to create further embodiments. The various described examples and preferred embodiments should not be construed as limiting the present disclosure to only the embodiments explicitly described. The description should be understood to support and encompass embodiments combining the explicitly described embodiment with any number of the disclosed elements and / or preferred elements. Furthermore, any permutation and combination of all elements described in this application should be considered as disclosed by the description of this application unless otherwise indicated by the context. For example, in some embodiments, the suitable amount of BNT411 is about 2 μg / kg to about 10 μg / kg body weight, or about 160 μg to about 800 μg in total, and / or about 4.55x10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9mol, and in some other embodiments, where the tumor or cancer being treated is small cell lung cancer (SCLC), e.g., extensive stage small cell lung cancer (ES-SCLC), in further embodiments, a suitable amount of BNT411 is about 2 μg / kg to about 10 μg / kg body weight, or a total of about 160 μg to about 800 μg, and / or about 4.55×10 mol to treat small cell lung cancer (SCLC), e.g., extensive stage small cell lung cancer (ES-SCLC). -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9 mol.

[0020] Preferably, the terms used herein are defined as set forth in “A multilingual glossary of biotechnological terms: (IUPAC Recommendations)”, H.G.W. Leuenberger, B. Nagel, and H. Kolbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).

[0021] The practice of the present disclosure employs, unless otherwise indicated, conventional chemical, biochemical, cell biology, immunological, and recombinant DNA techniques as described in the art (e.g., Organikum, Deutscher Verlag der Wissenschaften, Berlin 1990; Streitwieser / Heathcook, "Organische Chemie", VCH, 1990; Beyer / Walter, "Lehrbuch der Organischen Chemie", S. Hirzel Verlag Stuttgart, 1988; Carey / Sundberg, "Organische Chemie", VCH, 1995; March, "Advanced Organic Chemistry", John Wiley & Sons, 1985; Rompp Chemie Lexikon, Falbe / Regitz (Hrsg.), Georg Thieme Verlag Stuttgart, New York, 1989; Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al., J. Molecular Cloning: A Laboratory Manual, 2nd Edition ... See al.eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989.

[0022] All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "etc.") provided herein is intended merely to better illustrate the disclosure and does not impose limitations on the scope of the disclosure as claimed. No language in this specification should be construed as indicating any non-claimed element essential to the practice of the disclosure.

[0023] Recitation of ranges of values ​​herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and unless otherwise stated herein, each separate value is incorporated herein as if it were individually recited herein.

[0024] Several documents are cited throughout the text of this specification. Each document cited herein, whether supra or infra, including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc., is hereby incorporated by reference in its entirety. Nothing herein should be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0025] definition The following provide definitions that apply to all aspects of this disclosure. The following terms have the following meanings unless otherwise indicated. Terms not defined have their art-wide accepted meanings.

[0026] Throughout this specification and the claims that follow, unless the context otherwise requires, the word "comprise" and variations such as "comprising" are understood to mean the inclusion of a stated member, integer or step or group of members, integers or steps, but not the exclusion of any other member, integer or step or group of members, integers or steps. The term "consisting essentially of" means excluding essentially significant other members, integers or steps. The term "comprising" encompasses the term "consisting essentially of", which in turn encompasses the term "consisting of". Thus, for each occurrence in this application, the term "comprising" may be replaced with the term "consisting essentially of" or "consisting of". Similarly, for each occurrence in this application, the term "consisting essentially of" may be replaced with the term "consisting of".

[0027] As used in the context of describing this disclosure (particularly in the context of the claims), the terms "a," "an," and "the," and similar references, unless otherwise indicated herein or clearly contradicted by context, should be construed to encompass both the singular and the plural.

[0028] As used herein, "and / or" should be interpreted as a specific disclosure of each of the two specified features or components, with or without the other. For example, "X and / or Y" should be interpreted as a specific disclosure of (i) X, (ii) Y, and (iii) each of X and Y, as if each were individually set forth herein.

[0029] In the context of the present disclosure, the term "about" indicates an interval of accuracy that a person skilled in the art would understand to still guarantee the technical effect of the feature in question. This term typically indicates a deviation from the indicated numerical value of ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05%, for example ±0.01%. As will be understood by a person skilled in the art, such specific deviations for the numerical value of a given technical effect depend on the nature of the technical effect. For example, a natural or biological technical effect may generally have such a deviation larger than that of an artificial or engineered technical effect.

[0030] The term "binding agent" in the context of this disclosure refers to any agent that can bind to a desired antigen. In certain embodiments of the present disclosure, the binding agent is an antibody, an antibody fragment, or a construct thereof. The binding agent may also include synthetic, modified, or non-naturally occurring moieties, particularly non-peptide moieties. Such moieties may link desired antigen-binding functional groups or regions, such as, for example, antibodies or antibody fragments. In some embodiments, the binding agent is a synthetic construct that includes antigen-binding CDRs or variable regions.

[0031] As used herein, "immune checkpoint" refers to regulators of the immune system, particularly costimulatory and inhibitory signals that regulate the magnitude and quality of T cell activity, e.g., the magnitude and quality of T cell receptor recognition of antigen. In certain embodiments, the immune checkpoint is an inhibitory signal. In certain embodiments, the inhibitory signal is the interaction between PD-1 and PD-L1 and / or PD-L2. Molecules that prevent the interaction between PD-1 and one or more of its binding partners to eliminate T cell dysfunction resulting from signaling on the PD-1 signaling axis, thereby restoring or enhancing T cell function (e.g., proliferation, cytokine production, target cell killing), are also referred to herein as "PD-1 axis binding antagonists." As used herein, PD-1 axis binding antagonists include PD-1 binding antagonists, PD-L1 binding antagonists, and PD-L2 binding antagonists.

[0032] Additional immune checkpoint proteins (such as receptors and their ligands) that can be targeted in accordance with the present disclosure are described and reviewed herein in Pardoll, D., Nature. 12:252-264, 2012.

[0033] The terms "checkpoint inhibitor" (CPI) and "immune checkpoint (ICP) inhibitor" are used interchangeably herein. The terms refer to molecules, such as binding agents, that inhibit immune checkpoints, particularly molecules that inhibit the inhibitory signals of immune checkpoints, that reduce, inhibit, hinder or negatively regulate one or more checkpoint proteins, or that reduce, inhibit, hinder or negatively regulate the expression of one or more checkpoint proteins, either in whole or in part. In some embodiments, the immune checkpoint inhibitor binds to one or more checkpoint proteins. In some embodiments, the immune checkpoint inhibitor binds to one or more molecules that regulate the checkpoint proteins. In some embodiments, the immune checkpoint inhibitor binds to precursors of one or more checkpoint proteins, for example at the DNA or RNA level. Any agent that functions as a checkpoint inhibitor according to the present disclosure can be used. The term "partially" as used herein means at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of a level, e.g., a level of inhibition of a checkpoint protein.

[0034] In some embodiments, the checkpoint inhibitor can be any compound, such as any binding agent, that inhibits the inhibitory signal of immune checkpoint. In some embodiments, the inhibitory signal is the interaction between PD-1 and PD-L1 and / or PD-L2. In some embodiments, the checkpoint inhibitor is at least one selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a PD-L2 inhibitor. In some embodiments, the checkpoint inhibitor can be a blocking antibody, such as a PD-1 blocking antibody, a PD-L1 blocking antibody, or a PD-L2 blocking antibody. Examples of PD-1 blocking antibodies include pembrolizumab, nivolumab, cemiplimab, and spartalizumab. Examples of PD-L1 blocking antibodies include atezolizumab, durvalumab, and avelumab.

[0035] The term "immunoglobulin" relates to proteins of the immunoglobulin superfamily, preferably antibodies or antigen receptors such as B-cell receptors (BCR). Immunoglobulins are characterized by structural domains, i.e. immunoglobulin domains, with a characteristic immunoglobulin (Ig) fold. The term encompasses membrane-bound and soluble immunoglobulins. Membrane-bound immunoglobulins are also called surface or membrane immunoglobulins, which are generally part of the BCR. Soluble immunoglobulins are generally called antibodies.

[0036] The structure of immunoglobulins has been well characterized. See, for example, Fundamental Immunology Ch. 7 (Paul, W., ed., 2 nd ed. Raven Press, NY (1989). In summary, immunoglobulins generally contain several chains, typically two identical heavy chains and two identical light chains linked via disulfide bonds. These chains are primarily L or VL (variable light chain) domain / region, C L or CL (constant light chain) domain / region, V H or a VH (variable heavy) domain / region, andH or CH (constant heavy chain) domain / region C H 1(CH1), C H 2(CH2), C H 3(CH3) and C HThe heavy chain constant region is typically composed of three domains, CH1, CH2, and CH3. The hinge region is the region between the CH1 and CH2 domains of the heavy chain and is highly flexible. Disulfide bonds in the hinge region are part of the interaction between the two heavy chains in an IgG molecule. Each light chain is typically composed of VL and CL. The light chain constant region is typically composed of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability (or hypervariable regions where the sequence and / or the shape of structurally defined loops can be hypervariable), also called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL is typically composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mol. Biol. 196, 901-917 (1987)). Unless otherwise indicated or contradicted by context, CDR sequences herein are identified according to the rules of IMGT using DomainGapAlign (Lefranc MP., Nucleic Acids Research 1999;27:209-212 and Ehrenmann F., Kaas Q. and Lefranc M.-P. Nucleic Acids Res., 38, D301-307 (2010); see also internet http address www.imgt.org. Unless otherwise indicated or contradicted by context, references to amino acid positions of constant regions in this disclosure are according to EU numbering (Edelman et al., Proc Natl Acad Sci USA. 1969 May;63(1):78-85; Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition. 1991 NIH Publication No.91-3242).

[0037] There are five types of mammalian immunoglobulin heavy chains, namely α, δ, ε, γ and μ, which constitute the different classes of antibodies, namely IgA, IgD, IgE, IgG and IgM. In contrast to the heavy chains of soluble immunoglobulins, the heavy chains of membrane or surface immunoglobulins contain a transmembrane domain and a short cytoplasmic domain at their carboxy termini. In mammals, there are two types of light chains, namely lambda and kappa. Immunoglobulin chains contain a variable region and a constant region. The constant region is essentially conserved within the different isotypes of immunoglobulins, while the variable part is highly diverse and is responsible for antigen recognition.

[0038] The terms "amino acid" and "amino acid residue" may be used interchangeably herein and should not be understood as limiting. Amino acids are organic compounds that contain an amine (-NH2) functional group and a carboxyl (-COOH) functional group along with a side chain (R group) specific to each amino acid. In the context of the present disclosure, amino acids may be classified based on their structure and chemical characteristics. Thus, the classes of amino acids may be reflected in one or both of the following tables: [Table 1] [Table 2]

[0039] For the purposes of this disclosure, a "variant" of an amino acid sequence (peptide or polypeptide) includes an amino acid insertion variant, an amino acid addition variant, an amino acid deletion variant, and / or an amino acid substitution variant. The term "variant" includes all mutants, splice variants, post-translational modification variants, conformational variants, isoforms, allelic variants, species variants, and species homologs, particularly those that occur naturally. The term "variant" particularly includes fragments of an amino acid sequence.

[0040] Amino acid insertion variants include the insertion of a single or two or more amino acids into a specific amino acid sequence. In the case of amino acid sequence variants with insertions, one or more amino acid residues are inserted into a specific site of the amino acid sequence, although random insertion with appropriate screening of the resulting product is also possible.

[0041] Amino acid addition variants include amino- and / or carboxy-terminal fusions of one or more amino acids, for example 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids.

[0042] Amino acid deletion mutants are characterized by the removal of one or more amino acids from the sequence, for example, the removal of 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. The deletion may be at any position in the protein. Amino acid deletion mutants that include deletions at the N-terminus and / or C-terminus of the protein are also called N-terminus and / or C-terminus truncation mutants.

[0043] Amino acid substitution variants are characterized by the removal of at least one residue in the sequence and the insertion of another in its place. Substitution of one amino acid for another can be classified as conservative or non-conservative substitution. Modifications at positions in the amino acid sequence that are not conserved between homologous proteins or peptides and / or replacement of amino acids with other amino acids with similar properties are preferred. Preferably, the amino acid changes in peptides and protein variants are conservative amino acid changes, i.e., substitutions of similarly charged or uncharged amino acids. Conservative amino acid changes include the substitution of one of a family of amino acids whose side chains are related. In the context of the present disclosure, a "conservative substitution" is the substitution of one amino acid residue with another amino acid with similar structural and / or chemical characteristics, such a substitution of one amino acid residue for another amino acid residue of the same class as defined in either of the two tables above: for example, leucine can be substituted with isoleucine, since both are aliphatic branched hydrophobic. Similarly, aspartic acid can be substituted with glutamic acid, since both are small negatively charged residues. Naturally occurring amino acids may also be generally divided into four families: acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified together as aromatic amino acids. In some embodiments, conservative amino acid substitutions include substitutions within the following groups: -Glycine, Alanine; -valine, isoleucine, leucine; -Aspartic acid, glutamic acid; -Asparagine, glutamine; -Serine, Threonine; -Lysine, Arginine; and -Phenylalanine, tyrosine.

[0044] As used herein, the term "amino acid corresponding to position ..." and similar expressions refer to the amino acid position number in the human IgG1 heavy chain. Corresponding amino acid positions in other immunoglobulins can be found by alignment with human IgG1. Thus, an amino acid or segment in one sequence that "corresponds to" an amino acid or segment in another sequence is one that aligns with the other amino acid or segment, typically with default settings, using ALIGN, ClustalW or similar standard sequence alignment programs, and has at least 50%, at least 80%, at least 90%, or at least 95% identity with the human IgG1 heavy chain. Methods for aligning sequences or segments in sequences, thereby determining positions in sequences that correspond to amino acid positions according to the present disclosure, are believed to be well known in the art.

[0045] The term "antibody" (Ab) in the context of the present disclosure refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or any derivative thereof, that has the ability to specifically bind to an antigen (particularly an epitope on an antigen) under typical physiological conditions, preferably having a half-life of a significant period, such as at least about 30 minutes, at least about 45 minutes, at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 days or more, etc., or any other relevant functionally defined period (e.g., a time sufficient to induce, promote, enhance and / or modulate a physiological response associated with antibody binding to an antigen and / or a time sufficient for the antibody to recruit effector activity). In particular, the term "antibody" refers to a glycoprotein that comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. The term "antibody" includes monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies, and any combination of the above. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The variable and constant regions are also referred to herein as variable and constant domains, respectively. The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs of VH are referred to as HCDR1, HCDR2 and HCDR3 (or CDR-H1, CDR-H2 and CDR-H3), and the CDRs of VL are referred to as LCDR1, LCDR2 and LCDR3 (or CDR-L1, CDR-L2 and CDR-L3). The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.The constant region of an antibody comprises a heavy chain constant region (CH) and a light chain constant region (CL), and the CH can be further subdivided into a constant domain CH1, a hinge region, and constant domains CH2 and CH3 (arranged from amino-terminus to carboxy-terminus in the following order: CH1, CH2, CH3). The constant region of an antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells), and components of the complement system, e.g., C1q. An antibody can be an intact immunoglobulin from natural or recombinant sources, or an immunologically active portion of an intact immunoglobulin. An antibody is typically a tetramer of an immunoglobulin molecule. An antibody can exist in various forms, including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)2, as well as single chain antibodies and humanized antibodies.

[0046] The variable regions of the heavy and light chains of immunoglobulin molecules comprise the binding domain that interacts with antigen. The terms "binding region" and "antigen-binding region" are used interchangeably herein and refer to the region that interacts with antigen and includes both VH and VL regions. Antibodies as used herein include not only monospecific antibodies, but also multispecific antibodies that contain multiple, for example, two or more, for example, three or more different antigen-binding regions.

[0047] As mentioned above, the term antibody in this specification includes antigen-binding fragments, i.e., fragments of antibodies that retain the ability to specifically bind to antigens, unless otherwise specified or clearly contradicted by the context. It has been shown that the antigen-binding function of an antibody can be performed by a fragment of a full-length antibody. Examples of antigen-binding fragments encompassed by the term "antibody" include: (i) Fab' or Fab fragments, monovalent fragments consisting of VL, VH, CL and CH1 domains, or monovalent antibodies as described in WO 2007 / 059782 (Genmab); (ii) F(ab')2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments essentially consisting of VH and CH1 domains; (iv) Fv fragments essentially consisting of the VL and VH domains of a single arm of an antibody; (v) essentially consisting of the VH domain, also called domain antibodies (Holt et al; Trends Biotechnol. 2003 Nov; 21 (11):484-90) dAb fragments (Ward et al., Nature 341 , 544-546(1989));(vi) camelid or nanobody molecules (Revets et al; Expert Opin Biol Ther. 2005 Jan; 5 (1):111-24); and (vii) isolated complementarity determining regions (CDRs). Additionally, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be engineered using recombinant techniques to produce a single protein chain in which the VL and VH regions pair to form a monovalent molecule (known as a single-chain antibody or single-chain Fv (scFv), see, e.g., Bird et al., Science 2003). 242 , 423-426 (1988) and Huston et al., PNAS USA 85, 5879-5883 (1988)). Such single chain antibodies are encompassed by the term antibody unless otherwise specified or clearly indicated by the context. Although such fragments are generally included within the meaning of antibody, they collectively and each independently are unique features of the present disclosure and exhibit different biological properties and usefulness. These and other useful antibody fragments in the context of the present disclosure, as well as bispecific formats of such fragments, are further discussed herein. The term antibody, unless otherwise specified, should also be understood to include antibody-like polypeptides such as polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies and humanized antibodies, as well as antibody fragments (antigen-binding fragments) that retain the ability to specifically bind to an antigen provided by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques.

[0048] The generated antibody can have any isotype. As used herein, the term "isotype" refers to the immunoglobulin class (e.g., IgG (IgG1, IgG2, IgG3, IgG4, etc.), IgD, IgA (IgA1, IgA2, etc.), IgE, IgM, or IgY) encoded by heavy chain constant region genes. When a particular isotype, e.g., IgG1, is referred to herein, the term is not limited to a particular isotype sequence, e.g., a particular IgG1 sequence, but is used to indicate that the antibody is closer in sequence to that isotype, e.g., IgG1, than to other isotypes. Thus, for example, the IgG1 antibodies disclosed herein can be sequence variants of naturally occurring IgG1 antibodies, including mutations in the constant region.

[0049] IgG1 antibodies can exist in multiple polymorphic variants called allotypes (reviewed in Jefferis and Lefranc 2009.mAbs Vol 1 Issue 4 1-7), all of which are suitable for use in some of the embodiments herein. Common allotypic variants in the human population are those designated by the letters a, f, n, z, or combinations thereof. In any of the embodiments herein, the antibody may comprise a heavy chain Fc region that comprises a human IgG Fc region. In a further embodiment, the human IgG Fc region comprises a human IgG1.

[0050] The term "multispecific antibody" in the context of the present disclosure refers to an antibody having at least two different antigen-binding regions defined by different antibody sequences. In some embodiments, the different antigen-binding regions bind to different epitopes on the same antigen. However, in some preferred embodiments, the different antigen-binding regions bind to different target antigens. In some embodiments, the multispecific antibody is a "bispecific antibody" or "bs". Multispecific antibodies such as bispecific antibodies can be of any format, including any of the bispecific or multispecific antibody formats described herein below.

[0051] The term "full length" when used in reference to an antibody indicates that the antibody is not a fragment, but includes all of the domains of a particular isotype that are normally found for that isotype in nature, e.g., the VH, CH1, CH2, CH3, hinge, VL and CL domains of an IgG1 antibody.

[0052] The term "human antibody" as used herein is intended to include antibodies having variable and framework regions derived from human germline immunoglobulin sequences and human immunoglobulin constant domains. The human antibodies disclosed herein may contain amino acid residues (e.g., mutations, insertions, or deletions introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo) that are not encoded by human germline immunoglobulin sequences. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another non-human species, such as a mouse, have been grafted onto human framework sequences.

[0053] The term "chimeric antibody" as used herein refers to an antibody in which the variable region is derived from a non-human species (e.g., from a rodent) and the constant region is derived from a different species, such as human. Chimeric antibodies can be produced by antibody engineering. "Antibody engineering" is a term used collectively for the modification of different types of antibodies, and the process for antibody engineering is well known to those skilled in the art. In particular, chimeric antibodies can be produced by using standard DNA techniques such as those described in Sambrook et al., 1989, Molecular Cloning: A laboratory Manual, New York: Cold Spring Harbor Laboratory Press, Ch. 15. Thus, chimeric antibodies can be genetically engineered or enzymatically engineered recombinant antibodies. It is within the knowledge of those skilled in the art to produce chimeric antibodies, and therefore the production of chimeric antibodies can be carried out by methods other than those described herein. Chimeric monoclonal antibodies for therapeutic applications to humans have been developed to reduce the expected antibody immunogenicity of non-human antibodies, e.g., rodent antibodies. They typically contain a non-human (e.g., mouse or rabbit) variable region specific for an antigen of interest, as well as the heavy and light chain domains of a human constant antibody. The term "variable region" or "variable domain" as used in the context of a chimeric antibody refers to the region that contains the CDR and framework regions of both the heavy and light chains of an immunoglobulin, as described below.

[0054] The term "humanized antibody" as used herein refers to a genetically engineered non-human antibody comprising a human antibody constant domain and a non-human variable domain modified to contain a high level of sequence homology to the human variable domain. This can be achieved by grafting the six non-human antibody complementarity determining regions (CDRs) that together form the antigen binding site into a homologous human acceptor framework region (FR) (see WO 92 / 22653 and EP 0629240). Substitution (back mutation) of framework residues from the parent antibody (i.e., non-human antibody) into the human framework region may be required to fully reconstitute the binding affinity and specificity of the parent antibody. Structural homology modeling can help to identify amino acid residues in the framework region that are important for the binding properties of the antibody. Thus, a humanized antibody may comprise non-human CDR sequences, primarily human framework regions optionally containing one or more amino acid back mutations to non-human amino acid sequences, and a fully human constant region. Optionally, further amino acid modifications, not necessarily back mutations, may be applied to obtain a humanized antibody with favorable characteristics such as affinity and biochemical properties.

[0055] As used herein, a protein "derived from" another protein, e.g., a parent protein, means that one or more amino acid sequences of the protein are identical or similar to one or more amino acid sequences of the other or parent protein. For example, an antibody, binding arm, antigen binding region or constant region, etc. derived from another or parent antibody, binding arm, antigen binding region or constant region, has one or more amino acid sequences that are identical or similar to those of the other or parent antibody, binding arm, antigen binding region or constant region. Examples of such one or more amino acid sequences include, but are not limited to, VH and VL CDRs, and / or one or more or all of the framework regions, VH, VL, CL, hinge or CH regions. For example, a humanized antibody may be described herein as "derived from" a non-human parent antibody, meaning that at least the VL and VH CDR sequences are identical or similar to those of the VH and VL CDR sequences of said non-human parent antibody. A chimeric antibody may be described herein as "derived from" a non-human parent antibody, meaning that typically the VH and VL sequences may be identical or similar to those of the non-human parent antibody. Another example is a binding arm or antigen-binding region that may be described herein as "derived from" a particular parent antibody, meaning that said binding arm or antigen-binding region typically comprises the same or similar VH and / or VL CDRs, or VH and / or VL sequences as the binding arm or antigen-binding region of said parent antibody. However, as described elsewhere herein, amino acid modifications, such as mutations, can be made to the CDRs, constant regions, or elsewhere in the antibody, binding arm, antigen-binding region, etc., to introduce desired characteristics. When used in the context of one or more sequences derived from a first or parent protein, a "similar" amino acid sequence preferably has at least about 50%, e.g., at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 97%, 98% or 99% sequence identity.

[0056] Non-human antibodies can be generated in many different species, such as mice, rabbits, chickens, guinea pigs, llamas, and goats.

[0057] Monoclonal antibodies can be produced by a variety of techniques, including conventional monoclonal antibody techniques, such as the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256:495 (1975). Other techniques for producing monoclonal antibodies can be used, such as viral or oncogenic transformation of B lymphocytes, or phage display techniques using libraries of antibody genes, and such methods are well known to those of skill in the art.

[0058] Hybridoma production in such non-human species is a very well-established procedure. Immunization protocols and techniques for isolating spleen cells of immunized animals / non-human species for fusion are known in the art. Fusion partners (e.g., mouse myeloma cells) and fusion procedures are also known.

[0059] As used herein, unless contradicted by context, the term "Fab arm" or "arm" refers to one heavy-light chain pair, and is used interchangeably herein with "half molecule."

[0060] The term "binding arm comprising an antigen-binding region" refers to an antibody molecule or fragment that comprises an antigen-binding region. Thus, a binding arm can comprise, for example, the six VH and VL CDR sequences, a VH and VL sequence, a Fab or Fab' fragment, or a Fab arm.

[0061] As used herein, unless otherwise contradicted by the context, the term "Fc region" refers to an antibody region consisting of two Fc sequences of an immunoglobulin heavy chain, said Fc sequences including at least a hinge region, a CH2 domain, and a CH3 domain. In some embodiments, the term "Fc region" as used herein refers to a region including at least a hinge region, a CH2 domain, and a CH3 domain in the N-terminal to C-terminal direction of an antibody. The Fc region of an antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and components of the complement system.

[0062] The term "hinge region" as used herein refers to the hinge region of an immunoglobulin heavy chain. Thus, for example, the hinge region of a human IgG1 antibody corresponds to amino acids 216-230 according to the EU numbering as described in Kabat (Kabat, EA et al., Sequences of proteins of immunological interest. 5th Edition-US Department of Health and Human Services, NIH publication No. 91-3242, pp 662, 680, 689 (1991)). However, the hinge region may be of any of the other subtypes described herein.

[0063] The term "CH1 region" or "CH1 domain" as used herein refers to the CH1 region of an immunoglobulin heavy chain. Thus, for example, the CH1 region of a human IgG1 antibody corresponds to amino acids 118-215 according to the EU numbering as set forth in Kabat, supra. However, the CH1 region may be of any of the other subtypes described herein.

[0064] The term "CH2 region" or "CH2 domain" as used herein refers to the CH2 region of an immunoglobulin heavy chain. Thus, for example, the CH2 region of a human IgG1 antibody corresponds to amino acids 231-340 according to the EU numbering as set forth in Kabat (supra). However, the CH2 region may be of any of the other subtypes described herein.

[0065] The term "CH3 region" or "CH3 domain" as used herein refers to the CH3 region of an immunoglobulin heavy chain. Thus, for example, the CH3 region of a human IgG1 antibody corresponds to amino acids 341-447 according to the EU numbering system as set forth in Kabat, supra. However, the CH3 region may be of any of the other subtypes described herein.

[0066] The term "monovalent antibody", in the context of the present disclosure, means that an antibody molecule is capable of binding to a single molecule of antigen and is therefore not capable of antigen cross-linking.

[0067] Based on the type of receptor through which the interferons signal, they are typically divided into three classes: type I interferons, type II interferons, and type III interferons. All type I interferons bind to a specific cell surface receptor complex known as the IFN-α / β receptor (IFNAR), which consists of the IFNAR1 and IFNAR2 chains.

[0068] The type I interferons present in humans are IFNα, IFNβ, IFNε, IFNκ and IFNω. Generally, type I interferons are produced when the body recognizes a virus that has invaded the body. They are produced by fibroblasts and monocytes. Once released, type I interferons bind to specific receptors on target cells, resulting in the expression of proteins that prevent the virus from producing and replicating its RNA and DNA. IFNβ proteins are produced in large quantities by fibroblasts. They have antiviral activity that is mainly involved in the innate immune response. Two types of IFNβ have been described: IFNβ1 and IFNβ3. Natural and recombinant forms of IFNβ1 have antiviral, antibacterial, and anticancer properties. According to the present disclosure, the type I interferon is preferably IFNα. "IFNa" or "IFNα" are used interchangeably herein to mean interferon alpha (Uniprot#P01563). Dendritic cells are a major source of IFNa, and this protein is involved not only in the innate immune response to viral infection but also in cell differentiation and antitumor responses.

[0069] Type II interferons (IFNγ in humans), also known as immune interferons, are activated by IL12. Additionally, type II interferons are released by cytotoxic T cells and T helper cells.

[0070] Type III interferons signal through a receptor complex consisting of IL10R2 (also called CRF2-4) and IFNLR1 (also called CRF2-12). Although more recently discovered than types I and II IFNs, recent information has demonstrated the importance of type III IFNs in several types of viral or fungal infections.

[0071] As used herein, "IP-10" refers to interferon gamma-inducible protein 10 (also known as 10 kDa interferon-gamma-inducible protein or CXCL10) (Uniprot#P02778). IP-10 is induced in a variety of cells in response to interferon gamma. IP-10 inhibits bone marrow colony formation and angiogenesis, stimulates NK and T cell migration, regulates T cell maturation, and modulates adhesion molecule expression.

[0072] As used herein, "IFN gamma" refers to interferon gamma (Uniprot#P01579). Its main function is to activate macrophages and increase the expression of class II MHC on APCs. IFN gamma stimulated macrophages are more phagocytic, more capable of killing intracellular pathogens, and have increased capacity to present antigens.

[0073] "IL6" and "IL-6" are used interchangeably herein to refer to interleukin-6 (Uniprot#P05231). IL-6 is a cytokine released by leukocytes in response to several inducing stimuli. In addition to its role as an acute phase reactant and endogenous pyrogen, IL-6 is also involved in B cell differentiation into plasma cells. IL-6 is not normally detectable in normal serum, plasma, cerebrospinal fluid (CSF) or synovial fluid. Elevated levels are observed in various inflammatory processes, including infections (endotoxemia) and collagen vascular diseases.

[0074] "TNFa" and "TNFα" are used interchangeably herein and refer to tumor necrosis factor alpha (Uniprot#P01375). TNFa is secreted by macrophages, monocytes, neutrophils, T cells and NK cells after many different stimuli, including interferons, IL-2, GM-CSF, bradykinin, inhibitors of immune complexes, cyclooxygenase and PAF (platelet activating factor).

[0075] As used herein, the terms "bind" or "capable of binding" in the context of the binding of an antibody to a given antigen or epitope typically refer to a binding rate of about 10% or more as determined using biolayer interferometry (BLI) or, for example, surface plasmon resonance (SPR) technology on a BIAcore 3000 instrument using the antigen as the ligand and the antibody as the analyte. -7 M or less, for example, about 10 -8 M or less, for example, about 10 -9 M or less, about 10 -10 M or less, or about 10 -11 M or lower K D An antibody binds with an affinity corresponding to its K for binding to a nonspecific antigen other than the given antigen or a closely related antigen (e.g., BSA, casein). D at least 10 times lower, such as at least 100 times lower, such as at least 1,000 times lower, such as at least 10,000 times lower, such as at least 100,000 times lower, D The higher the affinity, the greater the amount of the antibody's K D Since it depends on the antibody's K D is very low (i.e., the antibody is highly specific), the degree to which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 10,000-fold.

[0076] As used herein, "k d ”(seconds -1 The term k ) refers to the dissociation rate constant of a particular antibody-antigen interaction. off Also called value.

[0077] As used herein, "K D The term "" (M) refers to the dissociation equilibrium constant of a particular antibody-antigen interaction.

[0078] Two antibodies have the "same specificity" if they bind to the same antigen and the same epitope. Whether an antibody being tested recognizes the same epitope as a particular antigen-binding antibody, i.e., whether the antibody binds to the same epitope, can be tested by various methods well known to those skilled in the art.

[0079] Competition between antibodies can be detected by cross-blocking assay. For example, a competitive ELISA assay can be used as a cross-blocking assay. For example, a target antigen can be coated on the well of a microtiter plate, and an antigen-binding antibody and a candidate competitive test antibody can be added. The amount of antigen-binding antibody bound to the antigen in the well indirectly correlates with the binding ability of the candidate competitive test antibody that competes for binding to the same epitope. Specifically, the greater the affinity of the candidate competitive test antibody for the same epitope, the less the amount of antigen-binding antibody that binds to the antigen-coated well. The amount of antigen-binding antibody bound to the well can be measured by labeling the antibody with a detectable or measurable labeling substance.

[0080] An antibody that competes with another antibody for binding to an antigen, e.g., an antibody comprising the heavy and light chain variable regions described herein, or that has the specificity for an antigen of another antibody, e.g., an antibody comprising the heavy and light chain variable regions described herein, may be a variant of the heavy and / or light chain variable regions described herein, e.g., an antibody comprising modified CDRs and / or a degree of identity as described herein.

[0081] As used herein, an "isolated multispecific antibody" is intended to refer to a multispecific antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated bispecific antibody that specifically binds PD-1 and a heterologous protein is substantially free of monospecific antibodies that specifically bind PD-1 or a heterologous protein).

[0082] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

[0083] The present disclosure also describes multispecific antibodies, e.g., bispecific antibodies, comprising functional variants of the VL region, VH region, or one or more CDRs of the bispecific antibodies disclosed herein. A functional variant of a VL, VH, or CDR used in the context of a bispecific antibody still allows each antigen-binding region of the bispecific antibody to retain at least a significant proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity and / or specificity / selectivity of the parent bispecific antibody, and in some cases, such a bispecific antibody may be associated with higher affinity, selectivity, and / or specificity than the parent bispecific antibody.

[0084] Such functional variants typically retain significant sequence identity to the parent bispecific antibody. The percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap (i.e., % homology = number of identical positions / total number of positions x 100). The percent identity between two nucleotide or amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11-17 (1988) incorporated into the ALIGN program (version 2.0), for example, using a PAM120 weighted residue table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch, J. Mol. Biol. 48, 444-453 (1970).

[0085] Exemplary variants include those which differ from the VH and / or VL and / or CDRs of a parent sequence primarily by conservative substitutions; for example, 12, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 of the substitutions in the variant are conservative amino acid residue substitutions.

[0086] In the context of this disclosure, conservative substitutions may be defined by substitutions within the classes of amino acids defined in Tables 1 and 2.

[0087] "Programmed Death 1 (PD-1)" receptor refers to an immunosuppressive receptor belonging to the CD28 family. PD-1 (also known as CD279 or SLEB2) is expressed primarily on T cells previously activated in vivo and binds to two ligands, PD-L1 (also known as B7-H1, B7-4, CD274 or B7-H) and PD-L2 (also known as B7-DC, Btdc or CD273). As used herein, the term "PD-1" includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs that share at least one common epitope with hPD-1. The sequence of human PD-1 is known (see, for example, Genbank accession number AAC51773.1). "Programmed death-ligand 1 (PD-L1)" is one of two cell surface glycoprotein ligands for PD-1 (the other being PD-L2) that downregulates T cell activation and cytokine secretion upon binding to PD-1. As used herein, the term "PD-L1" includes human PD-L1 (hPD-L1), variants, isoforms and species homologs of hPD-L1, such as macaque (Macaca fascicularis), African elephant, wild boar and mouse PD-L1 (see, e.g., Genbank Accession Nos. NP_054862.1, XP_005581836, XP_003413533, XP_005665023 and NP_068693, respectively), and analogs that share at least one common epitope with hPD-L1. The sequence of human PD-L1 is known (see, for example, Genbank Accession No. NP_054862, where amino acids 1-18 are predicted to be the signal peptide). The sequence of macaque (Macaca fascicularis) PD-L1 is set forth in Genbank Accession No. XP_005581836, where amino acids 1-18 are predicted to be the signal peptide. As used herein, the term "PD-L2" includes human PD-L2 (hPD-L2), variants, isoforms, and species homologs of hPD-L2, and analogs that share at least one shared epitope with hPD-L2.The ligands of PD-1 (PD-L1 and PD-L2) are expressed on the surface of antigen-presenting cells, such as dendritic cells or macrophages, and other immune cells. Binding of PD-1 to PD-L1 or PD-L2 results in downregulation of T-cell activation. Cancer cells expressing PD-L1 and / or PD-L2 can switch off T cells expressing PD-1 resulting in suppression of anti-cancer immune responses. The interaction between PD-1 and its ligands results in a reduction of tumor-infiltrating lymphocytes, a reduction in T-cell receptor-mediated proliferation, and immune evasion by cancerous cells. Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1, and the effect is additive if the interaction of PD-1 with PD-L2 is blocked as well.

[0088] Many immune checkpoints are regulated by the interaction between specific receptor and ligand pairs as described above. Thus, immune checkpoint proteins mediate immune checkpoint signaling. For example, checkpoint proteins directly or indirectly regulate T cell activation, T cell proliferation and / or T cell function. Cancer cells often exploit these checkpoint pathways to protect themselves from attack by the immune system. Thus, in some embodiments, the function of the checkpoint protein regulated according to the present disclosure is typically the regulation of T cell activation, T cell proliferation and / or T cell function. Thus, immune checkpoint proteins regulate and maintain self-tolerance as well as the duration and magnitude of physiological immune responses. Many immune checkpoint proteins belong to the B7:CD28 family or tumor necrosis factor receptor (TNFR) superfamily, and activate signaling molecules recruited to the cytoplasmic domain by binding to specific ligands (Suzuki et al., 2016, Jap J Clin Onc, 46:191-203).

[0089] As used herein, the term "immune checkpoint modulator" or "checkpoint modulator" refers to a molecule or compound that modulates the function of one or more checkpoint proteins. Immune checkpoint modulators can typically modulate self-tolerance and / or the magnitude and / or duration of immune response. Preferably, immune checkpoint modulators modulate the function of one or more human checkpoint proteins and are therefore "human checkpoint modulators". Specifically, human checkpoint modulators are immune checkpoint inhibitors.

[0090] The term "dysfunction" as used herein refers to immune cells in a state of reduced immune responsiveness to antigenic stimulation. Dysfunction includes unresponsiveness to antigen recognition and impaired ability to translate antigen recognition into downstream T cell effector functions, such as proliferation, cytokine production (e.g., IL-2) and / or target cell killing.

[0091] The term "anergy" as used herein refers to a state of unresponsiveness to antigenic stimulation resulting from defective or insufficient signals delivered via T cell receptor (TCR). T cell anergy can also occur upon stimulation by antigen in the absence of costimulation, resulting in cells becoming resistant to subsequent activation by antigen even in the context of costimulation. The unresponsive state can often be relieved by the presence of IL-2. Anergic T cells do not undergo clonal expansion and / or do not acquire effector functions.

[0092] The term "exhaustion" as used herein refers to immune cell exhaustion, e.g. T cell exhaustion as a state of T cell dysfunction resulting from persistent TCR signaling that occurs during many chronic infections and cancers. It is distinct from anergy in that it occurs by persistent signaling, not by defective or insufficient signaling. Exhaustion is defined by insufficient effector function, persistent expression of inhibitory receptors, and a transcriptional state that differs from functional effector or memory T cells. Exhaustion prevents optimal control of disease (e.g. infections and tumors). Exhaustion can result from both extrinsic negative regulatory pathways (e.g. immunomodulatory cytokines) as well as cell-intrinsic negative regulatory pathways (inhibitory immune checkpoint pathways as described herein).

[0093] "Enhancing T cell function" means inducing, directing or stimulating T cells so that they have sustained or amplified biological function, or to regenerate or reactivate exhausted or inactive T cells. Examples of enhancing T cell function include increased secretion of gamma-interferon from CD8+ T cells, increased proliferation, and increased antigen responsiveness (e.g., tumor clearance) compared to pre-intervention levels. In some embodiments, the level of enhancement is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 200% or more. Methods for measuring this enhancement are known to those skilled in the art.

[0094] As used herein, the term "inhibitory nucleic acid" or "inhibitory nucleic acid molecule" refers to a nucleic acid molecule, such as DNA or RNA, that reduces, inhibits, prevents or negatively regulates one or more checkpoint proteins, either in whole or in part. Inhibitory nucleic acid molecules include, but are not limited to, oligonucleotides, siRNA, shRNA, antisense DNA or RNA molecules, and aptamers (e.g., DNA or RNA aptamers).

[0095] The term "oligonucleotide" as used herein refers to a nucleic acid molecule capable of decreasing protein expression, particularly expression of a checkpoint protein, such as the checkpoint proteins described herein. Oligonucleotides are short DNA or RNA molecules that typically contain 2-50 nucleotides. Oligonucleotides can be single-stranded or double-stranded. Checkpoint inhibitor oligonucleotides can be antisense oligonucleotides.

[0096] Antisense oligonucleotides are single-stranded DNA or RNA molecules that are complementary to a given sequence, particularly the sequence of the nucleic acid sequence (or a fragment thereof) of a checkpoint protein. Antisense RNA is typically used to prevent the protein translation of mRNA, for example, the mRNA that codes for a checkpoint protein, by binding to said mRNA. Antisense DNA is typically used to target a specific complementary (coding or non-coding) RNA. If binding occurs, such DNA / RNA hybrids can be degraded by the enzyme RNase H. Furthermore, morpholino antisense oligonucleotides can be used for gene knockdown in vertebrates. For example, Kryczek et al., 2006 (J Exp Med, 203:871-81) designed a B7-H4-specific morpholino that specifically blocks B7-H4 expression in macrophages, resulting in increased T cell proliferation and reduced tumor volume in mice with tumor-associated antigen (TAA)-specific T cells.

[0097] The terms "siRNA" or "small interfering RNA" or "small inhibitory RNA" are used interchangeably herein to refer to double-stranded RNA molecules, typically 20-25 base pairs in length, that interfere with the expression of a specific gene with which they have a complementary nucleotide sequence, e.g., a gene encoding a checkpoint protein. In some embodiments, the siRNA interferes with the mRNA, thus blocking translation, e.g., translation of an immune checkpoint protein. Transfection of exogenous siRNA can be used for gene knockdown, but the effect may be only transient, especially in rapidly dividing cells. Stable transfection can be achieved, for example, by RNA modification or by using an expression vector. Modifications and vectors useful for stable transfection of cells with siRNA are known in the art. siRNA sequences can also be modified to introduce a short loop between the two strands resulting in a "small hairpin RNA" or "shRNA". shRNA can be processed into functional siRNA by Dicer. shRNAs have relatively low degradation and turnover rates. Thus, immune checkpoint inhibitors can be shRNAs.

[0098] The term "aptamer" as used herein refers to a single-stranded nucleic acid molecule, such as DNA or RNA, typically 25-70 nucleotides in length, that can bind to a target molecule, such as a polypeptide. In some embodiments, the aptamer binds to an immune checkpoint protein, such as an immune checkpoint protein described herein. For example, an aptamer according to the present disclosure can specifically bind to an immune checkpoint protein or polypeptide, or a molecule in a signaling pathway that regulates the expression of an immune checkpoint protein or polypeptide. The generation and therapeutic use of aptamers is well known in the art (see, e.g., U.S. Pat. No. 5,475,096).

[0099] The term "small molecule inhibitor" or "small molecule" is used interchangeably herein and refers to a low molecular weight organic compound, usually up to 1000 daltons, that reduces, inhibits, prevents or negatively regulates one or more checkpoint proteins, either in whole or in part, as described above. Such small molecule inhibitors are usually synthesized by organic chemistry, but can also be isolated from natural sources, such as plants, fungi, and microorganisms. The low molecular weight allows the small molecule inhibitor to diffuse rapidly across cell membranes. For example, various A2AR antagonists known in the art are organic compounds with molecular weights of less than 500 daltons.

[0100] The term "cell-based therapy" refers to the transplantation of cells (e.g., T lymphocytes, dendritic cells, or stem cells) that express an immune checkpoint inhibitor into a subject for the purpose of treating a disease or disorder (e.g., a cancer disease).

[0101] The term "oncolytic virus" as used herein refers to a virus that can selectively replicate and slow the growth or induce the death of cancerous or hyperproliferative cells, either in vitro or in vivo, while having no or minimal effect on normal cells.The oncolytic virus for delivery of immune checkpoint inhibitors comprises an expression cassette that can code for an immune checkpoint inhibitor, such as an inhibitory nucleic acid molecule, such as siRNA, shRNA, oligonucleotide, antisense DNA or RNA, aptamer, antibody or fragment thereof, or soluble immune checkpoint protein or fusion.The oncolytic virus is preferably replication-competent, and the expression cassette is under the control of a viral promoter, such as a synthetic early / late poxvirus promoter. Exemplary oncolytic viruses include vesicular stomatitis virus (VSV), rhabdoviruses (e.g., Seneca Valley virus; picornaviruses such as SVV-001), coxsackieviruses, parvoviruses, Newcastle disease virus (NDV), herpes simplex virus (HSV; OncoVEX GMCSF), retroviruses (e.g., influenza virus), measles virus, reovirus, Sindbis virus, vaccinia virus (including Copenhagen, Western Reserve, and Wyeth strains) as illustratively described in WO 2017 / 209053, and adenoviruses (e.g., Delta-24, Delta-24-RGD, ICOVIR-5, ICOVIR-7, Onyx-015, ColoAd1, H101, AD5 / 3-D24-GMCSF). The generation of recombinant oncolytic viruses containing soluble forms of immune checkpoint inhibitors and methods of their use are disclosed in International Publication No. WO 2018 / 022831, which is incorporated by reference in its entirety. Oncolytic viruses can be used as attenuated viruses.

[0102] A "treatment cycle" is defined herein as the period within the range of effect of separate doses of a compound (such as BNT411 and / or one or more additional therapeutic agents) due to its pharmacokinetics, or in other words, the period after the subject's body is essentially free of the administered binding agent. For example, multiple small doses within a short time frame of 2-12 hours or within 2-24 hours, such as on the same day, may be equivalent to a single larger dose.

[0103] In the present context, the term "treatment", "treat" or "therapeutic intervention" refers to the management and care of a subject with the aim of combating a condition, such as a disease or disorder. The term is intended to include the full range of treatments for a given condition suffered by a subject, such as the administration of a therapeutically effective compound to alleviate symptoms or complications, to slow the progression of a disease, disorder or condition, to alleviate or reduce symptoms and complications, and / or to cure or eliminate a disease, disorder or condition, as well as to prevent a condition, where prevention is to be understood as the management and care of an individual with the aim of combating a disease, condition or disorder, and includes the administration of an active compound to prevent the onset of symptoms or complications. In some embodiments, "treatment" refers to the administration of an effective amount of a therapeutically active compound (such as BNT411 of the present disclosure and / or one or more additional therapeutic agents) to alleviate, ameliorate, arrest or eradicate (cure) a symptom or disease state.

[0104] Resistance to, failure to respond to, and / or recurrence from treatment with a compound of the present disclosure (such as BNT411 and / or one or more additional therapeutic agents) can be determined according to Response Evaluation Criteria in Solid Tumors; version 1.1 (RECIST Criteria v1.1). The RECIST Criteria are set forth in the following table (LD: longest dimension). [Table 3]

[0105] "Best overall response" is the best response recorded from the start of treatment to disease progression / recurrence (using the smallest measurement recorded after the start of treatment as the criterion for PD). Subjects with CR or PR are considered to be objective responders. Subjects with CR, PR or SD are considered to be in disease control. Subjects with NE are counted as non-responders. "Best overall response" is the best response recorded from the start of treatment to disease progression / recurrence (using the smallest measurement recorded after the start of treatment as the criterion for PD). Subjects with CR, PR or SD are considered to be in disease control. Subjects with NE are counted as non-responders.

[0106] "Duration of response (DOR)" applies only to subjects with a confirmed best overall response of CR or PR and is defined as the time from first documentation of an objective tumor response (CR or PR) to the date of first PD, or death from the underlying cancer.

[0107] "Progression-free survival (PFS)" is defined as the number of days from day 1 of cycle 1 to first documented progression or death from any cause.

[0108] "Overall survival (OS)" is defined as the number of days from day 1 of cycle 1 to death from any cause. If the subject is not known to have died, OS is censored at the last date the subject is known to be alive (at or before the cutoff date).

[0109] In the context of this disclosure, the term "therapeutic regimen" refers to a structured treatment plan designed to improve and maintain health.

[0110] The term "effective amount" or "therapeutically effective amount" refers to an amount effective at dosages and for periods of time necessary to achieve a desired therapeutic result. The therapeutically effective amount of a compound (such as BNT411, an antibody, or a fragment of an antibody) may vary depending on factors such as the disease state, age, sex, and weight of an individual, and the ability of the compound to induce a desired response in an individual. A therapeutically effective amount is also an amount in which any toxic or adverse effects of the compound are outweighed by the therapeutically beneficial effects. If the patient's response is inadequate at the initial dose, a higher dose (or a substantially higher dose achieved by a different, more localized route of administration) may be used. If a dose causes undesirable side effects in the patient, a lower dose (or a substantially lower dose achieved by a different, more localized route of administration) may be used.

[0111] As used herein, the term "cancer" includes diseases characterized by abnormally regulated cell growth, proliferation, differentiation, adhesion, and / or migration. "Cancer cells" refers to abnormal cells that grow by rapid and unregulated cell proliferation and continue to grow after the stimuli that initiated the new growth have ceased.

[0112] The term "cancer" according to the present disclosure includes leukemia, seminoma, melanoma, sarcoma, myeloma (such as multiple myeloma), teratoma, lymphoma (such as Hodgkin's lymphoma, non-Hodgkin's lymphoma), mesothelioma, neuroblastoma, glioma, myelodysplastic syndrome, rectal cancer, endometrial cancer, ureteral cancer, renal cancer, kidney cancer, urothelial cancer, bladder cancer, esophageal cancer, adrenal gland cancer, adrenal cortical carcinoma, thyroid cancer, blood cancer, skin cancer (Merkel cell carcinoma, Cancers of the brain, cervical cancer, malignant solitary fibrous tumor, intestinal cancer, liver cancer, thymoma and thymic cancer, colon cancer, stomach cancer, intestinal cancer, head and neck cancer, gastric cancer, digestive cancer, lymph node cancer, esophageal cancer, colorectal cancer, pancreatic cancer, ear, nose and throat (ENT) cancer, breast cancer, prostate cancer, penile cancer, uterine cancer, ovarian cancer and lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)) and metastases thereof. Examples thereof are lung carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, renal cell carcinoma, cervical carcinoma, or metastases of the above cancer types or tumors.

[0113] The term "cancer" according to the present disclosure also includes cancer metastasis. "Metastasis" means the spread of cancer cells from their original site to another part of the body. The formation of metastasis is a very complex process, which depends on the detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membrane to enter the body cavities and vessels, and then transport by blood, followed by invasion of the target organ. Finally, the growth of new tumors at the target site, i.e., secondary or metastatic tumors, depends on angiogenesis. Tumor metastasis often occurs even after removal of the primary tumor, since tumor cells or components remain and may develop metastatic potential. In some embodiments, the term "metastasis" according to the present disclosure relates to "distant metastasis", which refers to metastasis away from the primary tumor and regional lymph node system.

[0114] As used herein, terms such as "reduce," "inhibit," "prevent," and "negatively modulate" refer to the ability to cause an overall decrease in levels, for example, about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, or about 75% or more. The term "inhibit" or similar phrases includes complete or essentially complete inhibition, i.e., a reduction to zero or essentially zero.

[0115] In some embodiments, terms such as "increase" or "enhance" relate to an increase or enhancement of, for example, levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, or at least about 100%.

[0116] As used herein, "physiological pH" refers to a pH of about 7.4. In some embodiments, the physiological pH is 7.3 to 7.5. In some embodiments, the physiological pH is 7.35 to 7.45. In some embodiments, the physiological pH is 7.3, 7.35, 7.4, 7.45, or 7.5.

[0117] As used in this disclosure, "% w / v" refers to weight / volume percent, which is a unit of concentration that measures the amount of solute in grams (g) expressed as a percentage of the total volume of a solution in milliliters (mL).

[0118] As used in this disclosure, "wt. %" refers to weight percent, which is a unit of concentration measuring the amount of a substance in grams (g) expressed as a percentage of the total weight of the entire composition in grams (g).

[0119] The term "freezing" refers to the solidification of a liquid, usually accompanied by the removal of heat.

[0120] The term "lyophilizing" or "freeze-drying" refers to the lyophilization of a substance by freezing the substance and then reducing the surrounding pressure (e.g., less than 15 Pa, e.g., less than 10 Pa, less than 5 Pa, or less than 1 Pa) to allow the freezing medium in the substance to sublime directly from the solid phase to the gas phase. Thus, the terms "lyophilizing" and "freeze-drying" are used interchangeably herein.

[0121] The term "spray drying" refers to spray drying a substance by mixing a (heated) gas with an atomized (atomized) fluid in a vessel (spray dryer), where the solvent from the formed droplets evaporates, resulting in a dry powder.

[0122] The term "reconstitute" refers to adding a solvent, such as water, to a dried product to return it to a liquid state, such as its original liquid state.

[0123] The term "recombinant" in the context of this disclosure means "created through genetic engineering." In some embodiments, a "recombinant entity" in the context of this disclosure is not naturally occurring.

[0124] The term "naturally occurring" as used herein refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that exists in an organism (including viruses), can be isolated from a source in nature, and has not been intentionally modified by humans in a laboratory, is naturally occurring. The term "found in nature" means "existing in nature", and includes known objects as well as objects that have not yet been discovered and / or isolated from nature, but may be discovered and / or isolated from natural sources in the future.

[0125] As used herein, the terms "room temperature" and "ambient temperature" are used interchangeably herein and refer to a temperature of at least about 15° C., e.g., from about 15° C. to about 35° C., from about 15° C. to about 30° C., from about 15° C. to about 25° C., or from about 17° C. to about 22° C. Such temperatures include 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., and 22° C.

[0126] According to the present disclosure, the term "peptide" includes oligopeptides and polypeptides and refers to a substance that contains about 2 or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, about 16 or more, about 20 or more, and up to about 50, about 100, or about 150 consecutive amino acids linked together by peptide bonds. The term "protein" refers to larger peptides, particularly peptides having at least about 151 amino acids, although the terms "peptide" and "protein" are generally used synonymously herein.

[0127] The term "portion" refers to a fraction. With respect to a particular structure, such as an amino acid sequence or a protein, the term "portion" may refer to a contiguous or discontinuous fraction of said structure.

[0128] The terms "portion" and "fragment" are used interchangeably herein and refer to a contiguous element. For example, a portion of a structure, such as an amino acid sequence or a protein, refers to a contiguous element of said structure. When used in relation to a composition, the term "portion" means a portion of the composition. For example, a portion of a composition can be any portion between 0.1% and 99.9% (e.g., 0.1%, 0.5%, 1%, 5%, 10%, 50%, 90%, or 99%) of said composition.

[0129] With respect to an amino acid sequence (peptide or polypeptide), a "fragment" relates to a portion of the amino acid sequence, i.e. a sequence that represents an amino acid sequence truncated at the N-terminus and / or C-terminus. A C-terminally truncated fragment (N-terminal fragment) can be obtained, for example, by translation of a truncated open reading frame lacking the 3' end of the open reading frame. A N-terminally truncated fragment (C-terminal fragment) can be obtained, for example, by translation of a truncated open reading frame lacking the 5' end of the open reading frame, as long as the truncated open reading frame contains an initiation codon that serves to initiate translation. A fragment of an amino acid sequence comprises, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the amino acid sequence. A fragment of an amino acid sequence preferably comprises at least 6, in particular at least 8, at least 12, at least 15, at least 20, at least 30, at least 50 or at least 100 consecutive amino acids from the amino acid sequence.

[0130] According to the present disclosure, a portion or fragment of a peptide or polypeptide preferably has at least one functional property of the peptide or polypeptide from which it is derived. Such functional properties include pharmacological activity, interaction with other peptides or polypeptides, enzymatic activity, interaction with antibodies, and selective binding of nucleic acids. For example, a pharmacologically active fragment of a peptide or polypeptide has at least one of the pharmacological activities of the peptide or polypeptide from which it is derived. A portion or fragment of a peptide or polypeptide preferably comprises a sequence of at least 6, particularly at least 8, at least 10, at least 12, at least 15, at least 20, at least 30, or at least 50 consecutive amino acids of the peptide or polypeptide. A portion or fragment of a peptide or polypeptide preferably comprises a sequence of up to 8, particularly up to 10, up to 12, up to 15, up to 20, up to 30, or up to 55 consecutive amino acids of the peptide or polypeptide.

[0131] "Variant" as used herein with respect to an amino acid sequence (peptide or polypeptide) means an amino acid sequence that differs from a parent amino acid sequence by at least one amino acid (e.g., a different amino acid, or a modification of the same amino acid). The parent amino acid sequence can be a natural or wild-type (WT) amino acid sequence, or can be a modified form of the wild-type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, e.g., 1 to about 20 amino acid modifications compared to the parent, preferably 1 to about 10 or 1 to about 5 amino acid modifications.

[0132] By "wild-type" or "WT" or "native" herein is meant an amino acid sequence found in nature, including allelic variations. A wild-type amino acid sequence, peptide, or protein has an amino acid sequence that has not been intentionally modified.

[0133] In some embodiments, the degree of similarity, preferably identity, between a given amino acid sequence and an amino acid sequence that is a variant of said given amino acid sequence is at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the degree of similarity or identity is given for an amino acid region that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably given for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids, in some embodiments consecutive amino acids. In some embodiments, the degree of similarity or identity is given for the entire length of the reference amino acid sequence. Alignment to determine sequence similarity, preferably sequence identity, can be performed using tools known in the art, preferably using best sequence alignment, for example using Align, using standard settings, preferably EMBOSS::Needle, matrix:Blosum62, gap open 10.0, gap extension 0.5.

[0134] "Sequence similarity" refers to the percentage of amino acids that are identical or represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences refers to the percentage of amino acids that are identical between the sequences. "Sequence identity" between two nucleic acid sequences refers to the percentage of nucleotides that are identical between the sequences.

[0135] The terms "% identical" and "% identity" or similar terms are intended to refer in particular to the percentage of nucleotides or amino acids that are identical in optimal alignment between the sequences being compared.The percentage is purely statistical, and the difference between two sequences may be, but is not necessarily, randomly distributed over the entire length of the sequences being compared.The comparison of two sequences is usually carried out by comparing sequences over segments or "comparison windows" after optimal alignment to identify local regions of corresponding sequences. The optimal alignment for comparison can be performed manually or by using the local homology algorithm of Smith and Waterman, 1981, Ads App.Math.2,482, by using the local homology algorithm of Neddleman and Wunsch, 1970, J.Mol.Biol.48,443, by using the similarity search algorithm of Pearson and Lipman, 1988, Proc.Natl Acad.Sci.USA 88,2444, or by using computer programs using said algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA of Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, the percent identity of two sequences is determined by using the BLASTN or BLASTP algorithm available on the National Center for Biotechnology Information (NCBI) website (e.g., blast.ncbi.nlm.nih.gov / Blast.cgi). In some embodiments, the algorithm parameters used for the BLASTN algorithm on the NCBI website include: (i) expectation threshold set to 10; (ii) word size set to 28; (iii) maximum match within the query range set to 0; (iv) match / mismatch score set to 1, -2; (v) gap cost set to linear; and (vi) a filter for low complexity regions is used.In some embodiments, the algorithm parameters used for the BLASTP algorithm on the NCBI website include: (i) expectation threshold set to 10; (ii) word size set to 3; (iii) maximum match within the query range set to 0; (iv) matrix set to BLOSUM62; (v) gap costs set to presence: 11, extension: 1; and (vi) conditional composition score matrix adjustment.

[0136] The percent identity is obtained by determining the number of identical positions where the compared sequences match, dividing this number by the number of positions being compared (e.g., the number of positions in a reference sequence) and multiplying this result by 100.

[0137] In some embodiments, the degree of similarity or identity is given for a region that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the full length of the reference sequence. For example, if the reference amino acid sequence consists of 200 amino acid residues, the degree of identity is given for at least about 100, at least about 120, at least about 140, at least about 160, at least about 180 or about 200 amino acid residues, in some embodiments, consecutive amino acid residues. In some embodiments, the degree of similarity or identity is given for the full length of the reference sequence.

[0138] Homologous amino acid sequences, according to the present disclosure, exhibit an identity of at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, preferably at least 95%, at least 98 or at least 99% of the amino acid residues.

[0139] The amino acid sequence variants described herein can be readily prepared by one of skill in the art, for example, by recombinant DNA manipulation. The manipulation of DNA sequences to prepare peptides or polypeptides having substitutions, additions, insertions or deletions is described in detail, for example, in Sambrook et al. (1989). Furthermore, the peptides and amino acid variants described herein can be readily prepared using known peptide synthesis techniques, for example, by solid phase synthesis and similar methods.

[0140] In some embodiments, the fragment or variant of an amino acid sequence (peptide or polypeptide) is preferably a "functional fragment" or "functional variant". The term "functional fragment" or "functional variant" of an amino acid sequence relates to any fragment or variant that exhibits one or more functional properties identical or similar to those of the amino acid sequence from which it is derived, i.e., functionally equivalent. With respect to an antigen or antigen sequence, one particular function is one or more immunogenic activities exhibited by the amino acid sequence from which the fragment or variant is derived. The term "functional fragment" or "functional variant" as used herein refers in particular to a variant molecule or sequence that includes an amino acid sequence that is altered by one or more amino acids compared to the amino acid sequence of the parent molecule or sequence, yet still performs one or more of the functions of the parent molecule or sequence, e.g., is capable of inducing an immune response. In some embodiments, modification of the amino acid sequence of the parent molecule or sequence does not significantly affect or change the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced but still significantly present, for example, the immunogenicity of the functional variant may be at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the parent molecule or sequence, however, in other embodiments, the immunogenicity of the functional fragment or functional variant may be enhanced compared to the parent molecule or sequence.

[0141] An amino acid sequence (peptide or polypeptide) "derived from" a specified amino acid sequence (peptide or polypeptide) refers to the origin of the initial amino acid sequence. In some embodiments, an amino acid sequence derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical, or homologous to the particular sequence or a fragment thereof. An amino acid sequence derived from a particular amino acid sequence may be a variant of the particular sequence or a fragment thereof. For example, it will be understood by those skilled in the art that antigens suitable for use herein may be modified to differ in sequence from the naturally occurring or native sequence from which they are derived while retaining the desired activity of the native sequence.

[0142] In some embodiments, "isolated" means modified or removed from the natural state. For example, a nucleic acid, peptide, or polypeptide that is naturally present in a living animal is not "isolated," but the same nucleic acid, peptide, or polypeptide that is partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid, peptide, or polypeptide may exist in a substantially purified form, or may exist in a non-native environment, such as, for example, a host cell.

[0143] The term "genetic modification" or simply "modification" includes the transfection of a cell with a nucleic acid.

[0144] The term "transfection" refers to the introduction of a nucleic acid, particularly RNA, into a cell. For the purposes of this disclosure, the term "transfection" also includes the introduction of a nucleic acid into a cell or the uptake of a nucleic acid by such a cell, and the cell may be present in a subject, e.g., a patient. Thus, according to the present disclosure, cells for transfection of a nucleic acid as described herein may be present in vitro or in vivo, e.g., the cell may form part of an organ, tissue and / or organism of a patient. According to the present disclosure, transfection may be transient or stable. In some applications of transfection, it is sufficient that the transfected genetic material is only expressed transiently. RNA may be transfected into a cell to transiently express its encoded protein. Since the nucleic acid introduced in the transfection process is not usually integrated into the nuclear genome, the foreign nucleic acid is diluted or degraded by mitosis. Cells that allow episomal amplification of the nucleic acid greatly reduce the dilution rate. If it is desired that the transfected nucleic acid actually remains in the genome of the cell and its daughter cells, stable transfection must occur. Such stable transfection can be achieved by using a virus-based or transposon-based system for transfection.Generally, the nucleic acid encoding the antigen is transiently transfected into the cell.RNA can be transfected into the cell to transiently express its encoded peptide or polypeptide.

[0145] According to the present disclosure, an analog of a peptide or polypeptide is a modified form of said peptide or polypeptide from which it is derived, and has at least one functional property of said peptide or polypeptide. For example, a pharmacologically active analog of a peptide or polypeptide has at least one pharmacological activity of the peptide or polypeptide from which it is derived. Such modifications include any chemical modification, including single or multiple substitutions, deletions and / or additions of any molecule associated with the peptide or polypeptide, such as carbohydrates, lipids and / or peptides or polypeptides. In some embodiments, an "analog" of a peptide or polypeptide includes modified forms resulting from glycosylation, acetylation, phosphorylation, amidation, palmitoylation, myristoylation, isoprenylation, lipidation, alkylation, derivatization, introduction of a protecting / blocking group, proteolytic cleavage, or binding to an antibody or another cellular ligand. The term "analog" also covers all functional chemical equivalents of said peptides and polypeptides.

[0146] As used herein, "activation" or "stimulation" refers to the state of immune effector cells, such as T cells, that are stimulated sufficiently to induce detectable cell proliferation. Activation can also involve the initiation of signal transduction pathways, the induction of cytokine production, and detectable effector functions. The term "activated immune effector cells" refers, among other things, to immune effector cells that undergo cell division.

[0147] The term "priming" refers to the process by which an immune effector cell, such as a T cell, first contacts its specific antigen, resulting in differentiation into an effector cell, such as an effector T cell.

[0148] The term "clonal expansion" or "expansion" refers to the process by which a particular entity increases. In the context of the present disclosure, the term is preferably used in relation to an immunological response in which immune effector cells are stimulated by an antigen, proliferate, and the specific immune effector cells that recognize said antigen are amplified. Preferably, clonal expansion results in differentiation of immune effector cells.

[0149] An "antigen" according to the present disclosure encompasses any substance that induces an immune response and / or any substance against which an immune mechanism, such as an immune response or a cellular response, is directed. It also includes situations in which an immune response or immune mechanism is directed against one or more antigenic peptides, particularly when the antigen is processed into an antigenic peptide and presented in association with an MHC molecule. In particular, an "antigen" relates to any substance, preferably a peptide or polypeptide, that reacts specifically with an antibody or a T lymphocyte (T cell). According to the present disclosure, the term "antigen" includes any molecule that contains at least one epitope, such as a T cell epitope. Preferably, an antigen in the context of the present disclosure is a molecule that, optionally after processing, preferably induces an immune response specific to the antigen (including cells expressing the antigen). In some embodiments, the antigen is a disease-related antigen, such as a tumor antigen, a viral antigen, or a bacterial antigen, or an epitope derived from such an antigen.

[0150] According to the present disclosure, any suitable antigen that is a candidate for immune response can be used, and the immune response can be both humoral and cellular immune response. In the context of some embodiments of the present disclosure, the antigen is preferably presented by cells, preferably antigen-presenting cells, in association with MHC molecules, resulting in an immune response against the antigen. The antigen is preferably a product that corresponds to or is derived from a naturally occurring antigen. Such naturally occurring antigens may include or be derived from allergens, viruses, bacteria, fungi, parasites and other infectious agents and pathogens, or the antigen may be a tumor antigen. According to the present disclosure, the antigen may correspond to a naturally occurring product, such as a viral protein, or a part thereof.

[0151] The term "disease-associated antigen" is used in its broadest sense to refer to any antigen associated with a disease. A disease-associated antigen is a molecule that contains an epitope that stimulates the host's immune system to generate a cellular antigen-specific immune response and / or a humoral antibody response against the disease. Disease-associated antigens include pathogen-associated antigens, i.e., antigens associated with infection by microorganisms, typically microbial antigens (such as bacterial or viral antigens), or antigens associated with cancer, typically tumors, e.g., tumor antigens.

[0152] In some preferred embodiments, the antigen is a tumor antigen, i.e., a part of a tumor cell, particularly one that is present mainly intracellularly or as a surface antigen of the tumor cell. In another embodiment, the antigen is a pathogen-associated antigen, i.e., an antigen derived from a pathogen, such as an antigen derived from a virus, a bacterium, a single-cell organism, or a parasite, e.g., a viral antigen, such as a viral ribonucleoprotein or coat protein. In particular, the antigen is capable of modulating, in particular, cells of the immune system, preferably CD4, in particular through modulating the activity of T-cell receptors. + and CD8 + It should be presented by MHC molecules resulting in lymphocyte activation.

[0153] The term "tumor antigen" refers to a component of a cancer cell that may originate from the cytoplasm, cell surface or cell nucleus. In particular, the term refers to an antigen that is produced intracellularly or as a surface antigen on a tumor cell. For example, tumor antigens include carcinoembryonic antigen, α1-fetoprotein, isoferritin, and fetal sulfoglycoprotein, α2-H-ferroprotein and γ-fetoprotein, as well as various viral tumor antigens. According to the present disclosure, tumor antigens preferably include any antigen that is characteristic of a tumor or cancer and tumor or cancer cells in terms of type and / or expression level.

[0154] The term "viral antigen" refers to any viral component that has antigenic properties, i.e., is capable of eliciting an immune response in an individual. A viral antigen can be a viral ribonucleoprotein or an envelope protein.

[0155] The term "bacterial antigen" refers to any bacterial component that has antigenic properties, i.e., is capable of eliciting an immune response in an individual. Bacterial antigens may be derived from the bacterial cell wall or cytoplasmic membrane.

[0156] The term "epitope" refers to an antigenic determinant in a molecule such as an antigen, i.e., a portion or fragment of a molecule that is recognized by the immune system, e.g., by antibodies, T cells or B cells, especially when presented in the context of an MHC molecule. In some embodiments, "epitope" refers to a protein determinant that can specifically bind to an antibody. Epitopes usually consist of surface groups of molecules, such as amino acids or sugar side chains, and usually have specific three-dimensional structural features and specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that binding to the former is lost in the presence of denaturing solvents, but not to the latter. Epitopes may include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding, e.g., amino acid residues that are effectively blocked or covered by the specific antigen-binding peptide (in other words, the amino acid residues are within the footprint of the specific antigen-binding peptide).

[0157] An epitope of a protein preferably comprises a continuous or discontinuous portion of said protein and is preferably about 5 to about 100, preferably about 5 to about 50, more preferably about 8 to about 0, and most preferably about 10 to about 25 amino acids in length, for example, the epitope may be preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. It is particularly preferred that an epitope in the context of the present disclosure is a T cell epitope.

[0158] Terms such as "epitope", "fragment of an antigen", "immunogenic peptide" and "antigenic peptide" are used interchangeably herein and preferably relate to an incomplete form of an antigen that can induce an immune response against the antigen or against a cell that expresses or contains the antigen and preferably presents the antigen. Preferably, these terms relate to an immunogenic portion of an antigen. Preferably, an immunogenic portion of an antigen is a portion of the antigen that is recognized (i.e. specifically bound) by a T cell receptor, especially when presented in the context of an MHC molecule. Certain preferred immunogenic portions bind to MHC class I or class II molecules. The term "epitope" refers to a portion or fragment of a molecule such as an antigen that is recognized by the immune system. For example, an epitope can be recognized by a T cell, a B cell or an antibody. An epitope of an antigen may comprise a continuous or discontinuous portion of the antigen and may be about 5 to about 100, e.g., about 5 to about 50, more preferably about 8 to about 30, and most preferably about 8 to about 25 amino acids in length, e.g., an epitope may be preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. In some embodiments, an epitope is about 10 to about 25 amino acids in length. The term "epitope" includes T cell epitopes.

[0159] The term "T cell epitope" refers to a portion or fragment of a protein that is recognized by a T cell when presented in association with an MHC molecule. The term "major histocompatibility complex" and the abbreviation "MHC" refer to a complex of genes that includes MHC class I and MHC class II molecules and is present in every vertebrate. MHC proteins or molecules are important for signaling between lymphocytes and antigen-presenting or diseased cells in an immune response, and MHC proteins or molecules bind peptide epitopes and present them for recognition by the T cell receptor on T cells. Proteins encoded by MHC are expressed on the surface of cells and present both self antigens (peptide fragments from the cell itself) and non-self antigens (e.g., fragments of invading microorganisms) to T cells. For class I MHC / peptide complexes, the bound peptide is typically about 8 to about 10 amino acids in length, although longer or shorter peptides can be effective. In the case of class II MHC / peptide complexes, the binding peptides are typically from about 10 to about 25 amino acids in length, particularly from about 13 to about 18 amino acids in length, although longer and shorter peptides may also be effective.

[0160] A peptide or polypeptide antigen can be 2-100 amino acids in length, including, for example, 5 amino acids, 10 amino acids, 15 amino acids, 20 amino acids, 25 amino acids, 30 amino acids, 35 amino acids, 40 amino acids, 45 amino acids, or 50 amino acids. In some embodiments, a peptide can be more than 50 amino acids. In some embodiments, a peptide can be more than 100 amino acids.

[0161] A peptide or polypeptide antigen can be any peptide or polypeptide that is capable of inducing or increasing the ability of the immune system to generate antibody and T cell responses against the peptide or polypeptide.

[0162] In some embodiments, the vaccine antigen, i.e. the antigen whose inoculation into a subject induces an immune response, is recognized by immune effector cells. Preferably, when the vaccine antigen is recognized by immune effector cells, in the presence of an appropriate co-stimulatory signal, it can induce the stimulation, priming and / or expansion of immune effector cells bearing an antigen receptor that recognizes the vaccine antigen. In the context of the embodiments of the present disclosure, the vaccine antigen is preferably presented or present on the surface of a cell, preferably on the surface of an antigen-presenting cell. In some embodiments, the antigen is presented by a diseased cell (such as a tumor cell or an infected cell). In some embodiments, the antigen receptor is a TCR that binds to an epitope of the antigen presented in the context of MHC. In some embodiments, the binding of the TCR, when expressed by and / or present on a T cell, to an antigen presented by a cell, such as an antigen-presenting cell, results in the stimulation, priming and / or expansion of said T cell. In some embodiments, binding of the TCR when expressed by and / or present on a T cell to an antigen presented on a diseased cell results in cytolysis and / or apoptosis of the diseased cell, with the T cell preferably releasing cytotoxic factors such as perforin and granzymes.

[0163] In some embodiments, the antigen receptor is an antibody or a B cell receptor that binds to an epitope in the antigen. In some embodiments, the antibody or B cell receptor binds to a natural epitope of the antigen.

[0164] The term "expressed on the cell surface" or "associated with the cell surface" means that a molecule, such as an antigen, is located in association with the plasma membrane of a cell, with at least a portion of the molecule facing the extracellular space of said cell and accessible from the outside of said cell, for example by an antibody located on the outside of said cell. In this context, a portion is preferably at least 4, preferably at least 8, preferably at least 12, more preferably at least 20 amino acids. The association may be direct or indirect. For example, the association may be by one or more transmembrane domains, one or more lipid anchors, or by interaction with any other protein, lipid, saccharide, or other structure that may be found on the outer leaflet of the plasma membrane of the cell. For example, a molecule associated with the surface of a cell may be a transmembrane protein with an extracellular portion, or may be a protein that associates with the surface of a cell by interacting with another protein that is a transmembrane protein.

[0165] "Cell surface" or "surface of a cell" is used according to its normal meaning in the art and thus includes the outside of a cell that is accessible to binding by proteins and other molecules. An antigen is expressed on the surface of a cell if it is located on the surface of the cell and is accessible to binding, for example, by an antigen-specific antibody added to the cell.

[0166] The term "extracellular portion" or "exodomain" in the context of the present disclosure refers to a part of a molecule, such as a protein, that faces the extracellular space of a cell and is preferably accessible from the outside of said cell, for example by binding to a molecule, such as an antibody, that is located on the outside of said cell. Preferably, the term refers to one or more extracellular loops or domains or fragments thereof.

[0167] The terms "T cell" and "T lymphocyte" are used interchangeably herein and refer to T helper cells (CD4 + Cytotoxic T cells (CTL, CD8 +The term "antigen-specific T cell" or similar terms refers to a T cell that recognizes the antigen that the T cell targets, particularly when presented on the surface of an antigen-presenting cell or a diseased cell such as a cancer cell in association with an MHC molecule, and preferably exerts the effector function of the T cell. A T cell is considered specific for an antigen if it kills a target cell expressing the antigen. T cell specificity can be assessed using any of a variety of standard techniques, for example, in a chromium release assay or proliferation assay. Alternatively, the synthesis of lymphokines (such as interferon gamma) can be measured.

[0168] The term "target" refers to an agent, such as a cell or tissue, that is the target of an immune response, such as a cellular immune response. Targets include cells that present an antigen or an antigen epitope, i.e., a peptide fragment derived from an antigen. In some embodiments, a target cell is a cell that expresses an antigen, and preferably presents said antigen with class I MHC.

[0169] "Antigen processing" refers to the breakdown of an antigen into processing products that are fragments of the antigen (e.g., breakdown of proteins into peptides), and the association (e.g., by binding) of one or more of these fragments with an MHC molecule for presentation to a specific T cell by a cell, preferably an antigen-presenting cell.

[0170] "Antigen-responsive CTL" refers to a CD8 CTL that is responsive to an antigen or a peptide derived from the antigen, which is presented together with class I MHC on the surface of an antigen-presenting cell. + It means T cells.

[0171] According to the present disclosure, CTL responsiveness may include sustained calcium flux, cell division, production of cytokines such as IFN-γ and TNF-α, upregulation of activation markers such as CD44 and CD69, and specific cytolytic killing of target cells expressing tumor antigens. CTL responsiveness may also be determined using artificial reporters that pinpoint CTL responsiveness.

[0172] The terms "immune response" and "immune reaction" are used interchangeably herein in their conventional sense and refer to an integrated body response to an antigen, preferably a cellular immune response, a humoral immune response, or both. According to the present disclosure, the terms "immune response to" or "immune response against" in reference to an agent such as an antigen, cell, or tissue, refer to an immune response such as a cellular response to the agent. An immune response can be detected by the expression of antibodies against one or more antigens, and the expression of antigen-specific T lymphocytes, preferably CD4+, which can be detected in various in vitro proliferation or cytokine production tests. + and CD8 + T lymphocytes, more preferably CD8 + The reaction may include one or more responses selected from the group consisting of: T lymphocyte expansion.

[0173] The terms "induce an immune response" and "elicit an immune response" and similar terms in the context of the present disclosure refer to the induction of an immune response, preferably a cellular immune response, a humoral immune response, or both. The immune response can be protective / preventive / prophylactic and / or therapeutic. The immune response can be directed against any immunogen or antigen or antigenic peptide, preferably a tumor-associated antigen or a pathogen-associated antigen (e.g., an antigen of a virus (such as influenza virus (A, B, or C), CMV, or RSV)). "Induce" in this context can mean that there was no immune response against a particular antigen or pathogen before induction, but it can also mean that there is some immune response against a particular antigen or pathogen before induction, and that said immune response is enhanced after induction. Thus, "induce an immune response" in this context also includes "enhance an immune response". Preferably, after inducing an immune response in an individual, said individual is protected from developing a disease, such as an infectious disease or a cancerous disease, or the disease state is ameliorated by inducing an immune response.

[0174] "Cellular immune response", "cellular response", "cell-mediated immunity" or similar terms are meant to include a cellular response to cells characterized by expression of antigens and / or presentation of antigens by class I or class II MHC. Cellular responses involve cells called T cells or T lymphocytes that act as either "helpers" or "killers". Helper T cells (CD4 + T cells, also called killer cells, play a central role by regulating the immune response and are involved in the production of immune cells that are involved in immune responses. + T cells or CTLs) kill cells, including diseased cells.

[0175] The term "humoral immune response" refers to the process in living organisms whereby antibodies are produced in response to agents and organisms, ultimately neutralizing and / or eliminating them. The specificity of the antibody response is mediated by T cells and / or B cells through membrane-bound receptors that bind to a monospecific antigen. After binding of the appropriate antigen and receiving a variety of other activation signals, B lymphocytes divide, producing memory B cells and antibody-secreting plasma cell clones, each of which produces antibodies that recognize the same antigenic epitope recognized by its antigen receptor. Memory B lymphocytes remain dormant until subsequently activated by their specific antigen. These lymphocytes provide the cellular basis of memory and the augmentation of the antibody response that occurs upon reexposure to the specific antigen.

[0176] The terms "vaccination" and "immunization" refer to the process of treating an individual for therapeutic or prophylactic reasons and, as described herein, relate to a procedure in which one or more immunogens or antigens or derivatives thereof, for example in the form of RNA encoding same, are administered to an individual to stimulate an immune response against said one or more immunogens or antigens, or against cells characterized by the presentation of said one or more immunogens or antigens.

[0177] By "cells characterized by antigen presentation" or "cells presenting antigen" or "MHC molecules presenting antigens on the surface of antigen-presenting cells" or similar expressions is meant cells such as diseased cells, in particular tumor cells or infected cells, or antigen-presenting cells which present antigens or antigenic peptides, either directly or after processing, in association with MHC molecules, preferably MHC class I and / or MHC class II molecules, most preferably MHC class I molecules.

[0178] In the context of the present disclosure, the term "transcription" refers to the process by which the genetic code in a DNA sequence is transcribed into RNA, particularly mRNA, which can then be translated into a peptide or polypeptide.

[0179] The term "expression" as used herein is defined as the transcription and / or translation of a particular nucleotide sequence. With respect to RNA, the term "expression" or "translation" refers to the process in the ribosomes of a cell in which a chain of mRNA directs the assembly of a sequence of amino acids to create a peptide or polypeptide.

[0180] As used herein, the term "optional" or "optionally" means that the subsequently described event, circumstance, or condition may or may not occur, and that the description includes cases where said event, circumstance, or condition occurs and cases where it does not occur.

[0181] As used herein, "endogenous" refers to any substance that is produced from or within an organism, cell, tissue or system.

[0182] As used herein, the terms "linked," "fused," or "fusion" are used interchangeably. These terms refer to the association of two or more elements or components or domains.

[0183] The term "disease" (also referred to herein as "disorder") refers to an abnormal condition that affects an individual's body. A disease is often interpreted as a medical condition associated with certain symptoms and signs. A disease can be caused by an externally derived agent, such as an infection, or an internal malfunction, such as an autoimmune disease. In humans, "disease" is often used more broadly to refer to any condition that causes pain, dysfunction, suffering, social problems, or death to the affected individual, or similar problems to those who come into contact with the individual. In this broader sense, disease sometimes includes damage, incapacity, disability, syndrome, infection, single symptoms, deviant behavior, and atypical changes in structure and function, although in other contexts and for other purposes, these may be considered distinct categories. Diseases usually affect individuals not only physically but also emotionally, as suffering from and living with many diseases can change one's outlook on life and personality. One example of a disease is a tumor or cancer.

[0184] The term "therapeutic treatment" refers to any treatment that improves the health status and / or extends (increases) the life span of an individual. Said treatment may eliminate the disease in an individual, halt or delay the onset of the disease in an individual, inhibit or delay the onset of the disease in an individual, reduce the frequency or severity of symptoms in an individual, and / or reduce recurrence in an individual who currently has or has previously had the disease.

[0185] The term "prophylactic treatment" or "preventive treatment" refers to any treatment aimed at preventing the occurrence of a disease in an individual. The terms "prophylactic treatment" or "preventive treatment" are used interchangeably herein. Similarly, the term "prophylactic method" in the context of disease progression, such as tumor or cancer progression, refers to any method aimed at preventing the disease from progressing in an individual.

[0186] The terms "individual" and "subject" are used interchangeably herein. These terms refer to a human or another mammal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate), or any other non-mammalian, including bird (chicken), fish, or any other animal species, that may be affected or susceptible to a disease or disorder (e.g., cancer, infectious disease), but may or may not have a disease or disorder, or may require preventive intervention such as vaccination, or may have a need for intervention such as protein supplementation. In many embodiments, the individual is a human. Unless otherwise specified, the terms "individual" and "subject" do not denote a particular age, and thus encompass adults, elderly people, children, and newborns. In an embodiment of the present disclosure, an "individual" or "subject" is a "patient."

[0187] The term "patient" refers to an individual or subject for treatment, particularly an affected individual or subject, especially an affected human.

[0188] The medical preparations described herein, particularly the kits, may include instruction materials or instructions. As used herein, "instruction materials" or "instructions" include publications, records, drawings, or any other medium of expression that can be used to convey the usefulness of the compositions and methods of the present disclosure. The instruction materials of the kits of the present disclosure may be, for example, attached to a container containing the compositions / formulations of the present disclosure, or shipped together with a container containing the compositions / formulations. Alternatively, the instruction materials may be shipped separately from the container, with the intention that the instruction materials and the composition are used in conjunction by the recipient.

[0189] Prodrugs of certain compounds described herein are compounds that undergo chemical conversion under physiological conditions upon administration to an individual to provide the specific compound. Furthermore, prodrugs can be converted to the specific compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the specific compound when, for example, placed in a transdermal patch reservoir with appropriate enzymes or chemical reagents. Exemplary prodrugs are in vivo hydrolyzable esters (using alcohol or carboxy groups contained in the specific compound) or amides (using amino or carboxy groups contained in the specific compound). Specifically, any amino group contained in the specific compound and carrying at least one hydrogen atom can be converted to a prodrug form. Exemplary N-prodrug forms include carbamates, Mannich bases, enamines, and enaminones.

[0190] In this specification, the structural formula of a compound may represent a specific isomer of said compound. However, it should be understood that the present disclosure includes all isomers and isomeric mixtures, such as structurally occurring geometric isomers, optical isomers based on asymmetric carbons, stereoisomers, tautomers, etc., and is not limited to the description of the formula. Furthermore, in this specification, the structural formula of a compound may represent a specific salt and / or solvate of said compound. However, it should be understood that the present disclosure includes all salts (e.g., pharma- ceutically acceptable salts) and solvates (e.g., hydrates), and is not limited to the description of a specific salt and / or solvate.

[0191] "Isomers" are compounds that have the same molecular formula but differ in structure ("structural isomers") or in the geometric (spatial) arrangement of functional groups and / or atoms ("stereoisomers"). "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A "racemic mixture" or "racemate" contains a pair of equal amounts of enantiomers and is designated by the prefix (±). "Diastereomers" are stereoisomers that are non-superimposable and are not mirror images of each other. "Tautomers" are structural isomers of the same chemical substance that, even when pure, spontaneously and reversibly interconvert due to the migration of individual atoms or groups of atoms; i.e., tautomers are in dynamic chemical equilibrium with each other. One example of a tautomer is a keto-enol tautomer. "Conformers" are stereoisomers that can formally be interconverted by merely rotation about a single bond and include in particular those resulting in different three-dimensional configurations of (hetero)cyclic rings, such as the cyclohexane chair, half-chair, boat, and twist-boat forms.

[0192] The term "solvate" as used herein refers to an addition complex of a material dissolved in a solvent (e.g., an organic solvent (e.g., an aliphatic alcohol (e.g., methanol, ethanol, n-propanol, isopropanol, etc.), acetone, acetonitrile, ether, dimethylsulfoxide (DMSO), etc.), water, or a mixture of two or more of these liquids), which addition complex exists in crystalline or mixed crystal form. The amount of solvent in the addition complex may be stoichiometric or non-stoichiometric. A "hydrate" is a solvate where the solvent is water.

[0193] In an isotopically labeled compound, one or more atoms are replaced by a corresponding atom having the same number of protons but a different number of neutrons. For example, a hydrogen atom may be replaced by a deuterium atom or a tritium atom. Exemplary isotopes that can be used in the present disclosure include deuterium, tritium, 11 C. 13 C. 14 C. 15 N, 18 F, 32 P, 32 S,35 S, 36 Cl and 125 Contains I.

[0194] The term "dose" as used herein generally refers to a "dosage" in terms of the amount of compound (such as BNT411) taken per administration, ie, per session.

[0195] An "adverse event" or AE is any untoward and unintended sign (including abnormal laboratory findings), symptom, or disease that is temporally associated with the use of a medical treatment or procedure, which may or may not be considered related to the medical treatment or procedure. In some embodiments, AEs are classified using the Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (Published: August 9, 2006).

[0196] Aspects and embodiments of the present disclosure In a first aspect, the present disclosure provides BNT411 (including a pharma- ceutically acceptable solvate or salt thereof) for use in a method for reducing or preventing tumor progression or treating cancer in a subject, the method comprising administering a suitable amount of BNT411 to the subject.

[0197] As demonstrated in the present disclosure, upon exposure to BNT411, higher amounts of IFNα were induced at much lower concentrations than comparable imidazoquinolines imiquimod, resiquimod and 852A. See, e.g., FIG. 1. Up to two orders of magnitude higher concentrations of BNT411 are required to induce secretion of pyrogenic proinflammatory cytokines (e.g., TNFα). See, e.g., FIG. 7. Taken together, this stronger activity and superior selectivity indicate higher potency and a broader therapeutic window of systemically administered BNT411. In vitro and in vivo studies with BNT411 in mouse models demonstrate the release of high levels of therapeutically relevant IFNα; see, e.g., FIG. 2. Furthermore, the present disclosure demonstrates that in mouse tumor models, BNT411 exhibits antitumor activity both as a monotherapy and in combination with standard therapies (e.g., in combination with platinum-based chemotherapeutic agents or checkpoint inhibitors). See, e.g., FIG. 4-FIG. 6. Furthermore, the inventors show for the first time that BNT411 (i) has an acceptable safety profile at several doses tested in human patients, (ii) induces a substantial cytokine response in human patients dominated by type I IFN, and (iii) does not result in substantial increases in proinflammatory cytokines such as tumor necrosis factor alpha (TNFα), and optionally TNFα and IL-6, at least at some therapeutically important doses. See, e.g., Examples 6 and 7 and Figure 8 of the present application.

[0198] Compound BNT411 The compound BNT411 has the formula: [ka] or a pharma- ceutically acceptable solvate and / or salt thereof.

[0199] In some embodiments, BNT411 is a solvate. In some embodiments, the solvate of BNT411 is selected from the group consisting of a hydrate and a dimethylsulfoxide solvate. In some embodiments, the solvate of BNT411 is a hydrate. In some embodiments, the solvate of BNT411 is a dimethylsulfoxide solvate.

[0200] In some embodiments, the BNT411 is anhydrous.

[0201] BNT411 is a selective TLR7 agonist. Signaling through TLR7 initiates a cascade of effects that result in a series of innate and adaptive immune mechanisms. In some embodiments, TLR7 engagement on plasmacytoid dendritic cells (pDCs) recruits MyD88, interferon regulatory factor 7 and NF-κB, which induces the secretion of IFNa and proinflammatory cytokines, maturation of antigen-presenting cells, and upregulation of co-stimulatory factors (CD80 / CD86) (see, for example, FIG. 3 of this disclosure; Gilliet et al. Nat Rev Immunol. 2008; 8:594-606; Swiecki and Colonna. Nat Rev Immunol. 2015; 15(8):471-485). IFNa is considered to be a key cytokine of TLR7 activation that promotes antitumor effects through multifaceted mechanisms (direct mediation of tumor cell death; antiangiogenesis; inhibition of suppressive regulatory T cells; activation of immune cells, Th1 response) (Smits et al., Oncologist. 2008; 13(8): 859-75). Furthermore, TLR7-induced maturation of pDCs into antigen-presenting cells upregulates the processing and (cross-)presentation of antigens released from dying tumor cells. Taken together, the concomitant occurrence of IFNa secretion and antigen (cross-)presentation promotes efficient priming and activation of antigen-specific CD4 and CD8 T cells and the expansion of cytotoxic T lymphocytes (CTLs). These CTLs migrate into tumor tissues, recognize tumor-specific antigens, and lyse tumor cells (Markov et al., Acta Naturae. 2016; 8(3): 17-30). Furthermore, TLR7 signaling promotes a strong innate immune response. As an example, IFNa secreted by pDCs activates natural killer (NK) cells, which enhances their cytotoxic potential against major histocompatibility complex (MHC)-deficient targets (Wiedemann et al., Oncoimmunology. 2016;5(7):e1189051).Furthermore, a decrease in the suppressive indicators of the tumor microenvironment is observed, as the frequency of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) is reduced and repolarization of tumor-associated macrophages is induced (Williams et al., NPJ Breast Cancer. 2016;2.pii:15025).

[0202] TLR7 ligands of the imidazoquinoline family, such as imiquimod, resiquimod or 852A, have been widely tested as immunotherapeutic agents. Although strong antitumor effects have been observed in animal models, only imiquimod has been approved for human use so far. Repeated iv administration of imiquimod at systemically effective IFNα-inducing dose levels is associated with dose-limiting adverse reactions (Witt et al., Cancer Research. 1993;53,5176-80; Holldack, Drug Discov Today. 2014;Apr;19(4):379-82). As a result, imiquimod is only registered for topical use in localized diseases such as basal cell carcinoma, genital warts and bladder cancer (Edwards, J Am Acad Dermatol. 2000; Jul; 43(1 Pt 2):S12-7; Spencer, Dermatol Surg. 2006; Jan; 32(1):63-9; Stanley, Clin Exp Dermatol. 2002; Oct; 27(7):571-7; Vacchelli et al., Oncoimmunology. 2012; 1(6):894-907). Similarly, repeated dosing regimens of resiquimod and 852A are poorly tolerated, limiting the clinical use of these compounds to the treatment of localized disease (Rook et al., Blood. 2015;17;126(12):1452-6; Sabado et al., Cancer Immunol Res. 2015;3(3):278-87; Geller et al., Cancer Immunol. Immunother. 2010;59:1877-84).

[0203] The extensive data on the potent antitumor activity of TLR7 agonists against animal cancer models is in stark contrast to the limited clinical efficacy of systemic TLR7 agonists observed so far. Without being bound by any theory, the reasons could be a combination of i) dose-limiting toxicity due to the release of a broad range of proinflammatory cytokines, ii) limited IFNa release due to low agonist potency, iii) pDC depletion due to short dosing intervals, and iv) the use of TLR7 agonists in monotherapy, whereas combination therapy is predicted to have greater efficacy as defined by the underlying mode of action.

[0204] The unfavorable safety profile of other TLR7 agonists may be due to the release of a broader set of proinflammatory cytokines in addition to the intended type I IFN induction (Gorden et al., J Immunol. 2005 Feb 1; 174(3): 1259-68; Hamm et al., J Immunotoxicol. 2009; Dec; 6(4): 257-65). The induction of a broader set of proinflammatory cytokines beyond IFNa is a known challenge for TLR7 agonists and is hypothesized to be related to TLR8 coactivation. To optimize the safety profile and increase the therapeutic window, BNT411 was developed, which selectively binds to TLR7.

[0205] As shown in this application, BNT411 primarily induces IFNa release at the doses tested. In addition to this improved cytokine profile, more IFNa is secreted than other TLR7 agonists, such as resiquimod. This optimized cytokine profile and increased efficacy provide a broad therapeutic window and result in a more favorable risk-benefit profile, as supported by the clinical safety data presented herein. See, for example, Example 7.

[0206] In some embodiments, the effect of TLR7 engagement by BNT411 results in immune responses that may synergize and complement current therapeutic regimens. For example, when tumor antigens are released via radiation / chemotherapy-induced cell death, pDC activation triggered by TLR7 may enhance the priming and expansion of antigen-specific cytotoxic T lymphocytes (CTLs). However, checkpoint blockade may counteract the immunosuppressive signals and avoid the exhaustion of CTLs working together with the changes in the tumor microenvironment (TME) induced by the downstream effects of TLR7 activation. As shown in this application (see Examples 3-5), BNT411 was tested in a syngeneic subcutaneous mouse CT-26 tumor model. BNT411 as a single agent was shown to cause tumor growth delay and increase the frequency of T cells specific for the gp70 antigen present on CT-26 tumor cells, indicating that adaptive immunity contributes to the antitumor effect. Furthermore, combining BNT411 with oxaliplatin had an even greater effect on tumor growth delay.

[0207] In some embodiments, the compound BNT411 is administered in an appropriate amount, i.e., for example, the amount of compound BNT411 administered in each dose and / or treatment cycle, capable of inducing intracellular signaling upon binding to TLR7 expressed on cells, particularly plasmacytoid dendritic cells (pDCs).

[0208] In some embodiments, the appropriate amount provides one or more of the following: Induction of secretion of IFNa and optionally IP-10 from cells (specifically blood cells, especially pDC); · recruiting MyD88, interferon regulatory factor 7 (IRF7) and / or NF-κB; Induction of a cytokine profile dominated by type I IFNs; · inducing maturation of pDCs into APCs, preferably thereby upregulating the processing and (cross-)presentation of antigens released from dying tumor cells; Activation of natural killer (NK) cells (specifically, by IFNa secreted by cells such as pDC).

[0209] In some embodiments, the appropriate amount induces secretion of IFNa from cells (particularly blood cells, particularly pDCs). In some embodiments, the amount of IFNa secreted from cells (particularly blood cells, particularly pDCs) is increased compared to control cells (particularly cells not treated with BNT411). In some embodiments, the increase in secreted IFNa is at least 10-fold (such as at least 20-fold, at least 30-fold, at least 40-fold, or at least 50-fold) compared to control cells.

[0210] In some embodiments, the appropriate amount induces secretion of IFNa and IP-10 from cells (particularly blood cells, particularly pDCs). In some embodiments, the amount of IFNa and IP-10 secreted from cells (particularly blood cells, particularly pDCs) is increased compared to control cells (particularly cells not treated with BNT411). In some embodiments, the increase in secreted IFNa is at least 10-fold (such as at least 20-fold, at least 30-fold, at least 40-fold, or at least 50-fold) compared to control cells, and / or the increase in secreted IP-10 is at least 10-fold (such as at least 20-fold, at least 30-fold, at least 40-fold, or at least 50-fold) compared to control cells. In some embodiments, the increase in secreted IFNa and secreted IP-10 is each at least 10-fold (such as at least 20-fold, at least 30-fold, at least 40-fold, or at least 50-fold) compared to control cells.

[0211] In some embodiments, the appropriate amount induces a cytokine profile dominated by type I IFN. The expression "type I IFN dominated cytokine profile" as used herein means that upon activation (particularly upon treatment with a TLR7 agonist), the cytokine profile secreted from cells (particularly blood cells, particularly pDCs) differs primarily from that secreted from control cells (i.e. non-activated cells, particularly cells not treated with a TLR7 agonist) in that IFNa (and optionally IP-10 or further type I IFN cytokines) are present and preferably increased in amount (at least 10-fold, e.g. at least 20-fold, at least 30-fold, at least 40-fold, or at least 50-fold). In certain embodiments, the expression "type I IFN dominated cytokine profile" as used herein means that upon activation (particularly upon treatment with a TLR7 agonist), the cytokine profile secreted from cells (particularly blood cells, particularly pDCs) differs primarily from the cytokine profile secreted from control cells (i.e. non-activated cells, particularly cells not treated with a TLR7 agonist) in that IFNa (and optionally IP-10 or further type I IFN cytokines) are present and preferably increased in amount (at least 10-fold, e.g. at least 20-fold, at least 30-fold, at least 40-fold, or at least 50-fold), and the amount of TNFa remains essentially unchanged (particularly, the amount of secreted TNFa upon activation is up to 2-fold (up to 1.5-fold, 1.4-fold, 1.3-fold, 1.2-fold, or 1.2-fold, etc.) of the amount of TNFa secreted without activation) or is decreased.

[0212] In some embodiments, the suitable amount recruits MyD88, interferon regulatory factor 7 (IRF7) and / or NF-κB.

[0213] In some embodiments, an appropriate amount results in maturation of pDCs into APCs, which in some embodiments upregulate the processing and (cross-)presentation of antigens released from dying tumor cells.

[0214] In some embodiments, by concomitant IFNa secretion and antigen (cross)presentation, an appropriate amount can promote efficient priming and activation of antigen-specific CD4 and CD8 T cells and expansion of cytotoxic T lymphocytes (CTLs). In some embodiments, these CTLs migrate into tumor tissue, recognize tumor-specific antigens, and lyse tumor cells.

[0215] In some embodiments, the appropriate amount results in activation of natural killer (NK) cells (specifically by IFNa secreted from cells such as pDCs). In certain embodiments, activation of NK cells promotes an innate immune response that enhances, for example, the cytotoxic potential of NK cells against MHC-deficient targets.

[0216] In some embodiments, the appropriate amount is safe. In some embodiments, a safe amount is an amount that does not result in adverse events associated with a medical treatment or procedure, particularly associated with administration of BNT411. In some embodiments, a safe amount is an amount that results in a maximum grade 3 adverse event. In some embodiments, a safe amount is an amount that results in a maximum grade 2 adverse event. In some embodiments, a safe amount is an amount that results in a maximum grade 3 adverse event associated with a medical treatment or procedure, particularly associated with administration of BNT411. In some embodiments, a safe amount is an amount that results in a maximum grade 2 adverse event associated with a medical treatment or procedure, particularly associated with administration of BNT411.

[0217] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 0.1 μg / kg to about 50 μg / kg body weight, or about 8 μg to about 4000 μg in total, and / or b) Approx. 0.23x10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18x10 in total -9mol~about 9100x10 -9 mol.

[0218] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 0.5 μg / kg to about 20 μg / kg body weight, or about 40 μg to about 1600 μg in total, and / or b) Approx. 1.14x10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight, or about 91x10 in total -9 mol~approx. 3640x10 -9 mol.

[0219] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 2 μg / kg to about 10 μg / kg body weight, or about 160 μg to about 800 μg in total, and / or b) Approx. 4.55x10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9 mol.

[0220] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 2 μg / kg to about 9 μg / kg body weight, or about 160 μg to about 720 μg in total, and / or b) Approx. 4.55x10 -9 mol / kg weight ~ approx. 20.5x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1638x10 -9 mol.

[0221] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 2 μg / kg to about 5 μg / kg body weight, or about 160 μg to about 400 μg in total, and / or b) Approx. 4.55x10 -9 mol / kg weight ~ approx. 11.4x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~about 910x10 -9 mol.

[0222] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 2.4 μg / kg to about 9.6 μg / kg body weight, or about 192 μg to about 768 μg in total, and / or b) Approximately 5.46x10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 437x10 in total -9 mol~about 1747x10 -9 mol.

[0223] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 4.8 μg / kg to about 9.6 μg / kg body weight, or about 384 μg to about 768 μg in total, and / or b) Approx. 10.9x10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 873x10 in total -9 mol~about 1747x10 -9 mol.

[0224] In some embodiments, for example, a suitable amount of BNT411 in each dose and / or each treatment cycle is a) about 4.8 μg / kg body weight, or about 384 μg in total, and / or b) Approx. 10.9x10 -9 mol / kg body weight, or about 874x10 in total -9 mol.

[0225] According to these embodiments, a dose defined in μg / kg body weight (or mol / kg body weight) may be converted to a uniform dose based on the median body weight of subjects to whom BNT411 is administered being 80 kg, or vice versa. Additionally, a dose defined in mol (or mol / kg body weight) may be converted to a dose in μg (or μg / kg body weight) based on the molecular weight of BNT411 (i.e., 439.55 g / mol for anhydrous BNT411), or vice versa.

[0226] BNT411 can be administered by any method and any route known in the art. In some embodiments, BNT411 is administered intravenously, intraarterially, subcutaneously, intradermally, intramuscularly, intranodal or intratumorally. In some embodiments, BNT411 is administered systemically, for example parenterally, particularly intravenously.

[0227] BNT411 may be administered in the form of any suitable pharmaceutical composition described herein. In some embodiments, BNT411 is administered in the form of an injection.

[0228] In some embodiments, BNT411 is administered in at least one treatment cycle. In some embodiments, each treatment cycle is about 2 weeks (14 days), 3 weeks (21 days) or 4 weeks (28 days). In some embodiments, each treatment cycle is 3 weeks (21 days).

[0229] In some embodiments, one dose of BNT411 is administered (e.g., infused) once a week (Q1W) for at least one treatment cycle. In some embodiments, one dose of BNT411 is administered (e.g., infused) Q1W for at least four treatment cycles, and then once every three weeks (Q3W). In some embodiments, administration of BNT411 is continued until disease progression, onset of unacceptable adverse effects, or death.

[0230] In some embodiments, each dose of BNT411 is infused over a minimum of 10 minutes, such as a minimum of 15 minutes, a minimum of 20 minutes, a minimum of 25 minutes, or a minimum of 30 minutes.

[0231] In some embodiments, each dose of BNT411 is administered as a bolus injection, such as a slow bolus injection. In some embodiments, each dose of BNT411 is administered as a bolus injection over a period of at least 1 minute, e.g., at least 2 minutes, at least 3 minutes, at least 4 minutes, or at least 5 minutes, and / or over a period of up to 9 minutes, e.g., up to 8 minutes, up to 7 minutes, up to 6 minutes, or up to 5 minutes. In some embodiments, each dose of BNT411 is administered as a bolus injection within 1-10 minutes, e.g., within 3-5 minutes.

[0232] Further treatment In certain embodiments, additional treatments may be administered to patients in combination with the BNT411 monotherapy described herein.Such additional treatments include classical cancer treatments, such as radiation therapy, surgery, hyperthermia and / or chemotherapy.Furthermore, such additional treatments include treatments that include immune checkpoint modulators.

[0233] Chemotherapy is a type of cancer treatment that uses one or more anticancer drugs (chemotherapeutic agents), usually as part of a standardized chemotherapy regimen. The term chemotherapy has come to imply the nonspecific use of intracellular toxins to inhibit mitosis. This connotation excludes more selective agents that block extracellular signals (signal transduction). The development of therapies using specific molecular or genetic targets that inhibit growth-promoting signals from classical endocrine hormones (mainly estrogens for breast cancer and androgens for prostate cancer) is now called hormone therapy. In contrast, other inhibition of growth signals, such as those associated with receptor tyrosine kinases, is referred to as targeted therapy.

[0234] Importantly, the use of drugs (whether chemotherapy, hormonal therapy or targeted therapy) constitutes a systemic therapy of cancer, in that they are introduced into the bloodstream and can therefore in principle address cancer at any anatomical location in the body. Systemic therapies are often used in combination with other modalities that constitute local therapies of cancer (i.e. treatments whose effectiveness is limited to the anatomical area to which they are applied), such as radiation therapy, surgery or hyperthermia.

[0235] Traditional chemotherapy agents are cytotoxic by preventing cell division (mitosis), but cancer cells vary widely in their sensitivity to these agents. For the most part, chemotherapy can be thought of as a way to damage or stress cells, which, if apoptosis is initiated, can result in cell death.

[0236] In some embodiments, the effect of TLR7 engagement by BNT411 results in immune responses that can synergize and complement current therapeutic regimens. For example, when tumor antigens are released via radiation / chemotherapy-induced cell death, pDC activation triggered by TLR7 can enhance the priming and expansion of antigen-specific cytotoxic T lymphocytes (CTLs). However, checkpoint blockade can counteract immune suppressive signals and avoid the exhaustion of CTLs working together with the changes in tumor microenvironment (TME) induced by the downstream effects of TLR7 activation. Therefore, in some embodiments, to avoid such checkpoint blockade, BNT411 therapy is combined with therapy using checkpoint modulators, particularly checkpoint inhibitors.

[0237] Further Therapeutic Agents In addition to monotherapy, in some embodiments, the compound BNT411 is used in combination with one or more additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents include therapeutic agents commonly used in the treatment of tumors or cancers described herein, such as checkpoint inhibitors (CPIs), chemotherapeutic agents (e.g., platinum-based chemotherapeutic agents and / or topoisomerase inhibitors), and combinations thereof.

[0238] Chemotherapeutic agents In some embodiments, the one or more additional therapeutic agents comprise one or more chemotherapeutic agents, particularly chemotherapeutic agents commonly used in the treatment of tumors or cancers as described herein.

[0239] Chemotherapeutic agents include alkylating agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, and cytotoxic antibiotics.

[0240] Alkylating agents have the ability to alkylate many molecules, including proteins, RNA, and DNA. Subtypes of alkylating agents are nitrogen mustards, nitrosoureas, tetrazines, aziridines, platinum-based chemotherapy compounds, and non-classical alkylating agents. Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, and busulfan. Nitrosoureas include N-nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU), and semustine (MeCCNU), fotemustine, and streptozotocin. Tetrazines include dacarbazine, mitozolomide, and temozolomide. Aziridines include thiotepa, mitomycin, and diaziquone (AZQ). Platinum-based chemotherapy compounds include cisplatin, carboplatin, and oxaliplatin. They impair cellular function by forming covalent bonds with amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules.Nonclassical alkylating agents include procarbazine and hexamethylmelamine.

[0241] Antimetabolites are a group of molecules that interfere with the synthesis of DNA and RNA. Many of them have structures similar to the building blocks of DNA and RNA. Antimetabolites resemble either nucleobases or nucleosides, but with altered chemical groups. These drugs exert their effect by blocking enzymes necessary for DNA synthesis or by incorporating into DNA or RNA. Subtypes of antimetabolites are antifolates, fluoropyrimidines, deoxynucleoside analogs, and thiopurines. Antifolates include methotrexate and pemetrexed. Fluoropyrimidines include fluorouracil and capecitabine. Deoxynucleoside analogs include cytarabine, gemcitabine, decitabine, azacytidine, fludarabine, nelarabine, cladribine, clofarabine, and pentostatin. Thiopurines include thioguanine and mercaptopurine.

[0242] Anti-microtubule agents block cell division by interfering with microtubule function. Vinca alkaloids prevent microtubule formation, while taxanes prevent microtubule disassembly. Vinca alkaloids include vinorelbine, vindesine, and vinflunine. Taxanes include docetaxel (Taxotere) and paclitaxel (Taxol).

[0243] Topoisomerase inhibitors are drugs that affect the activity of two enzymes: topoisomerase I and topoisomerase II, and include irinotecan, topotecan, camptothecin, etoposide, doxorubicin, mitoxantrone, teniposide, novobiocin, mervalone, and aclarubicin.

[0244] Cytotoxic antibiotics are a diverse group of drugs with various mechanisms of action. The common theme they share in their chemotherapeutic indications is to interrupt cell division. The most important subgroups are the anthracyclines (e.g. doxorubicin, daunorubicin, epirubicin, idarubicin pirarubicin, and aclarubicin) and bleomycin; other notable examples include mitomycin C, mitoxantrone, and actinomycin.

[0245] In some embodiments, lymphodepleting therapy may be applied, for example, by administering cyclophosphamide and fludarabine prior to administration of immune effector cells. Such therapy may increase cell persistence and the incidence and duration of clinical responses.

[0246] In some embodiments, the chemotherapeutic agent (or combination of two or more chemotherapeutic agents) is administered in an appropriate amount. In some embodiments, for example, the amount of chemotherapeutic agent (or combination of two or more chemotherapeutic agents) administered in each dose and / or treatment cycle can reduce or prevent, in whole or in part, the progression of a tumor or cancer.

[0247] For example, the amount of chemotherapeutic agent administered at each dose and / or each treatment cycle will depend, among other things, on the chemotherapeutic agent being administered.

[0248] In some embodiments, when the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent, for example, the amount of platinum-based chemotherapeutic agent administered in each dose and / or each treatment cycle is a) about 100-1000 mg in total, and / or b) Approximately 0.27x10 in total -3 ~2.7x10 -3 mol.

[0249] In some embodiments, when the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide), for example, the amount of topoisomerase inhibitor administered at each dose and / or each treatment cycle is a) about 150-400 mg in total, and / or b) Total is about 0.17x10 -3 ~0.68x10 -3 mol.

[0250] The chemotherapeutic agent may be administered by any method and any route known in the art. The method and route of administration depend on the type of chemotherapeutic agent used. In some embodiments, particularly in those embodiments where the chemotherapeutic agent includes a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is administered systemically, e.g., parenterally, particularly intravenously. In some embodiments, particularly in those embodiments where the chemotherapeutic agent includes a topoisomerase inhibitor (such as etoposide), the topoisomerase inhibitor is administered systemically, e.g., parenterally, particularly intravenously, or orally. In some embodiments, particularly in those embodiments where the chemotherapeutic agent includes a topoisomerase inhibitor (such as etoposide) and is administered more than once per treatment cycle, the routes of administration may be the same or different. In some embodiments, particularly those embodiments in which the chemotherapeutic agent includes a topoisomerase inhibitor (such as etoposide) and is administered more than once per treatment cycle, the first dose of the topoisomerase inhibitor in a treatment cycle is administered systemically, e.g., parenterally, particularly intravenously, and the second (and each subsequent dose) of the topoisomerase inhibitor in said treatment cycle is administered enterally, particularly orally.

[0251] The chemotherapeutic agent may be administered in the form of any suitable pharmaceutical composition described herein. In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is administered in the form of an infusion. In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is infused over a period of at least 30 minutes, for example, at least 40 minutes, at least 45 minutes, at least 50 minutes, or at least 60 minutes.

[0252] In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide), the topoisomerase inhibitor is administered in the form of an injection and / or a capsule (such as a soft capsule). In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide) and is administered more than once per treatment cycle, the dosage forms may be the same or different. In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide) and is administered more than once per treatment cycle, the first dose of the topoisomerase inhibitor in a treatment cycle is administered in the form of an injection, and the second (and each subsequent dose) of the topoisomerase inhibitor in said treatment cycle is administered in the form of a capsule (such as a soft capsule). In some embodiments, particularly those embodiments in which the chemotherapeutic agent includes a topoisomerase inhibitor (such as etoposide) and is administered in the form of an infusion, the topoisomerase inhibitor may be infused for any period of time, such as at least 5 minutes (e.g., at least 10 minutes, at least 15 minutes, at least 20 minutes, or at least 30 minutes) and / or up to 120 minutes (up to 100 minutes, up to 90 minutes, up to 80 minutes, up to 70 minutes, up to 60 minutes, up to 50 minutes, or up to 45 minutes, etc.).

[0253] In some embodiments, the chemotherapeutic agent is administered at least once over one treatment cycle. In some embodiments, particularly in embodiments where the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is administered at least once over two or more (such as 2-4) treatment cycles. In some embodiments, the treatment cycle has 3 weeks (21 days). In some embodiments, particularly in embodiments where the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is administered Q3W over at least two treatment cycles (such as 2-4 treatment cycles) (preferably on day 1 of a treatment cycle). In some embodiments, particularly in embodiments where the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is administered Q3W over at least four treatment cycles (preferably on day 1 of a treatment cycle).

[0254] In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide), the topoisomerase inhibitor is administered at least once over two or more (such as at least three, or at least four) treatment cycles. In some embodiments, the treatment cycle has three weeks (21 days). In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide), the topoisomerase inhibitor is administered three times in week one of the treatment cycle (preferably on days one, two, and three of the treatment cycle) over two or more (such as at least three, or at least four) treatment cycles. In some embodiments, particularly in those embodiments in which the chemotherapeutic agent comprises a topoisomerase inhibitor (such as etoposide), the topoisomerase inhibitor is administered three times in week one of the treatment cycle (preferably on days one, two, and three of the treatment cycle) over four treatment cycles.

[0255] In some embodiments, the one or more chemotherapeutic agents include a platinum-based chemotherapeutic agent. In some embodiments, the one or more chemotherapeutic agents include cisplatin, oxaliplatin, or carboplatin. In some embodiments, the one or more chemotherapeutic agents include oxaliplatin or carboplatin. In some embodiments, the one or more chemotherapeutic agents include carboplatin. In some embodiments, the platinum-based chemotherapeutic agent is administered in the amount specified above (e.g., about 100-1000 mg in total, and / or about 0.27x10 -3 ~2.7x10 -3 mol), by route (e.g., intravenous), in a form (e.g., infusion), over a period (e.g., over a minimum of 30 minutes), and / or in a dosage regimen (e.g., Q3W for 4 treatment cycles, preferably on day 1 of a treatment cycle).

[0256] In some embodiments, the one or more chemotherapeutic agents include a topoisomerase inhibitor, such as an inhibitor of topoisomerase I and / or topoisomerase II. In some embodiments, the one or more chemotherapeutic agents include a compound selected from the group consisting of irinotecan, topotecan, camptothecin, etoposide, ciprofloxacin, doxorubicin, mitoxantrone, teniposide, novobiocin, mervalone, and aclarubicin. In some embodiments, the one or more chemotherapeutic agents include a compound selected from the group consisting of etoposide, ciprofloxacin, and doxorubicin. In some embodiments, the one or more chemotherapeutic agents include etoposide. In some embodiments, the topoisomerase inhibitor is administered in the amounts specified above (e.g., about 150-400 mg in total, and / or about 0.17x10 mg in total). -3 ~0.68x10 -3 mol), by route (e.g., intravenously or orally), in a form (e.g., injection or capsule), within a period (e.g., at least 5 minutes), and / or in a dosage regimen (e.g., three times in week 1 of a treatment cycle (preferably on days 1, 2, and 3 of a treatment cycle) over four treatment cycles).

[0257] Checkpoint inhibitors In some embodiments, immune checkpoint inhibitors suitable for use in the methods disclosed herein are antagonists of inhibitory signals, such as antibodies targeting PD-1 or PD-L1. These ligands and receptors, as well as other checkpoint proteins, such as receptors and their ligands, are described and reviewed in Pardoll, D., Nature. 12: 252-264, 2012. Additional immune checkpoint proteins that can be targeted according to the present disclosure are described herein.

[0258] In some embodiments, the immune checkpoint inhibitor prevents an inhibitory signal associated with an immune checkpoint. In some embodiments, the immune checkpoint inhibitor is an antibody or fragment thereof that disrupts or inhibits inhibitory signaling associated with an immune checkpoint. In some embodiments, the immune checkpoint inhibitor is a small molecule inhibitor that disrupts or inhibits inhibitory signaling. In some embodiments, the immune checkpoint inhibitor is a peptide-based inhibitor that disrupts or inhibits inhibitory signaling. In some embodiments, the immune checkpoint inhibitor is an inhibitory nucleic acid molecule that disrupts or inhibits inhibitory signaling.

[0259] In some embodiments, inhibition or blocking of inhibitory immune checkpoint signaling as described herein results in the prevention or reversal of immune suppression and establishment or enhancement of T cell immunity, particularly against cancer cells. In some embodiments, inhibition of immune checkpoint signaling as described herein reduces or inhibits immune system dysfunction. In some embodiments, inhibition of immune checkpoint signaling as described herein causes dysfunctional immune cells to be less dysfunctional. In some embodiments, inhibition of immune checkpoint signaling as described herein causes dysfunctional T cells to be less dysfunctional.

[0260] In some embodiments, immune checkpoint inhibitors prevent interactions between checkpoint blockade proteins, for example, interactions between PD-1 and PD-L1 or PD-L2.

[0261] The immune checkpoint inhibitor may be an antibody, its antigen-binding fragment or a construct thereof, comprising an antibody portion with an antigen-binding fragment of the required specificity. The antibody or its antigen-binding fragment is as described herein. The immune checkpoint inhibitor antibody or its antigen-binding fragment includes, in particular, an antibody or its antigen-binding fragment that binds to an immune checkpoint protein, such as an immune checkpoint receptor or an immune checkpoint receptor ligand. The antibody or its antigen-binding fragment may also be conjugated to further moieties, as described herein. In particular, the antibody or its antigen-binding fragment is a chimerized antibody, a humanized antibody or a human antibody. Preferably, the immune checkpoint inhibitor antibody or its antigen-binding fragment is an antagonist of an immune checkpoint receptor or an immune checkpoint receptor ligand.

[0262] In some preferred embodiments, the antibody that is an immune checkpoint inhibitor is an isolated antibody.

[0263] In some embodiments, the immune checkpoint inhibitor is an antibody, fragment, construct thereof, or antibody mimetic that prevents an interaction between checkpoint blockade proteins, for example, an antibody, fragment, construct thereof, or antibody mimetic that prevents the interaction between PD-1 and PD-L1 or PD-L2.

[0264] Immune checkpoint inhibitors can be inhibitory nucleic acid molecules such as oligonucleotides, siRNAs, shRNAs, antisense DNA or RNA molecules, and aptamers (e.g., DNA or RNA aptamers), particularly antisense oligonucleotides. In some embodiments, immune checkpoint inhibitors that are siRNAs interfere with mRNA and thus block translation, e.g., translation of immune checkpoint proteins, e.g., translation of PD-1, PD-L1 and / or PD-L2.

[0265] The checkpoint inhibitor may also be in the form of a soluble form of the molecule (or a variant thereof) itself, such as a soluble PD-L1 or a PD-L1 fusion.

[0266] In the context of the present disclosure, multiple checkpoint inhibitors can be used, and multiple checkpoint inhibitors target different checkpoint pathways or the same checkpoint pathway.Preferably, multiple checkpoint inhibitors are different checkpoint inhibitors.Preferably, when multiple different checkpoint inhibitors are used, in particular at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different checkpoint inhibitors are used, preferably 2, 3, 4 or 5 different checkpoint inhibitors are used, more preferably 2, 3 or 4 different checkpoint inhibitors are used, even more preferably 2 or 3 different checkpoint inhibitors are used, and most preferably 2 different checkpoint inhibitors are used.

[0267] In some embodiments, the immune checkpoint inhibitor is a PD-1 axis binding antagonist. As used herein, PD-1 axis binding antagonists include PD-1 binding antagonists, PD-L1 binding antagonists, and PD-L2 binding antagonists.

[0268] The term "PD-1 binding antagonist" refers to a molecule that reduces, blocks, inhibits, abrogates, or prevents signal transduction resulting from the interaction of PD-1 with one or more of its binding partners, e.g., PD-L1, PD-L2. In some embodiments, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to one or more of its binding partners. In certain aspects, a PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and / or PD-L2. For example, PD-1 binding antagonists include anti-PD-1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, abrogate, or prevent signal transduction resulting from the interaction of PD-1 with PD-L1 and / or PD-L2. In some embodiments, the PD-1 binding antagonist reduces negative costimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes that are mediated by signaling through PD-1, rendering dysfunctional T cells less dysfunctional (e.g., enhancing effector responses to antigen recognition). In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody.

[0269] The term "PD-L1 binding antagonist" refers to a molecule that reduces, blocks, inhibits, abrogates, or prevents signal transduction resulting from the interaction of PD-L1 with one or more of its binding partners, e.g., PD-1, B7-1. In some embodiments, a PD-L1 binding antagonist is a molecule that inhibits the binding of PD-L1 to one or more of its binding partners. In certain aspects, a PD-L1 binding antagonist inhibits the binding of PD-L1 to PD-1 and / or B7-1. In some embodiments, PD-L1 binding antagonists include anti-PD-L1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, abrogate, or prevent signal transduction resulting from the interaction of PD-L1 with one or more of its binding partners, e.g., PD-1, B7-1. In some embodiments, the PD-L1 binding antagonist reduces negative costimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes that are mediated by signaling through PD-L1, rendering dysfunctional T cells less dysfunctional (e.g., enhancing effector responses to antigen recognition). In some embodiments, the PD-L1 binding antagonist is an anti-PD-L1 antibody.

[0270] The term "PD-L2 binding antagonist" refers to a molecule that reduces, blocks, inhibits, abrogates, or prevents signal transduction resulting from the interaction of PD-L2 with one or more of its binding partners, such as PD-1. In some embodiments, a PD-L2 binding antagonist is a molecule that inhibits the binding of PD-L2 to one or more of its binding partners. In certain aspects, a PD-L2 binding antagonist inhibits the binding of PD-L2 to PD-1. In some embodiments, PD-L2 antagonists include anti-PD-L2 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, abrogate, or prevent signal transduction resulting from the interaction of PD-L2 with one or more of its binding partners, such as PD-1. In some embodiments, the PD-L2 binding antagonist reduces negative costimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes that are mediated by signaling through PD-L2, rendering dysfunctional T cells less dysfunctional (e.g., enhancing effector responses to antigen recognition). In some embodiments, the PD-L2 binding antagonist is an immunoadhesin.

[0271] In some embodiments, the inhibitory immune modulator (immune checkpoint blockade) is a component of the PD-1 / PD-L1 or PD-1 / PD-L2 signaling pathway. Thus, in some embodiments of the present disclosure, the checkpoint inhibitor is an inhibitor of the PD-1 signaling pathway. In certain embodiments, the checkpoint inhibitor of the PD-1 signaling pathway is a PD-1 inhibitor. In certain embodiments, the checkpoint inhibitor of the PD-1 signaling pathway is a PD-1 ligand inhibitor, such as a PD-L1 inhibitor or a PD-L2 inhibitor. In some preferred embodiments, the checkpoint inhibitor of the PD-1 signaling pathway is an antibody, antigen-binding portion thereof, or construct thereof that disrupts or inhibits the interaction between the PD-1 receptor and one or more of its ligands, PD-L1 and / or PD-L2. Antibodies that bind to PD-1 and disrupt or inhibit the interaction between PD-1 and one or more of its ligands are known in the art. In certain embodiments, the antibody, antigen-binding portion thereof, or construct thereof specifically binds to PD-1. In certain embodiments, the antibody, antigen-binding portion thereof, or construct thereof specifically binds to PD-L1 and disrupts or inhibits its interaction with PD-1, thereby increasing immune activity. In certain embodiments, the antibody, antigen-binding portion thereof, or construct thereof specifically binds to PD-L2 and disrupts or inhibits its interaction with PD-1, thereby increasing immune activity.

[0272] In some embodiments, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its ligand binding partner. In certain aspects, the PD-1 ligand binding partner is PD-L1 and / or PD-L2.

[0273] In some embodiments, a PD-L1 binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partner. In certain aspects, the PD-L1 binding partner is PD-1 and / or B7-1.

[0274] In some embodiments, a PD-L2 binding antagonist is a molecule that inhibits the binding of PD-L2 to its binding partner. In certain aspects, the PD-L2 binding partner is PD-1.

[0275] The antagonist can be an antibody, an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.

[0276] In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody (eg, a human antibody, a humanized antibody, or a chimeric antibody).

[0277] In some embodiments, the PD-L1 binding antagonist is an anti-PD-L1 antibody.

[0278] PD-1 axis binding antagonists, such as anti-PD-1 antibodies and anti-PD-L1 antibodies, can be administered by any method and any route known in the art. The method and route of administration depend on the type of PD-1 axis binding antagonist used.

[0279] The PD-1 axis binding antagonist may be administered in the form of any suitable pharmaceutical composition as described herein.

[0280] PD-1 axis binding antagonists, such as anti-PD-1 and anti-PD-L1 antibodies, can be administered in the form of nucleic acid, such as DNA or RNA, encoding the PD-1 axis binding antagonist, such as anti-PD-1 or anti-PD-L1 antibodies. For example, the antibody can be delivered encoded in an expression nucleic acid, as described herein. The nucleic acid molecule can be delivered by itself, for example in the form of a plasmid or mRNA molecule, or can be complexed with any other nucleic acid particle, such as a delivery vehicle, for example a liposome, lipoplex, or nucleic acid-lipid particle. PD-1 axis binding antagonists, such as anti-PD-1 and anti-PD-L1 antibodies, can also be administered via an oncolytic virus that contains an expression cassette encoding the PD-1 axis binding antagonist.

[0281] Exemplary PD-1 inhibitors include, but are not limited to, anti-PD-1 antibodies, such as BGB-A317 (BeiGene; see U.S. Pat. No. 8,735,553, WO 2015 / 35606, and U.S. Patent Application Publication No. 2015 / 0079109), lambrolizumab (disclosed, for example, as hPD109A and its humanized derivatives h409A1, h409A16, and h409A17 in WO 2008 / 156712), AB137132 (Abcam), EH12.2H7, and RMP1-14 (#BE0146; Bioxcell Lifesciences Pvt. LTD.), MIH4 (Affymetrix eBioscience), nivolumab (OPDIVO, BMS-936558; Bristol Myers Squibb; U.S. Pat. No. 8,008,449; WO 2013 / 173223; WO 2006 / 121168), pembrolizumab (KEYTRUDA; MK-3475; Merck; WO 2008 / 156712), pidilizumab (CT-011; CureTech; Hardy et al., 1994, Cancer Res.,54(22):5793-6 and WO 2009 / 101611), PDR001 (Novartis; see WO 2015 / 112900), MEDI0680 (AMP-514; AstraZeneca; see WO 2012 / 145493), TSR-042 (see WO 2014 / 179664), cemiplimab (REGN-2810; Regeneron; H4H7798N; see U.S. Patent Application Publication Nos. 2015 / 0203579 and WO 2015 / 112800), JS001 (TAIZHOU JUNSHI PHARMA; Si-Yang Liu et al. al.,2007,J.Hematol.Oncol.70:136), AMP-224(GSK-2661380;Li et al.,2016,Int J Mol Sci,17(7):1151 and WO 2010 / 027827 and WO 2011 / 066342), PF-06801591 (Pfizer), tislelizumab (BGB-A317; BeiGene; see WO 2015 / 35606, U.S. Pat. No. 9,834,606 and U.S. Patent Application Publication No. 2015 / 0079109), BI 754091, SHR-1210 (see WO 2015 / 085847), and antibodies 17D8, 2D3, 4H1, 4A11, 7D3 and 5F4 described in WO 2006 / 121168; INCSHR1210 (Jiangsu Hengrui Medicine; also known as SHR-1210; see WO 2015 / 085847), TSR-042 (Tesaro Biopharmaceutical; also known as ANB011; see WO 2014 / 179664), GLS-010 (Wuxi / Harbin Gloria Pharmaceuticals; also known as WBP3055; see Si-Yang et al., 2017, J. Hematol. Oncol. 70:136), STI-1110 (Sorrento Therapeutics; see WO 2014 / 194302), AGEN2034 (Agenus; see WO 2017 / 040790), MGA012 (Macrogenics; see WO 2017 / 19846), IBI308 (Innovent; see WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 132825 and WO 2017 / 133540), cetrelimab (JNJ-63723283; JNJ-3283; Calvo et al. al., J. Clin. Oncol. 36, no. 5_suppl(2018)58), genolimzumab (CBT-501; see Patel et al., J. ImmunoTher. Cancer, 2017, 5(Suppl 2):P242), and satsunlimab (PF-06801591; Youssef et al., Proc. Am. Assoc. Cancer Res. Ann.Meeting 2017; Cancer Res 2017; 77(13 Suppl):Abstract), toripalimab (JS-001; see U.S. Patent Application Publication No. 2016 / 0272708), camrelizumab (SHR-1210; INCSHR-1210; see U.S. Patent Application Publication No. 2016 / 376367; Huang et al., Clin. Cancer Res. 2018; 24(6):1296-1304), spartalizumab (PDR001; WO 2017 / 106656; see Naing et al., J. Clin. Oncol. 34, no. 15_suppl(2016)3060-3060), BCD-100 (JSC BIOCAD, Russia; see WO 2018 / 103017), balstilimab (AGEN2034; see WO 2017 / 040790), sintilimab (IBI-308; see WO 2017 / 024465 and WO 2017 / 133540), ezabenlimab (BI-754091; U.S. Patent Application Publication No. 2017 / 334995; Johnson et al., J. Clin. Oncol. 36, no.5_suppl(2018)212-212), zimberelimab (GLS-010; see WO 2017 / 025051), LZM-009 (see U.S. Patent Application Publication No. 2017 / 210806), AK-103 (see WO 2017 / 071625, WO 2017 / 166804, and WO 2018 / 036472), retifanlimab (MGA-012; WO 2017 / 0198 46), Sym-021 (see WO 2017 / 055547), CS1003 (see China Patent No. 107840887), e.g. U.S. Patent No. 7,488,802, U.S. Patent No. 8,008,449, U.S. Patent No. 8,168,757, WO 03 / 042402, WO 2010 / 089411 (which further discloses anti-PD-L1 antibodies), WO 2010 / 036959, WO 2011 / No. 159877 (which further discloses antibodies against TIM-3), WO 2011 / 082400, WO 2011 / 161699, WO 2009 / 014708, WO 03 / 099196, WO 2009 / 114335, WO 2012 / 145493 (which further discloses antibodies against PD-L1), WO 2015 / 035606, WO 2014 / 055648 (which discloses antibodies against anti-KI No. 8,168,757, U.S. Patent Application Publication No. 2016 / 0272708 and U.S. Patent No. 8,354,509, e.g., the anti-PD-1 antibodies described in Shaabani et al., 2018, Expert Op Ther Pat., 28(9):665-678 and Sasikumar and Ramachandra, 2018, BioDrugs, 32(5):481-497, siRNAs against PD-1, e.g., as disclosed in WO 2019 / 000146 and WO 2018 / 103501, soluble PD-1 proteins, e.g., as disclosed in WO 2018 / 222711, and oncolytic viruses containing a soluble form of PD-1, e.g., as described in WO 2018 / 022831.

[0282] In certain embodiments, the PD-1 inhibitor is nivolumab (OPDIVO; BMS-936558), pembrolizumab (KEYTRUDA; MK-3475), pidilizumab (CT-011), PDR001, MEDI0680 (AMP-514), TSR-042, REGN2810, JS001, AMP-224 (GSK-2661380), PF-06801591, BGB-A317, BI 754091, or SHR-1210.

[0283] In certain embodiments, the inhibitory immunomodulator is an anti-PD-1 antibody or antigen-binding fragment thereof that comprises the complementarity determining region (CDR) of one of the anti-PD-1 antibodies or antigen-binding fragments described above, such as the CDR of one of the anti-PD-1 antibodies or antigen-binding fragments selected from the group consisting of nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003.

[0284] In some embodiments, the CDRs of the anti-PD-1 antibody are delineated using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NTH Publication No. 91-3242).

[0285] In certain embodiments, the inhibitory immunomodulator is an anti-PD-1 antibody or antigen-binding fragment thereof that comprises the heavy and light chain variable regions of one of the anti-PD-1 antibodies or antigen-binding fragments described above, such as the heavy and light chain variable regions of one of the anti-PD-1 antibodies or antigen-binding fragments selected from the group consisting of nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003.

[0286] In certain embodiments, the inhibitory immunomodulator is an anti-PD-1 antibody or antigen-binding fragment thereof selected from the group consisting of nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003.

[0287] The anti-PD-1 antibodies of the present disclosure are preferably monoclonal and may be multispecific antibodies, human antibodies, humanized antibodies or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, and PD-1 binding fragments of any of the above. In some embodiments, the anti-PD-1 antibodies described herein specifically bind to PD-1 (e.g., human PD-1). The immunoglobulin molecules of the present disclosure may be of any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass of immunoglobulin molecule.

[0288] In certain embodiments of the disclosure, the anti-PD-1 antibody is an antigen-binding fragment (e.g., a human antigen-binding fragment) as described herein, including, but not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fv (scFv), single-chain antibodies, disulfide-linked Fv (sdFv), and VFv. L or V H Antigen-binding fragments, including single chain antibodies, may contain the variable region alone or in combination with all or a portion of the hinge region, CH1, CH2, CH3, and CL domains. Antigen-binding fragments containing any combination of the variable region and the hinge region, CH1, CH2, CH3, and CL domains are also included in the disclosure. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camelid, horse, or chicken.

[0289] The anti-PD-1 antibodies disclosed herein may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of PD-1, or may be specific for both PD-1 and a heterologous protein. See, for example, PCT Publications WO 93 / 17715; WO 92 / 08802; WO 91 / 00360; WO 92 / 05793; Tutt, et al., 1991, J.Immunol. 147:60 69; U.S. Patent No. 4,474,893; U.S. Patent No. 4,714,681; U.S. Patent No. 4,925,648; U.S. Patent No. 5,573,920; U.S. Patent No. 5,601,819; Kostelny et al., 1992, J.Immunol. 148:1547 1553.

[0290] The anti-PD-1 antibodies disclosed herein may be described or designated in terms of the particular CDRs they contain.The precise amino acid sequence boundaries of a given CDR or FR can be determined by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (the “Kabat” numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 (the “Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (the “Contact” numbering scheme); Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003;27(1):55-77 (the "IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol, 2001;309(3):657-70, (the "Aho" numbering scheme); and Martin et al., "Modeling antibody hypervariable loops: a combined algorithm," PNAS, 1989,86(23):9268-9272, (the "AbM" numbering scheme). The boundaries of a given CDR may vary depending on the scheme used to identify it.In some embodiments, the CDRs or each particular CDR (e.g., CDR-H1, CDR-H2, CDR-H3) of a given antibody or region thereof (e.g., its variable region) should be understood to encompass the CDRs as (or specific to) defined by any of the above schemes. For example, a particular CDR (e.g., CDR-H3) may be associated with a given V. H or V L When a region amino acid sequence is described as including the amino acid sequence of the corresponding CDR in the variable region, it is understood that such CDR has the sequence of the corresponding CDR (e.g., CDR-H3) in the variable region as defined by any of the above schemes. Schemes for identifying a particular CDR or CDRs, e.g., as defined by the Kabat, Chothia, AbM or IMGT methods, may be specified.

[0291] In some embodiments, the numbering of the amino acid residues in the CDR sequences of the anti-PD-1 antibodies or antigen-binding fragments thereof provided herein is according to the IMGT numbering scheme as described in Lefranc, MP et al., Dev. Comp. Immunol., 2003, 27, 55-77.

[0292] In some embodiments, the anti-PD-1 antibody disclosed herein comprises the CDRs of the antibody nivolumab. See WO 2006 / 121168. In some embodiments, the CDRs of the antibody nivolumab are depicted using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses an anti-PD-1 antibody or derivative thereof comprising a heavy chain variable domain or a light chain variable domain, said variable domain comprising (a) a set of three CDRs, said set of CDRs being derived from the monoclonal antibody nivolumab, and (b) a set of four framework regions, said set of framework regions being different from the set of framework regions of the monoclonal antibody nivolumab, and said anti-PD-1 antibody or derivative thereof binds to PD-1. In certain embodiments, the anti-PD-1 antibody is nivolumab.

[0293] The anti-PD-1 antibodies disclosed herein may also be described or specified in terms of their binding affinity to PD-1 (e.g., human PD-1). Preferred binding affinities include those with a binding affinity of 5x10 -2 M, 10 -2 M, 5x10 -3 M, 10 -3 M, 5x10 -4 M, 10 -4 M, 5x10 -5 M, 10 -5 M, 5x10 -6 M, 10 -6 M, 5x10 -7 M, 10 -7 M, 5x10 -8 M, 10 -8 M,5x10 -9 M, 10 -9 M, 5x10 -10 M, 10 -10 M, 5x10 -11 M, 10 -11 M, 5x10-12 M, 10 -12 M, 5x10 -13 M, 10 -13 M, 5x10 -14 M, 10 -14 M, 5x10 -15 M or 10 -15 Those having a dissociation constant or Kd less than M are included.

[0294] Anti-PD-1 antibodies also include derivatives and constructs that are modified by the covalent attachment of any type of molecule to the antibody, i.e., such that the covalent attachment does not prevent the antibody from binding to PD-1. For example, but not limited to, anti-PD-1 antibody derivatives include antibodies that have been modified by, for example, glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, and the like. Any of a number of chemical modifications can be made by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like. Additionally, the derivatives or constructs can include one or more non-classical amino acids.

[0295] Exemplary PD-1 ligand inhibitors are PD-L1 inhibitors and PD-L2 inhibitors, including, but not limited to, MEDI4736 (durvalumab; AstraZeneca; see WO 2011 / 066389), MSB-0010718C (see U.S. Patent Application Publication No. 2014 / 0341917), YW243.55.S70 (see SEQ ID NO: 20 in WO 2010 / 077634 and U.S. Patent No. 8,217,149), MIH1 (Affymetrix eBioscience; European Patent No. 3 230 319), MDX-1105 (Roche / Genentech; see WO 2013019906 and U.S. Patent No. 8,217,149), STI-1014 (Sorrento; see WO 2013 / 181634), CK-301 (checkpoint therapeutics), KN035 (3D Med / Alphamab; see Zhang et al., 2017, Cell Discov. 3:17004), atezolizumab (TECENTRIQ; RG7446; MPDL3280A; R05541267; see U.S. Patent No. 9,724,413), BMS-936559 (Bristol Myers Squibb; see U.S. Patent No. 7,943,743, WO 2013 / 173223), avelumab (Bavencio; see U.S. Patent Application Publication No. 2014 / 0341917), LY3300054 (Eli Lilly Co.), CX-072 (Proclaim-CX-072; also known as CytomX; see WO 2016 / 149201), FAZ053, KN035 (see WO 2017020801 and WO 2017020802), MDX-1105 (see U.S. Patent Application Publication No. 2015 / 0320859), anti-PD-L1 antibodies such as 3G10, 12A4 (also known as BMS-936559), 10A5, 5F8, 10H10, 1B12, 7H1 No. 7,943,743, including 11E6, 12B7, and 13G4; the anti-PD-L1 antibodies disclosed in WO 2010 / 077634, U.S. Patent No. 8,217,149, WO 2010 / 036959, WO 2010 / 077634, WO 2011 / 066342, U.S. Patent No. 8,217,149, U.S. Patent No. 7,943,743, WO 2010 / 089411, U.S. Patent No. 7,635,757, U.S. Patent No. 8,217,149, U.S. Patent No. 2009 / 0317368, WO 2011 / 066389, WO 2017 / 034916, WO 2017 / 020291, WO 2017 / 020858, WO 2017 / 020801, WO 2016 / 111645, WO 2016 / 197367, WO 2016 / 061142, WO 2016 / 149201, WO 2016 / 000619, WO 2016 / 160792, WO These include the anti-PD-L1 antibodies described in WO 2016 / 022630, WO 2016 / 007235, WO 2015 / 179654, WO 2015 / 173267, WO 2015 / 181342, WO 2015 / 109124, WO 2018 / 222711, WO 2015 / 112805, WO 2015 / 061668, WO 2014 / 159562, WO 2014 / 165082 and WO 2014 / 100079.

[0296] In some embodiments, the one or more chemotherapeutic agents comprises atezolizumab.

[0297] According to the present disclosure, immune checkpoint inhibitors are inhibitors of inhibitory checkpoint proteins, but preferably not inhibitors of stimulatory checkpoint proteins.

[0298] In some preferred embodiments, the immune checkpoint inhibitor is an antibody, particularly an antagonistic or blocking antibody, that interferes with or inhibits one of the inhibitory immune checkpoint signaling pathways described herein. In some preferred embodiments, the immune checkpoint inhibitor is an antibody, particularly an antagonistic or blocking antibody, that interferes with or inhibits the PD-1 pathway (the interaction of PD-1 with one or more of its ligands, such as PD-L1 and / or PD-L2). In some preferred embodiments, the immune checkpoint inhibitor is an antibody, particularly an antagonistic or blocking antibody, that interferes with or inhibits the interaction between PD-1 and PD-L1.

[0299] The checkpoint inhibitor can be administered in the form of an immune checkpoint inhibitor, such as an inhibitory nucleic acid molecule or a nucleic acid, such as a DNA or RNA molecule, that codes for an antibody or a fragment thereof.For example, an antibody can be delivered encoded in an expression vector, as described herein.The nucleic acid molecule can be delivered by itself, for example in the form of a plasmid or an mRNA molecule, or can be complexed with a delivery vehicle, such as a liposome, lipoplex, or nucleic acid-lipid particle.The checkpoint inhibitor can also be administered via an oncolytic virus that contains an expression cassette that codes for the checkpoint inhibitor.The checkpoint inhibitor can also be administered by administering endogenous or allogeneic cells that can express the checkpoint inhibitor, for example in the form of cell-based therapy.

[0300] In some embodiments, the cell-based therapy comprises genetically engineered cells. In some embodiments, the genetically engineered cells express immune checkpoint inhibitors as described herein. In some embodiments, the genetically engineered cells express immune checkpoint inhibitors that are inhibitory nucleic acid molecules such as siRNA, shRNA, oligonucleotides, antisense DNA or RNA, aptamers, antibodies or fragments thereof, or soluble immune checkpoint proteins or fusions. The genetically engineered cells may also express additional agents that enhance T cell function. Such agents are known in the art. Cell-based therapy for use in inhibiting immune checkpoint signaling is disclosed, for example, in International Publication No. WO 2018 / 222711, the entirety of which is incorporated herein by reference.

[0301] In some embodiments, the checkpoint inhibitor is administered in an appropriate amount. In some embodiments, for example, the amount of checkpoint inhibitor administered in each dose and / or treatment cycle can reduce, inhibit, hinder, or negatively regulate one or more checkpoint proteins, or can reduce, inhibit, hinder, or negatively regulate the expression of one or more checkpoint proteins, either entirely or partially. Thus, an appropriate amount of checkpoint inhibitor according to the present disclosure can reduce, inhibit, hinder, or negatively regulate one or more checkpoint proteins, either entirely or partially, or can reduce, inhibit, hinder, or negatively regulate the expression of one or more checkpoint proteins. Thus, in some embodiments, the checkpoint inhibitor prevents the inhibitory signal associated with immune checkpoint, which leads to the prevention or reversal of immune suppression and the establishment or enhancement of T cell immunity against cancer cells.

[0302] In some embodiments, the amount of checkpoint inhibitor administered in each dose and / or treatment cycle may be within a range in which, inter alia, more than 5%, preferably more than 10%, more preferably more than 15%, even more preferably more than 20%, even more preferably more than 25%, even more preferably more than 30%, even more preferably more than 35%, even more preferably more than 40%, even more preferably more than 45%, and most preferably more than 50% of said checkpoint inhibitor is bound to the checkpoint protein.

[0303] In some embodiments, for example, the amount of checkpoint inhibitor administered at each dose and / or each treatment cycle is a) about 100-2000 mg in total, and / or b) Approximately 0.20x10 in total -9 ~10x10 -6 mol.

[0304] In some embodiments, when the checkpoint inhibitor is an antibody (such as an anti-PD-L1 antibody, e.g., atezolizumab), for example, the amount of checkpoint inhibitor administered at each dose and / or each treatment cycle is a) about 1,000 to 1,400 mg in total, and / or b) Total is about 6.8x10 -6 ~9.7x10 -6 mol.

[0305] The checkpoint inhibitor can be administered by any method and any route known in the art. The method and route of administration depend on the type of checkpoint inhibitor used. In some embodiments, particularly those in which the checkpoint inhibitor is an antibody (such as an anti-PD-L1 antibody, e.g., atezolizumab), the checkpoint inhibitor is administered systemically, e.g., parenterally, particularly intravenously.

[0306] The checkpoint inhibitor may be administered in the form of any suitable pharmaceutical composition described herein. In some embodiments, particularly those in which the checkpoint inhibitor is an antibody (such as an anti-PD-L1 antibody, e.g., atezolizumab), the checkpoint inhibitor is administered in the form of an infusion.

[0307] In some embodiments, particularly those embodiments in which the checkpoint inhibitor is an antibody (such as an anti-PD-L1 antibody, e.g., atezolizumab), the checkpoint inhibitor is infused over a period of at least 30 minutes, e.g., at least 40 minutes, at least 45 minutes, at least 50 minutes, or at least 60 minutes.

[0308] In some embodiments, particularly those in which the checkpoint inhibitor is an antibody (such as an anti-PD-L1 antibody, e.g., atezolizumab), the checkpoint inhibitor is administered at least once per treatment cycle. In some embodiments, the treatment cycle has 3 weeks (21 days). In some embodiments, particularly those in which the checkpoint inhibitor is an antibody (such as an anti-PD-L1 antibody, e.g., atezolizumab), the checkpoint inhibitor is administered Q3W for at least two treatment cycles (preferably on day 1 of a treatment cycle). In some embodiments, particularly those in which the checkpoint inhibitor is an antibody (such as atezolizumab), the checkpoint inhibitor is administered Q3W for each treatment cycle (preferably on day 1 of a treatment cycle).

[0309] Further therapeutic combinations In addition to BNT411, a treatment regimen according to the present disclosure (e.g., according to the first, third and / or fifth aspects of the present disclosure) may further include administering to the subject two or more additional therapeutic agents.

[0310] In some embodiments, the treatment regimen according to the first aspect of the present disclosure may further comprise administering to the subject two or more additional therapeutic agents selected from the group consisting of a checkpoint inhibitor (CPI), a platinum-based chemotherapeutic agent, and a topoisomerase inhibitor.

[0311] In some embodiments, the treatment regimen according to the first aspect of the present disclosure may further comprise administering to the subject (i) a checkpoint inhibitor and a platinum-based chemotherapeutic agent, (ii) a checkpoint inhibitor and a topoisomerase inhibitor, or (iii) a checkpoint inhibitor, a platinum-based chemotherapeutic agent and a topoisomerase inhibitor.

[0312] In some embodiments, the treatment regimen according to the first aspect of the disclosure may further comprise administering to the subject an anti-PD-L1 antibody, a platinum-based chemotherapeutic agent (e.g. carboplatin), and a topoisomerase II inhibitor (e.g. etoposide).

[0313] In some embodiments, the treatment regimen according to the first aspect of the disclosure may further comprise administering to the subject two or more additional therapeutic agents selected from the group consisting of atezolizumab, carboplatin and etoposide.

[0314] In some embodiments, the treatment regimen according to the first aspect of the disclosure may further comprise administering to the subject atezolizumab, carboplatin, and etoposide.

[0315] In some embodiments, the two or more additional therapeutic agents are administered as disclosed above (e.g., with respect to dosage, route, form, duration and / or dosing regimen). For example, platinum-based chemotherapeutic agents that are part of a combination therapy of BNT411 and at least one additional therapeutic agent (such as a checkpoint inhibitor, a topoisomerase II inhibitor, or a combination of a checkpoint inhibitor and a topoisomerase II inhibitor) are administered in the amounts specified above (e.g., about 100-1000 mg in total, and / or about 0.27x10 mg in total). -3 ~2.7x10 -3mol), by the route specified above (e.g., intravenously), in the form specified above (e.g., infusion), within the time period specified above (e.g., over a minimum of 30 minutes), and / or at the dosing regimen specified above (e.g., Q3W for 4 treatment cycles, preferably on day 1 of a treatment cycle). Alternatively or additionally, in some embodiments, the checkpoint inhibitor that is part of a combination therapy of BNT411 and at least one additional therapeutic agent (such as a platinum-based chemotherapy agent, a topoisomerase II inhibitor, or a combination of a platinum-based chemotherapy agent and a topoisomerase II inhibitor) is administered in the amounts specified above (e.g., about 150-400 mg in total, and / or about 0.17x10 -3 ~0.68x10 -3 mol), by the route specified above (e.g., intravenously or orally), in the form specified above (e.g., injection or capsule), within the period of time specified above (e.g., at least 5 minutes), and / or at the dosage regimen specified above (e.g., 3 times in week 1 of a treatment cycle (preferably on day 1 (e.g., iv), day 2 (e.g., orally), and day 3 (e.g., orally) of a treatment cycle) over 4 treatment cycles.

[0316] In some embodiments, when BNT411 is administered in combination with one, two or more additional therapeutic agents, BNT411 is administered as disclosed above (e.g., with respect to dosage, route, form, duration and / or dosing regimen). Thus, in some embodiments, when BNT411 is administered in combination with one, two or more additional therapeutic agents, BNT411 is administered in the amounts specified above (e.g., about 2 μg / kg to about 10 μg / kg body weight, or about 160 μg to about 800 μg in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9mol) by the route specified above (e.g., intravenously), in the form specified above (e.g., infusion), within the period specified above (e.g., over a minimum of 15 minutes), and / or at the dose regimen specified above (e.g., Q1W for at least 4 treatment cycles, then once every 3 weeks (Q3W)). In some embodiments, BNT411 is administered Q1W on days 2, 8, and 15 of treatment cycles for 4 treatment cycles, then Q3W on day 2 of treatment cycle 5 and each subsequent treatment cycle.

[0317] Subjects and tumors or cancers to be treated The subjects treated in accordance with the present disclosure are preferably human subjects.

[0318] The tumor or cancer to be treated can be any tumor or cancer. Examples of tumors / cancers include, but are not limited to, leukemia, seminoma, melanoma, sarcoma, myeloma (such as multiple myeloma), teratoma, lymphoma (such as Hodgkin's lymphoma, non-Hodgkin's lymphoma), mesothelioma, neuroblastoma, glioma, myelodysplastic syndrome, rectal cancer, endometrial cancer, ureteral cancer, renal cancer, kidney cancer, urothelial cancer, bladder cancer, esophageal cancer, adrenal cancer, adrenal cortical cancer, thyroid cancer, blood cancer, skin cancer (Merkel cell cancer), brain cancer, cervical cancer, malignant solitary fibrous tumor, intestinal cancer, liver cancer, thymoma and thymic cancer, colon cancer, gastric cancer, intestinal cancer, head and neck cancer, stomach cancer, digestive cancer, lymph node cancer, esophageal cancer, colorectal cancer, pancreatic cancer, ear, nose and throat (ENT) cancer, breast cancer, prostate cancer, penile cancer, uterine cancer, ovarian cancer and lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)) and metastases thereof.

[0319] In some embodiments, the tumor or cancer being treated is a solid tumor or cancer.

[0320] In some embodiments, the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor, and mesothelioma.

[0321] In some embodiments, the tumor or cancer is selected from the group consisting of lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer, and pancreatic cancer.

[0322] In some embodiments, the subject is chemotherapy naive. Thus, in some embodiments, the subject has not received prior chemotherapy, i.e., the subject has not been administered any chemotherapy agent prior to treatment according to the present disclosure (particularly according to the first aspect, the third aspect and / or the fifth aspect).

[0323] The tumor or cancer may be specifically lung cancer. The lung cancer may be non-small cell lung cancer (NSCLC), such as squamous NSCLC or non-squamous NSCLC, or may be small cell lung cancer (SCLC), such as ES-SCLC. Lung cancer is the second most common malignant tumor with an estimated age-standardized incidence of 22.4 / 100,000 and is the leading cause of cancer death in both men and women (Kantar, 2021, SEER, 2018). Worldwide, approximately 2,206,771 new cases of lung cancer and 1,796,144 deaths are estimated in 2020 (GLOBOCAN, 2020). Non-small cell lung cancer (NSCLC) accounts for 85%-90% of all cases, with 5-year survival rates of approximately 18% across all stages of the disease and only 3.5% in metastatic disease (Jemal et al., 2011) (Kantar, 2021). In the 1L setting, treatment typically consists of platinum-based chemotherapy combined with immunotherapy or targeted therapy depending on molecular and biomarker analysis, as well as tumor histology (NCCN, 2021d). More recently, the advent of PD-1 and programmed death-ligand 1 (PD-L1) inhibitors has improved outcomes for patients without driver mutations (approximately 62% of the non-squamous population, and 77% of the squamous population (Kantar, 2021)). Further treatment options are needed for patients whose tumors do not harbor specific oncogenic mutations or express biomarkers for checkpoint inhibitor (CPI) options. Novel combinations with complementary approaches to enhance response may further address unmet needs in this population. In patients in the second-line (2L) setting, standard of care chemotherapy (SOC) is limited to platinum-based chemotherapy, CPI monotherapy, or docetaxel with or without ramucirumab, depending on previous treatment received. In patients in the third-line (3L) setting, chemotherapy monotherapy is the standard. Novel therapies are needed to limit toxicity and potentially increase efficacy in this population (NCCN, 2021d).

[0324] In some embodiments, the tumor or cancer is small cell lung cancer (SCLC), such as extensive-stage small cell lung cancer (ES-SCLC).

[0325] Treatment regimen BNT411 and, if present or used, one or more additional therapeutic agents can be administered as specified above, particularly with regard to dosage amount, route, form, duration and / or dose regimen.

[0326] In some embodiments, BNT411 is administered at about 2 μg / kg to about 10 μg / kg body weight, or at about 160 μg to about 800 μg total, and / or at about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9 In some embodiments, BNT411 is administered in an amount of about 2.4 μg / kg to about 9.6 μg / kg body weight (e.g., about 4.8 μg / kg to about 9.6 μg / kg body weight), or in a total amount of about 192 μg to about 768 μg (e.g., about 384 μg to about 768 μg), and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight (approximately 10.9x10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, etc.), or a total of about 437x10 -9 mol~about 1747x10 -9 mol(about 873x10 -9 mol~about 1747x10 -9 In some embodiments, BNT411 is administered at about 4.8 μg / kg body weight, or about 384 μg total, and / or about 10.9×10 -9 mol / kg body weight, or about 874x10 in total -9 It is administered in mol amounts.

[0327] In some embodiments, BNT411 is administered by any suitable method, for example, intravenously (eg, by infusion).

[0328] In some embodiments, when present or used, one or more additional therapeutic agents are administered by any suitable method, for example, intravenously (e.g., by infusion), intraarterially, subcutaneously, intradermally, intramuscularly, intranodal, intratumoral or orally (e.g., in the form of capsules such as soft capsules). In some embodiments, when one or more additional therapeutic agents include a checkpoint inhibitor and a platinum-based chemotherapeutic agent, the checkpoint inhibitor and the platinum-based chemotherapeutic agent are administered systemically, particularly intravenously (e.g., by infusion). In some embodiments, when one or more additional therapeutic agents include a topoisomerase inhibitor, the topoisomerase inhibitor is administered systemically, particularly intravenously (e.g., by infusion), or enterally, particularly orally (e.g., by capsules). In some embodiments, when one or more additional therapeutic agents include a topoisomerase inhibitor, the topoisomerase inhibitor is administered at least twice (such as at least three times) over at least one treatment cycle (e.g., over at least two, three or four treatment cycles). In certain embodiments, the first dose of the topoisomerase inhibitor of a treatment cycle is administered systemically, particularly intravenously (e.g., by injection). In some embodiments, the second dose of the topoisomerase inhibitor of said treatment cycle (and any subsequent doses, if present or used) is administered orally (e.g., by capsule).

[0329] In some embodiments, BNT411 and one or more additional therapeutic agents are administered to the subject for at least one treatment cycle, as specified above, particularly with respect to dosage amount, route, form, duration and / or dosing regimen.

[0330] In some embodiments, the treatment cycle is about 2 weeks (14 days), 3 weeks (21 days), or 4 weeks (28 days). In some embodiments, each treatment cycle is 3 weeks (21 days).

[0331] In some embodiments, BNT411 and, if present or used, one or more additional therapeutic agents are administered simultaneously. In some embodiments, BNT411 and, if present or used, one or more additional therapeutic agents are administered separately from the checkpoint inhibitor.

[0332] In some embodiments, BNT411 is administered Q1W for at least 2 (e.g., at least 3 or at least 4) treatment cycles. In some embodiments, BNT411 is administered Q1W on days 2, 8, and 15 of a treatment cycle. In some embodiments, each treatment cycle is 3 weeks (21 days). In some embodiments, BNT411 is administered Q1W for at least 2 (such as at least 3 or at least 4) treatment cycles, then once every 3 weeks (Q3W), particularly on day 2. In some embodiments, BNT411 is administered Q1W on days 2, 8, and 15 of a treatment cycle for 4 treatment cycles, then Q3W on day 2 of treatment cycle 5 and each subsequent treatment cycle.

[0333] In some embodiments, when the one or more additional therapeutic agents include a checkpoint inhibitor (such as an anti-PD-L1 antibody, e.g., atezolizumab), the checkpoint inhibitor is administered at least once per treatment cycle. In some embodiments, each treatment cycle is 3 weeks (21 days). In some embodiments, the checkpoint inhibitor is administered Q3W for at least two treatment cycles (preferably on day 1 of a treatment cycle). In some embodiments, the checkpoint inhibitor is administered Q3W for each treatment cycle (preferably on day 1 of a treatment cycle).

[0334] In some embodiments, when the one or more additional therapeutic agents include a platinum-based chemotherapeutic agent (such as carboplatin), the platinum-based chemotherapeutic agent is administered at least once for two or more (such as 2-4) treatment cycles. In some embodiments, each treatment cycle is 3 weeks (21 days). In some embodiments, the platinum-based chemotherapeutic agent is administered Q3W (preferably on day 1 of a treatment cycle) for at least two treatment cycles (such as 2-4 treatment cycles). In some embodiments, the platinum-based chemotherapeutic agent is administered Q3W (preferably on day 1 of a treatment cycle) for four treatment cycles (particularly treatment cycles 1, 2, 3 and 4 (or the first four treatment cycles)).

[0335] In some embodiments, when the one or more additional therapeutic agents include a topoisomerase inhibitor (such as etoposide), the topoisomerase inhibitor is administered at least once over two or more (such as at least three, or at least four) treatment cycles. In some embodiments, each treatment cycle is 3 weeks (21 days). In some embodiments, the topoisomerase inhibitor is administered three times in week 1 of a treatment cycle (preferably on days 1, 2, and 3 of a treatment cycle) over two or more (such as at least three, or at least four) treatment cycles. In some embodiments, the topoisomerase inhibitor is administered three times in week 1 of a treatment cycle (preferably on days 1, 2, and 3 of a treatment cycle) over four treatment cycles (particularly treatment cycles 1, 2, 3, and 4 (or the first four treatment cycles)).

[0336] In some embodiments, when the one or more additional therapeutic agents include a checkpoint inhibitor (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum-based chemotherapy agent (such as carboplatin), and a topoisomerase inhibitor (such as etoposide), the checkpoint inhibitor is administered Q3W for each treatment cycle (preferably on day 1 of the treatment cycle), the platinum-based chemotherapy agent is administered Q3W for four treatment cycles (particularly treatment cycles 1, 2, 3, and 4 (or the first four treatment cycles)), (preferably on day 1 of the treatment cycle), and the topoisomerase inhibitor is administered three times in week 1 of the treatment cycle (preferably on days 1, 2, and 3 of the treatment cycle) for four treatment cycles (particularly treatment cycles 1, 2, 3, and 4 (or the first four treatment cycles)). In some embodiments, BNT411 is administered Q1W on days 2, 8, and 15 of the treatment cycle for four treatment cycles, then Q3W on day 2 of treatment cycle 5 and each subsequent treatment cycle. In some embodiments, each treatment cycle is 3 weeks (21 days).

[0337] BNT411 and, if present or used, one or more additional therapeutic agents may be administered in any suitable form (e.g., naked per se). However, in some embodiments, BNT411 and, if present or used, one or more additional therapeutic agents are administered in the form of any suitable pharmaceutical composition described herein. In some embodiments, at least BNT411 is administered in the form of a separate pharmaceutical composition. In some embodiments, if one or more additional therapeutic agents are used, BNT411 and at least one (such as at least two or at least three) of the one or more additional therapeutic agents are administered in the form of a separate pharmaceutical composition. For example, in some embodiments, if the one or more additional therapeutic agents include a platinum-based chemotherapeutic agent, the platinum-based chemotherapeutic agent is administered in the form of a separate pharmaceutical composition. In some embodiments, if one or more additional therapeutic agents are used, BNT411 and any of the one or more additional therapeutic agents are administered in the form of separate pharmaceutical compositions (i.e., one pharmaceutical composition for BNT411 and one pharmaceutical composition for each of the one or more additional therapeutic agents).

[0338] composition The composition or pharmaceutical composition may be prepared as described in Remington: The Science and Practice of Pharmacy, 1999. thThe pharmaceutical composition may be formulated with carriers, excipients and / or diluents, including known adjuvants, and any other components suitable for pharmaceutical compositions, according to conventional techniques, such as those disclosed in The Pharmaceutical and Medical Devices Association, 1995, Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA. Pharmaceutical compositions may be formulated with carriers, excipients and / or diluents, including known adjuvants, and any other components suitable for pharmaceutical compositions. The pharmaceutically acceptable carriers or diluents, and any known adjuvants and excipients, should be suitable for BNT411, and / or one or more additional therapeutic agents, if present or used, and for the selected method of administration. In some embodiments, the compatibility of the pharmaceutical composition with carriers and other components is determined based on the lack of significant adverse effect (e.g., less than substantial effect [less than 10% relative inhibition, less than 5% relative inhibition, etc.]) on the desired biological properties of the selected compound or pharmaceutical composition.

[0339] In a second aspect, the present disclosure provides a method for the preparation of a medicament for use in a pharmaceutical composition comprising administering to a patient a medicament for use in a pharmaceutical composition ... -9 mol~about 9100x10 -9 In some embodiments, the compositions, particularly pharmaceutical compositions, comprising BNT411 in an amount of about 40 μg to about 1600 μg, or about 91×10 mol. -9 mol~approx. 3640x10 -9 In some embodiments, the composition, particularly the pharmaceutical composition, comprising BNT411 comprises about 160 μg to about 800 μg, or about 364×10 -9 mol~approx. 1820x10 -9 In some embodiments, the composition, particularly the pharmaceutical composition, comprising BNT411 comprises about 160 μg to about 720 μg, or about 364×10 -9 mol~approx. 1638x10 -9 In some embodiments, the composition, particularly the pharmaceutical composition, comprising BNT411 comprises about 192 μg to about 768 μg (such as about 384 μg to about 768 μg), or about 437×10 -9 mol~about 1747x10 -9 mol(about 873x10 -9 mol~about 1747x10-9 In some embodiments, the composition, particularly the pharmaceutical composition, comprising BNT411 comprises 384 μg, or about 874×10 -9 Contains BNT411 in molar amounts.

[0340] In some embodiments, the composition, particularly the pharmaceutical composition, comprising BNT411 is for systemic administration. In some embodiments, the composition is for injection or infusion, for example, intravenous injection or infusion. In some embodiments, the BNT411 is in an aqueous solution, for example, 0.9% NaCl (saline), in a volume of 1-500 ml, for example, 5-250 ml. In some embodiments, the composition is in a dosage unit form.

[0341] In some embodiments, the composition, particularly the pharmaceutical composition, comprising BNT411 is for use in a method for reducing or preventing tumor progression or treating cancer in a subject, particularly any method for reducing or preventing tumor progression or treating cancer in a subject described herein. Thus, in a third aspect, the present disclosure provides a composition, particularly the pharmaceutical composition, of the second aspect for use in a method for reducing or preventing tumor progression or treating cancer in a subject.

[0342] The embodiments disclosed herein with respect to the first aspect (particularly with respect to BNT411, its method of administration (particularly with respect to dosage, route, form, duration and / or dosage regimen), any one or more additional therapeutic agents (particularly with respect to dosage, route, form, duration and / or dosage regimen), the tumor / cancer to be treated, and / or the subject to be treated) also apply to the composition of the second aspect and / or the composition for use of the third aspect.

[0343] Thus, in some embodiments of the second and / or third aspects, the composition contains from about 0.1 μg / kg to about 50 μg / kg body weight of the compound, or from about 8 μg to about 4000 μg of the compound in total, and / or from about 0.23×10 -9mol / kg weight ~ approx. 114x10 -9 mol / kg body weight of compound, or about 18x10 -9 mol~about 9100x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0344] In some embodiments of the second and / or third aspects, the composition comprises from about 0.5 μg / kg to about 20 μg / kg body weight of the compound, or from about 40 μg to about 1600 μg of the compound in total, and / or from about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight of compound, or about 91x10 -9 mol~approx. 3640x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0345] In some embodiments of the second and / or third aspects, the composition comprises about 2 μg / kg to about 10 μg / kg body weight of the compound, or about 160 μg to about 800 μg of the compound in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight of compound, or about 364x10 -9 mol~approx. 1820x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0346] In some embodiments of the second and / or third aspects, the composition comprises about 2 μg / kg to about 9 μg / kg body weight of the compound, or about 160 μg to about 720 μg of the compound in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 20.5x10 -9 mol / kg body weight of compound, or about 364x10 -9 mol~approx. 1638x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0347] In some embodiments of the second and / or third aspects, the composition comprises about 2 μg / kg to about 5 μg / kg body weight of the compound, or about 160 μg to about 400 μg of the compound in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 11.4x10 -9 mol / kg body weight of compound, or about 364x10 -9 mol~about 910x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0348] In some embodiments of the second and / or third aspects, the composition contains about 2.4 μg / kg to about 9.6 μg / kg body weight of the compound, or about 192 μg to about 768 μg of the compound in total, and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight of compound, or about 437x10 -9 mol~about 1747x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0349] In some embodiments of the second and / or third aspects, the composition contains about 4.8 μg / kg to about 9.6 μg / kg body weight of the compound, or about 384 μg to about 768 μg of the compound in total, and / or about 10.9×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight of compound, or about 873x10 -9 mol~about 1747x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0350] In some embodiments of the second and / or third aspects, the composition contains about 4.8 μg of compound / kg body weight, or about 384 μg of compound in total, and / or about 10.9×10 -9 mol / kg body weight of compound, or about 874x10 -9 The compound is administered to the subject in an amount to provide 100 mol of the compound.

[0351] The compositions, particularly pharmaceutical compositions of BNT411 and, if present, at least one pharmaceutical composition of one or more additional therapeutic agents, may include diluents, fillers, salts, buffers, surfactants (e.g., non-ionic surfactants such as Tween-20 or Tween-80), stabilizers (e.g., sugars, or non-protein amino acids), preservatives, solubilizers, and / or other materials suitable for inclusion in a pharmaceutical composition.

[0352] Pharmaceutically acceptable carriers, excipients or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro edit. 1985).

[0353] Pharmaceutical carriers, excipients or diluents can be selected with regard to the intended route of administration and standard pharmaceutical practice.

[0354] Pharmaceutically acceptable carriers include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, antioxidants, and absorption delaying agents, etc. that are physiologically compatible with the active compounds, particularly BNT411, and / or one or more additional therapeutic agents used herein, if present or used.

[0355] Examples of suitable aqueous and non-aqueous carriers that can be used in the (pharmaceutical) compositions include water, saline, phosphate buffered saline, ethanol, dextrose, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, corn oil, peanut oil, cottonseed oil, and sesame oil, carboxymethylcellulose colloidal solutions, tragacanth gum, and injectable organic esters such as ethyl oleate, and / or various buffers. Other carriers are well known in the pharmaceutical art.

[0356] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the immediate preparation of sterile injectable solutions or dispersions.The use of such media and agents for pharmaceutically active substances is known in the art.Except where any conventional media or agent is incompatible with the active compound, its use in (pharmaceutical) compositions is contemplated.

[0357] The term "excipient" as used herein refers to a substance that may be present in the (pharmaceutical) composition of the present disclosure, but is not an active ingredient. Examples of excipients include, but are not limited to, carriers, binders, diluents, lubricants, thickeners, surfactants, preservatives, stabilizers, emulsifiers, buffers, flavorings, or colorings.

[0358] The term "diluent" refers to a diluting and / or thinning agent. Additionally, the term "diluent" includes any one or more of a fluid, liquid or solid suspension and / or mixing medium. Examples of suitable diluents include ethanol, glycerol and water.

[0359] The (pharmaceutical) compositions may also include pharma- ceutically acceptable antioxidants, such as: (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, and the like; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0360] The (pharmaceutical) composition may also contain isotonic agents, for example, sugars, polyalcohols, such as mannitol, sorbitol, glycerol or sodium chloride in the composition.

[0361] The (pharmaceutical) composition may also contain one or more adjuvants suitable for the selected route of administration, such as preservatives, wetting agents, emulsifiers, dispersing agents, preservatives or buffers that can enhance the shelf life or effectiveness of the composition. The compositions used herein may be prepared with carriers that protect the compound from rapid release, such as controlled release formulations, including implants, transdermal patches and microencapsulated delivery systems. Such carriers may include gelatin, glyceryl monostearate, glyceryl distearate, biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid, alone or with wax, or other materials known in the art. The method for preparing such formulations is generally known to those skilled in the art, see, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0362] "Pharmaceutically acceptable salts" include acid addition salts that may be formed, for example, by using pharma- ceutically acceptable acids, such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid, or phosphoric acid. In addition, suitable pharma- ceutically acceptable salts include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); ammonium (NH4 +); as well as salts formed with suitable organic ligands (e.g., quaternary ammonium and amine cations formed using counter anions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkylsulfonates and arylsulfonates). Illustrative examples of pharma- ceutically acceptable salts include, but are not limited to, acetates, adipates, alginates, arginates, ascorbates, aspartates, benzenesulfonates, benzoates, bicarbonates, bisulfates, bitartrates, borates, bromides, butyrates, calcium edetate, camphorates, camphorsulfonates, camsylates, carbonates, chlorides, citrates, clavulanates, cyclosalicylates, and the like. Pentanepropionate, Digluconate, Dihydrochloride, Dodecyl Sulfate, Edetate, Edisylate, Estolate, Esylate, Ethanesulfonate, Formate, Fumarate, Galactinate, Galacturonate, Gluceptinate, Glucoheptonate, Gluconate, Glutamate, Glycerophosphate, Glycolylarsanilate, Hemisulfate, Heptanoate, Hexanoate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride , hydroiodide, 2-hydroxyethanesulfonate, hydroxynaphthoate, iodide, isobutyrate, isothioate, lactate, lactobionate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate , pamoate (embonate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate / diphosphate, phthalate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, suberate, succinate, tannate, tartrate, theoclate, tosylate, triethiodide, undecanoate, valerate, and the like (see, for example, S. M. Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., 66, pp. 1-19 (1977)).Pharmaceutically non-acceptable salts may be used to prepare pharma-ceutically acceptable salts and are included in the disclosure.

[0363] In some embodiments, BNT411 and, if used, one or more additional therapeutic agents can be formulated to ensure proper distribution in vivo. Pharmaceutically acceptable carriers for parenteral administration include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is known in the art. Except in the case where a conventional media or agent is incompatible with the active compound, its use in the composition is contemplated. Other active or therapeutic compounds can also be incorporated into the composition.

[0364] Injectable pharmaceutical compositions must typically be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, microemulsions, liposomes, or other ordered structures suitable for high drug concentration. The carrier can be an aqueous or non-aqueous solvent or dispersion medium, including, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it is preferable to include an isotonic agent, for example, sugar, glycerol, polyalcohol such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable composition can be brought about by including an agent that delays absorption, for example, monostearate salts and gelatin in the composition. Sterile injection solution can be prepared by incorporating the required amount of active compound into a suitable solvent, for example, with one or combination of the components listed above as necessary, followed by sterilization precision filtration.Generally, dispersion is prepared by incorporating active compound into a sterile vehicle that contains a basic dispersion medium and other components required, for example, from those listed above.For the preparation of sterile powder for sterile injection solution, the example of preparation method is vacuum drying and lyophilization, which produces powder of active ingredient and any additional desired ingredients from the solution of active ingredient that has been previously sterilized and filtered.

[0365] Sterile injection solution can be prepared by incorporating the required amount of active compound into suitable solvent with one or combination of the above-listed components as necessary, followed by sterilization precision filtration.Generally, dispersion is prepared by incorporating active compound into sterile vehicle that contains basic dispersion medium and other components required from above-listed.In the case of sterile powder for preparing sterile injection solution, the example of preparation method is vacuum drying and lyophilization, which produces powder of active ingredient and any additional desired ingredients from the solution of active ingredient that has been previously sterilized and filtered.

[0366] kit In a fourth aspect, the disclosure provides a kit comprising (i) BNT411 and (ii) one or more additional therapeutic agents selected from the group consisting of a checkpoint inhibitor (CPI), a platinum-based chemotherapeutic agent, a topoisomerase inhibitor, and combinations thereof.

[0367] In some embodiments, the one or more additional therapeutic agents in the kit of the fourth aspect is selected from the group consisting of atezolizumab, carboplatin, etoposide, and combinations thereof.

[0368] In some embodiments, BNT411 and the one or more additional therapeutic agents are for systemic administration, particularly injection or infusion, for example intravenous injection or infusion.

[0369] In some embodiments, the kit of the fourth aspect is for use in a method for reducing or preventing tumor progression or treating cancer in a subject, particularly any method for reducing or preventing tumor progression or treating cancer in a subject as described herein.Thus, in a fifth aspect, the present disclosure provides a kit of the fourth aspect for use in a method for reducing or preventing tumor progression or treating cancer in a subject.

[0370] The embodiments disclosed herein with respect to the first aspect (particularly with respect to BNT411, its method of administration (particularly with respect to dosage, route, form, duration and / or dosage regimen), any one or more further therapeutic agents (particularly with respect to dosage, route, form, duration and / or dosage regimen), the tumor / cancer to be treated, and / or the subject to be treated) also apply to the kit of the fourth aspect and / or the kit for use of the fifth aspect.

[0371] In some embodiments, the kit comprises at least two containers, one of which contains BNT411 (by itself or in the form of a (pharmaceutical) composition) and a second container contains one or more additional therapeutic agents (by itself or in the form of a (pharmaceutical) composition). When the kit contains more than one additional therapeutic agent, it is preferred that the kit comprises at least three containers, one containing BNT411 (by itself or in the form of a (pharmaceutical) composition), one containing a first additional therapeutic agent (by itself or in the form of a (pharmaceutical) composition), and at least a third container containing a third additional therapeutic agent (by itself or in the form of a (pharmaceutical) composition). When the kit comprises at least three additional therapeutic agents, it is preferred that the kit comprises at least four containers, one containing BNT411 (by itself or in the form of a (pharmaceutical) composition), one containing the first additional therapeutic agent (by itself or in the form of a (pharmaceutical) composition), one containing the second additional therapeutic agent (by itself or in the form of a (pharmaceutical) composition), and at least a fourth container containing the third additional therapeutic agent (by itself or in the form of a (pharmaceutical) composition).

[0372] The embodiments disclosed herein with respect to any one of the first, second and third aspects (particularly with respect to BNT411, its method of administration (particularly with respect to dosage, route, form, duration and / or dosage regimen), the one or more further therapeutic agents (particularly with respect to dosage, route, form, duration and / or dosage regimen), the tumor / cancer to be treated, and / or the subject to be treated) also apply to the kit of the fourth aspect and / or the kit for use of the fifth aspect.

[0373] Further Aspects In a further aspect, the present disclosure provides a method for reducing or preventing tumor progression or treating cancer in a subject using the compound BNT411 described herein, for example using a composition described herein and / or a kit described herein. In some embodiments, such further aspects include (i) a method for reducing or preventing tumor progression or treating cancer in a subject, comprising administering to the subject BNT411 as specified in the first aspect of the present disclosure, (ii) a method for reducing or preventing tumor progression or treating cancer in a subject, comprising administering to the subject a composition as specified in the second or third aspect of the present disclosure, and (iii) a method for reducing or preventing tumor progression or treating cancer in a subject, comprising administering to the subject BNT411 and one or more additional therapeutic agents included in a kit as specified in the fourth or fifth aspect of the present disclosure.

[0374] Citation of documents and tests referenced herein is not intended as an admission that any of the foregoing is pertinent prior art. All statements regarding the contents of these documents are based on information available to the applicants and do not constitute any admission as to the accuracy of the contents of these documents.

[0375] The description (including the following examples) is presented to enable those skilled in the art to make and use the various embodiments. Descriptions of specific devices, techniques, and applications are provided only as examples. Various modifications to the examples described herein will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other examples and applications without departing from the spirit and scope of the various embodiments. Thus, the various embodiments are not intended to be limited to the examples described and shown herein, but should be accorded the scope consistent with the claims.

[0376] Further itemized embodiments are as follows: 1. A compound having the formula: [ka] or a pharma- ceutically acceptable solvate or salt thereof, wherein said method comprises administering to said subject an appropriate amount of the compound or a pharma- ceutically acceptable solvate or salt thereof.

[0377] 2. A compound for use according to item 1, wherein the appropriate amount of the compound is a therapeutically effective and safe amount.

[0378] 3. A suitable amount of the compound is about 0.1 μg / kg to about 50 μg / kg body weight, or about 8 μg to about 4000 μg in total, and / or about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18x10 in total -9 mol~about 9100x10 -9 mol of a compound for use in any one of the preceding items.

[0379] 4. A suitable amount of the compound is about 0.5 μg / kg to about 20 μg / kg body weight, or about 40 μg to about 1600 μg in total, and / or about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight, or about 91x10 in total -9 mol~approx. 3640x10 -9 mol of a compound for use in any one of the preceding items.

[0380] 5. A suitable amount of the compound is about 2 μg / kg to about 10 μg / kg body weight, or about 160 μg to about 800 μg in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9mol of a compound for use in any one of the preceding items.

[0381] 5a. A suitable amount of the compound is about 2.4 μg / kg to about 9.6 μg / kg body weight, or about 192 μg to about 768 μg in total, and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 437x10 in total -9 mol~about 1747x10 -9 mol of the compound for use according to any one of items 1 to 5.

[0382] 5b. A suitable amount of the compound is about 4.8 μg / kg to about 9.6 μg / kg body weight, or about 384 μg to about 768 μg in total, and / or about 10.9×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 873x10 in total -9 mol~about 1747x10 -9 mol of the compound for use according to any one of items 1 to 5.

[0383] 5c. A suitable amount of compound is about 4.8 μg / kg body weight, or about 384 μg in total, and / or about 10.9×10 -9 mol / kg body weight, or about 874x10 in total -9 mol of the compound for use according to any one of items 1 to 5.

[0384] 6. A compound for use according to any one of the preceding items which is a solvate.

[0385] 7. The compound for use according to item 6, wherein the solvate is selected from the group consisting of hydrates and dimethylsulfoxide solvates.

[0386] 8. A compound for use according to any one of items 1 to 5c, which is anhydrous.

[0387] 9. A compound for use according to any one of the preceding items, administered systemically, preferably intravenously.

[0388] 10. The compound for use of any one of the preceding items, wherein the subject is a human subject.

[0389] 11. The compound for use of any one of the preceding items, wherein the tumor or cancer is a solid tumor or cancer.

[0390] 12. The compound for use of any one of the preceding items, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancer, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor, and mesothelioma.

[0391] 13. The compound for use of any one of the preceding items, wherein the tumor or cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer and pancreatic cancer.

[0392] 14. The compound for use of any one of the preceding items, wherein the tumor or cancer is small cell lung cancer (SCLC), such as extensive stage small cell lung cancer (ES-SCLC).

[0393] 15. The compound for use of any one of the preceding items, wherein the subject is chemotherapy naive.

[0394] 16. The compound for use of any one of the preceding items, wherein the compound is administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days).

[0395] 17. The compound for use of any one of the preceding items, wherein one dose of the compound is administered once a week (Q1W) for at least one treatment cycle.

[0396] 18. The compound for use of any one of the preceding items, wherein one dose of the compound is administered Q1W, then once every three weeks (Q3W), for at least 4 treatment cycles.

[0397] 19. The compound for use according to any one of the preceding items, wherein each dose of the compound is infused over a minimum of 10 minutes, such as a minimum of 15 minutes, a minimum of 20 minutes, a minimum of 25 minutes or a minimum of 30 minutes.

[0398] 20. The compound for use of any one of the preceding items, wherein the method further comprises administering to said subject one or more additional therapeutic agents.

[0399] 21. The compound for use of item 20, wherein the one or more further therapeutic agents are selected from the group consisting of checkpoint inhibitors (CPIs), platinum-based chemotherapy agents, topoisomerase inhibitors and combinations thereof.

[0400] 22. The compound for use of item 20 or 21, wherein the one or more further therapeutic agents are selected from the group consisting of atezolizumab, carboplatin, etoposide and combinations thereof.

[0401] 23. The compound for use according to any one of items 20 to 22, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide.

[0402] 24. The compound for use of any one of items 20 to 23, wherein the one or more further therapeutic agents are administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days).

[0403] 25. The compound for use of any one of items 20-24, wherein one dose of each of the one or more further therapeutic agents is administered at least Q3W for at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

[0404] 26. The compound for use of any one of items 20-25, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide, wherein one dose of atezolizumab is administered Q3W (preferably on day 1 of a treatment cycle), one dose of carboplatin is administered Q3W (preferably on day 1 of a treatment cycle) for 4 treatment cycles, and one dose of etoposide is administered 3 times in week 1 of a treatment cycle (preferably on days 1, 2 and 3 of a treatment cycle) for 4 treatment cycles, each treatment cycle being 3 weeks (21 days).

[0405] 27. The compound for use of item 26, wherein one dose of the compound is administered Q1W (preferably on days 2, 8 and 15 of a treatment cycle) for 4 treatment cycles, then Q3W (preferably on day 2 of treatment cycle 5 and each subsequent treatment cycle).

[0406] 28. A compound having the formula: [ka] or a pharma- ceutically acceptable solvate or salt thereof, wherein the amount of the compound in the composition is about 8 μg to 4000 μg, or about 18×10 -9 mol~about 9100x10 -9 mol, composition.

[0407] 29. About 40 μg to about 1600 μg, or about 91 x 10 -9 mol~approx. 3640x10 -9 mol of the compound, preferably about 160 μg to about 800 μg, or about 364×10 -9 mol~approx. 1820x10 -9 mol of said compound.

[0408] 29a. Approximately 192 μg to approximately 768 μg, or approximately 437 x 10 -9 mol~about 1747x10 -9 30. The composition of claim 28 or 29, comprising mol of said compound.

[0409] 29b. Approximately 384 μg to approximately 768 μg, or approximately 873 x 10 -9 mol~about 1747x10 -9 30. The composition of claim 28 or 29, comprising mol of said compound.

[0410] 29c. Approximately 384 μg, or approximately 874 x 10 -9 30. The composition of claim 28 or 29, comprising mol of said compound.

[0411] 30. The composition of any one of items 28 to 29c, which is for systemic administration.

[0412] 31. The composition of any one of items 28 to 30, which is for injection or infusion, for example intravenous injection or infusion.

[0413] 32. The composition of any one of items 28 to 31, wherein the compound is in an aqueous solution, such as 0.9% NaCl (saline), in a volume of 1 to 500 ml, such as 5 to 250 ml.

[0414] 33. The composition of any one of items 28 to 32, which is in dosage unit form.

[0415] 34. The composition of any one of items 28 to 33 for use in a method for reducing or preventing the progression of a tumor or for treating cancer in a subject.

[0416] 35. About 0.1 μg / kg to about 50 μg / kg body weight of the compound, or about 8 μg to about 4000 μg of the compound in total, and / or about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight of compound, or about 18x10 -9mol~about 9100x10 -9 35. The composition for use according to item 34, wherein the composition is administered to a subject in an amount to provide 1.5 mol of the compound.

[0417] 36. The composition contains from about 0.5 μg / kg to about 20 μg / kg body weight of the compound, or from about 40 μg to about 1600 μg of the compound in total, and / or from about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight of compound, or about 91x10 -9 mol~approx. 3640x10 -9 36. The compound for use according to item 34 or 35, wherein the compound is administered to the subject in an amount to provide 1 mol of the compound.

[0418] 37. The composition contains about 2 μg / kg to about 10 μg / kg body weight of the compound, or about 160 μg to about 800 μg of the compound in total, and / or about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight of compound, or about 364x10 -9 mol~approx. 1820x10 -9 37. The compound for use according to any one of items 34 to 36, wherein the compound is administered to the subject in an amount to provide 100 mol of the compound.

[0419] 37a. The composition contains from about 2.4 μg / kg to about 9.6 μg / kg of body weight of the compound, or from about 192 μg to about 768 μg of the compound in total, and / or from about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight of compound, or about 437x10 -9 mol~about 1747x10 -9 38. The compound for use according to any one of items 34 to 37, wherein the compound is administered to the subject in an amount to provide 100 mol of the compound.

[0420] 37b. The composition contains from about 4.8 μg / kg to about 9.6 μg / kg of body weight of the compound, or from about 384 μg to about 768 μg of the compound in total, and / or from about 10.9×10 -9mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight of compound, or about 873x10 -9 mol~about 1747x10 -9 38. The compound for use according to any one of items 34 to 37, wherein the compound is administered to the subject in an amount to provide 100 mol of the compound.

[0421] 37c. The composition contains about 4.8 μg of compound / kg body weight, or about 384 μg of compound in total, and / or about 10.9×10 -9 mol / kg body weight of compound, or about 874x10 -9 38. The compound for use according to any one of items 34 to 37, wherein the compound is administered to the subject in an amount to provide 100 mol of the compound.

[0422] 38. The composition for use according to any one of items 34 to 37c, wherein the subject is a human subject.

[0423] 39. The composition for use according to any one of items 34 to 38, wherein the tumor or cancer is a solid tumor or cancer.

[0424] 40. The composition for use of any one of items 34 to 39, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancer, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor and mesothelioma.

[0425] 41. The composition for use of any one of items 34 to 40, wherein the tumor or cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer and pancreatic cancer.

[0426] 42. The composition for use according to any one of items 34 to 41, wherein the tumor or cancer is small cell lung cancer (SCLC), such as extensive stage small cell lung cancer (ES-SCLC).

[0427] 43. The composition for use according to any one of items 34 to 42, wherein the subject is chemotherapy naive.

[0428] 44. The composition for use of any one of items 34 to 43, wherein the composition is administered in at least one treatment cycle, each treatment cycle being for 3 weeks (21 days).

[0429] 45. The composition for use of any one of items 34 to 44, wherein one dose of the composition is administered once a week (Q1W) for at least one treatment cycle.

[0430] 46. ​​The composition for use of any one of items 34 to 45, wherein one dose of the composition is administered Q1W, then once every three weeks (Q3W) for at least four treatment cycles.

[0431] 47. The composition for use according to any one of items 34 to 46, which is infused over a period of at least 10 minutes, such as at least 15 minutes, at least 20 minutes, at least 25 minutes or at least 30 minutes.

[0432] 48. The composition for use of any one of items 34 to 47, wherein the method further comprises administering to the subject one or more additional therapeutic agents.

[0433] 49. The composition for use of item 48, wherein the one or more additional therapeutic agents are selected from the group consisting of checkpoint inhibitors (CPIs), platinum-based chemotherapy agents, topoisomerase inhibitors, and combinations thereof.

[0434] 50. The composition for use of item 48 or 49, wherein the one or more additional therapeutic agents are selected from the group consisting of atezolizumab, carboplatin, etoposide, and combinations thereof.

[0435] 51. The composition for use of any one of items 48 to 50, wherein the one or more additional therapeutic agents is a combination of atezolizumab, carboplatin and etoposide.

[0436] 52. The composition for use of any one of items 48 to 51, wherein the one or more additional therapeutic agents are administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days).

[0437] 53. The composition for use of any one of items 48-52, wherein one dose of each of the one or more additional therapeutic agents is administered at least Q3W for at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

[0438] 54. The composition for use of any one of items 48-53, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide, wherein one dose of atezolizumab is administered Q3W (preferably on day 1 of a treatment cycle), one dose of carboplatin is administered Q3W (preferably on day 1 of a treatment cycle) for 4 treatment cycles, and one dose of etoposide is administered three times in week 1 of a treatment cycle (preferably on days 1, 2 and 3 of a treatment cycle) for 4 treatment cycles, each treatment cycle being 3 weeks (21 days).

[0439] 55. The composition for use of item 54, wherein one dose of the composition is administered Q1W (preferably on days 2, 8 and 15 of a treatment cycle) for 4 treatment cycles, and then Q3W (preferably on days 2 of treatment cycle 5 and each subsequent treatment cycle).

[0440] 56.(i) A compound having the formula: [ka] or a pharma- ceutically acceptable solvate or salt thereof, and (ii) one or more additional therapeutic agents selected from the group consisting of checkpoint inhibitors (CPIs), platinum-based chemotherapeutic agents, topoisomerase inhibitors, and combinations thereof.

[0441] 57. The kit of item 56, wherein the one or more additional therapeutic agents are selected from the group consisting of atezolizumab, carboplatin, etoposide, and combinations thereof.

[0442] 58. The kit of item 56 or 57, wherein the compound and the one or more further therapeutic agents are for systemic administration, in particular for injection or infusion, such as intravenous injection or infusion.

[0443] 59. The kit of any one of items 56 to 58 for use in a method for reducing or preventing the progression of a tumor or treating cancer in a subject.

[0444] 60. The compound is administered in an amount of about 0.1 μg / kg to about 50 μg / kg body weight, or in a total amount of about 8 μg to about 4000 μg, and / or about 0.23 x 10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18x10 in total -9 mol~about 9100x10 -9 60. The kit for use of item 59, wherein the amount of the compound is administered to a subject in mol.

[0445] 61. The compound is administered in an amount of about 0.5 μg / kg to about 20 μg / kg body weight, or in a total amount of about 40 μg to about 1600 μg, and / or about 1.14 x 10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight, or about 91x10 in total -9 mol~approx. 3640x10 -9 61. The kit for use of item 59 or 60, wherein the amount of the compound is administered to the subject in an amount of 100 mol.

[0446] 62. The compound is administered at a dose of about 2 μg / kg to about 10 μg / kg body weight, or at a dose of about 160 μg to about 800 μg in total, and / or at a dose of about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364x10 in total -9 mol~approx. 1820x10 -9 62. A kit for use according to any one of items 59 to 61, wherein the kit is administered to a subject in an amount of 100 mol.

[0447] 62a. The compound is administered in an amount of about 2.4 μg / kg to about 9.6 μg / kg body weight, or in a total amount of about 192 μg to about 768 μg, and / or about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 437x10 in total -9 mol~about 1747x10 -9 63. A kit for use according to any one of items 59 to 62, wherein the kit is administered to a subject in an amount of 100 mol.

[0448] 62b. The compound is administered in an amount of about 4.8 μg / kg to about 9.6 μg / kg body weight, or in a total amount of about 384 μg to about 768 μg, and / or about 10.9×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 873x10 in total -9 mol~about 1747x10 -9 63. A kit for use according to any one of items 59 to 62, wherein the kit is administered to a subject in an amount of 100 mol.

[0449] 62c. The compound is administered at about 4.8 μg / kg body weight, or at about 384 μg in total, and / or at about 10.9×10 -9 mol / kg body weight, or about 874x10 in total -9 63. A kit for use according to any one of items 59 to 62, wherein the kit is administered to a subject in an amount of 100 mol.

[0450] 63. A kit for use of any one of items 59 to 62c, wherein the subject is a human subject.

[0451] 64. A kit for use of any one of items 59 to 63, wherein the tumor or cancer is a solid tumor or cancer.

[0452] 65. The kit for use of any one of items 59 to 64, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancer, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor, and mesothelioma.

[0453] 66. The kit for use of any one of items 59 to 65, wherein the tumor or cancer is selected from the group consisting of lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer and pancreatic cancer.

[0454] 67. A kit for use of any one of items 59 to 66, wherein the tumor or cancer is small cell lung cancer (SCLC), such as extensive stage small cell lung cancer (ES-SCLC).

[0455] 68. A kit for use of any one of items 59 to 67, wherein the subject is chemotherapy naive.

[0456] 69. A kit for use of any one of items 59 to 68, wherein the compound is administered in at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

[0457] 70. A kit for use of any one of items 59 to 69, wherein one dose of the compound is administered once a week (Q1W) for at least one treatment cycle.

[0458] 71. A kit for use of any one of items 59 to 70, wherein one dose of the compound is administered Q1W, then once every three weeks (Q3W) for at least four treatment cycles.

[0459] 72. The kit for use of any one of items 59 to 71, wherein each dose of compound is infused over a minimum of 10 minutes, such as a minimum of 15 minutes, a minimum of 20 minutes, a minimum of 25 minutes or a minimum of 30 minutes.

[0460] 73. The kit for use of any one of items 59 to 72, wherein the one or more additional therapeutic agents are administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days).

[0461] 74. The kit for use of any one of items 59 to 73, wherein one dose of each of the one or more additional therapeutic agents is administered at least Q3W for at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

[0462] 75. The kit for use of any one of items 59-74, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide, wherein one dose of atezolizumab is administered Q3W (preferably on day 1 of a treatment cycle), one dose of carboplatin is administered Q3W (preferably on day 1 of a treatment cycle) for 4 treatment cycles, and one dose of etoposide is administered three times in week 1 of a treatment cycle (preferably on days 1, 2 and 3 of a treatment cycle) for 4 treatment cycles, each treatment cycle being 3 weeks (21 days).

[0463] 76. A kit for use of item 75, wherein one dose of the compound is administered Q1W (preferably on days 2, 8 and 15 of a treatment cycle) for 4 treatment cycles, then Q3W (preferably on day 2 of treatment cycle 5 and each subsequent treatment cycle).

[0464] Further aspects of the present disclosure are disclosed herein. EXAMPLES

[0465] method Cytometric Bead Array (CBA) After performing serial dilutions of the test compounds (such as BNT411), transfer / pipette 5 μL of each sample into a single well of a 96-well plate. As a negative control, use plasma prepared from the whole blood of each donor. Then, 245 μL of RPMI medium is added to each well, resulting in a 1:50 dilution of each sample, called the spike solution. The heparinized whole blood is divided into the 96-well plate with a pipette. After seeding the whole blood, the prepared spike solution is added: seed 190 μL of whole blood into each well and add 10 μL of spike solution to obtain a final volume of 200 μL / well and a further 1:20 dilution of all samples. Finally, the plate is incubated at 37 °C and 5% CO2. After 24 h of incubation, the plate is centrifuged at 500 x g for 5 min. Collect plasma of all samples, transfer to a new 96-well plate, and freeze for at least 3 h at -15 °C to -25 °C until CBA is performed.

[0466] CBA is performed with frozen / thawed plasma samples according to the manufacturer's instructions for the ProCarta multiplex kit. For evaluation of cytokine concentrations, assay replicates of all samples are measured using a luminex system. After checking the standard curve using the instrument control system (Bio-Plex Manager 4.1.1), raw data are transferred to excel. Graphical analysis is performed using GraphPad Prism 6.

[0467] IFNa ELISA Serum levels of IFNα were measured by sandwich ELISA (Pbl Assay Systems) according to the manufacturer's instructions.

[0468] CT26 tumor model BALB / c mice were injected with 2.5x10 5 pieces~5x10 5 Each mouse was inoculated with CT26-WT by sc injection. After the tumors reached a palpable size, the mice were randomly divided into treatment and control groups. Tumor volumes were measured in an open-label manner using calipers and calculated according to the formula (axb 2 Tumor growth was recorded as the mean tumor size and standard error ignoring single distant outliers. 3 Treatment began 7–10 days after the mean volume of 100 μl of BNT411 was reached. BNT411 was administered at 3 mg / kg (75 μg / mouse; BALB / c mice) by i.v. injection into the retro-orbital venous plexus. The control group received an equal volume of 100 μl saline vehicle (0.1% 1 M HCl, 0.1% 1 M NaOH, 99.8% isotonic NaCl solution pH 5.63). EXAMPLES

[0469] Human PBMCs (peripheral blood mononuclear cells) were obtained from healthy donors and treated in vitro with BNT411 (concentration range: 0.1 nM-10 µM) or comparable imidazoquinolines (resiquimod (R848; concentration range: 0.6 nM-50 µM); 852A (concentration range: 0.6 nM-50 µM); or imiquimod (R837; concentration range: 0.6 nM-50 µM)). 24 h after stimulation, the secretion of several cytokines, including IFNa, was analyzed by multiplexed CBA. The results of the CBA measurements are shown in Figure 1 (data shown as mean ± standard deviation (SD), n = 5).

[0470] As can be seen from Figure 1, upon BNT411 exposure, significantly more IFNα was induced at lower concentrations (approximately 10-30 times lower concentrations) compared to the imidazoquinolines imiquimod (R837), resiquimod (R848) and 852A. Thus, Figure 1 demonstrates that BNT411 is more potent on human PBMCs than competing compounds such as resiquimod (R848) with respect to IFNα induction. Since IFNa is a key driver of the mode of action provided by TLR7 agonists, and an important biomarker for TLR7 activation, BNT411, when administered, exerts its effect as a selective TLR7 agonist, specifically binding to TLR7 on plasmacytoid dendritic cells (pDCs) and influencing their activation and maturation, cytotoxicity, and CD8 expression on antigen presenting cells (APCs). + It can be predicted to induce downstream activation and expansion of T cells and extensive modulation of the innate immune system, thereby enhancing pre-existing anti-tumor responses and inducing de novo responses, especially in combination with cytotoxic therapies and immune checkpoint inhibitors. EXAMPLES

[0471] This example was conducted for further in vivo experiments, particularly to determine the appropriate starting dose of BNT411 in tumor mouse models.

[0472] Female BALB / c mice were administered BNT411 at doses of 3, 5, 10 and 15 mg / kg retro-orbitally. Blood samples were taken 1 hour after compound application and analyzed by mouse IFNa ELISA. The results of the IFNa ELISA are shown in FIG. 2.

[0473] As can be seen from Figure 2, a dose of 3 mg / kg BNT411 induced stronger IFNa secretion compared to higher BNT411 doses, supporting the bell-shaped concentration-response curve as observed in human in vitro assays using whole blood preparations. Therefore, a dose of 3 mg / kg BNT411 was used for further in vivo experiments in mice. EXAMPLES

[0474] This experiment was performed to evaluate the antitumor efficacy of BNT411 alone. For this purpose, the CT26 tumor model was utilized.

[0475] Eight doses of BNT411 were administered iv at a dose level of 3 mg / kg, 4-5 days apart (days 14, 19, 23, 28, 33, 37, 42 and 47). See Figure 4A. At the start of treatment, tumors were 10 mm 3 The control group (n=13) received vehicle only. Adaptive immunity was assessed by analyzing gp70 antigen-specific T cell populations in blood and splenocytes 3 and 5 weeks after the first test drug administration. Gp70 is an immunodominant CD8 T cell in the CT26 tumor model. + It is an antigen recognized by T cells. The results of this experiment are shown in Figure 4B.

[0476] As can be seen in Figure 4B, BNT411 demonstrated strong tumor growth inhibition, with test / control values ​​of 43.3% on day 35 of the experiment. A Mann-Whitney test of individual tumor volumes on the same days showed a trend toward statistical significance (p=0.0513). On day 49, the final day of the experiment, 8 of 13 BNT411-treated animals and 2 of 13 vehicle-treated animals were still alive.

[0477] Furthermore, BNT411 treatment resulted in a 50-fold increase in blood IFNα levels measured 1 hour after the first dose compared to the control group. Increased frequencies of gp70+ T cells in blood were observed in BNT411-treated animals compared to the control group at day 35 (8.72% vs. 2.15%) and in splenocytes at day 50 (0.76% vs. 0.44%).

[0478] Blood parameters measured in serum on day 19 (alanine transaminase, aspartate transaminase, creatine kinase, glutamate dehydrogenase, lactate dehydrogenase, and bilirubin) were comparable between the BNT411 and control groups.

[0479] Thus, this example demonstrates that BNT411 exerts antitumor efficacy in monotherapy against immunogenic mouse tumor models, as exemplified by the mouse colorectal cancer cell line CT-26.In this context, BNT411 stimulates the innate and adaptive immune systems, as can be shown by the induction of IFNa secretion and the increase in the frequency of gp70+T cells specific to the gp70 antigen present on the surface of CT-26 tumor cells.Therefore, it can be argued that the antitumor activity of BNT411 is consistent with its hypothesized mode of action. EXAMPLES

[0480] This experiment was conducted to evaluate the antitumor efficacy of BNT411 in monotherapy and in combination with oxaliplatin in the CT26 tumor model.

[0481] Oxaliplatin was administered intraperitoneally (ip) (5 mg / kg, 4 times with 4-5 days between injections). BNT411 was administered iv (8 times at a single dose level of 3 mg / kg with 2-5 days between injections and at least 2 days after oxaliplatin therapy). See Figure 5A. Antitumor efficacy was assessed by group mean tumor volumes of the test group vs. the control group (vehicle only) on study days 33 and 42 (at least 50% of surviving test and control animals). IFNα levels in plasma were analyzed 1 hour after the first BNT411 administration, and gp70+ T cell populations in blood were analyzed on study days 34 and 41. The results of this experiment are shown in Figure 5B and Figure 5C.

[0482] As can be seen in Figure 5B, the BNT411 / oxaliplatin combination therapy showed the strongest antitumor efficacy with a T / C value of 34.3%, compared to 50.7% for oxaliplatin in monotherapy and 65.8% for BNT411 in monotherapy.

[0483] IFNα serum levels were statistically significantly increased in all BNT411-treated groups compared to the control group. See Figure 5C. IFNα levels in the BNT411 monotherapy group were statistically significantly higher than IFNα levels in the combination of BNT411 and oxaliplatin (two-way ANOVA test).

[0484] Tumor-specific gp70+ T cells were induced in all BNT411-treated groups on days 34-41 of the study (Mann-Whitney test).

[0485] In conclusion, BNT411 showed antitumor activity in monotherapy, and the combination of BNT411 with oxaliplatin had an additive effect on tumor growth retardation. EXAMPLES

[0486] This experiment was conducted to evaluate the antitumor efficacy of BNT411 in monotherapy and in combination with an anti-programmed cell death 1 ligand 1 (PD-L1) antibody (anti-PD-L1-mIgG1e3) in the CT26 tumor model.

[0487] Four groups of 10 animals were injected with 1x10 6 CT26 cells were inoculated (day 0). Anti-PD-L1 antibodies were administered intraperitoneally (ip; 200 μg per animal) and BNT411 was administered iv (3 mg / kg). All treatments were administered once every 5 days for a total of 6 doses. See Figure 6A. Body weight change and tumor growth were assessed on study day 21, when at least 9 animals in each group were alive. One mouse treated with both anti-PD-L1 antibodies and BNT411 had eliminated the initial tumor. The contralateral flank of this animal was re-inoculated with CT26 cells on study day 77 and received no further treatment. The results of this experiment are shown in Figure 6B and Figure 6C.

[0488] As can be seen from Figure 6B and Figure 6C, the combination of BNT411 and anti-PD-L1-mIgG1e3 resulted in significant (p≦0.05) inhibition of tumor growth and significantly (p≦0.05) less weight gain compared to the negative control treatment (isotype control antibody + 0.9% saline) or anti-PD-L1-mIgG1e3 alone after 5 doses of treatment. There was a significant (p≦0.05) survival benefit for all test article treatments compared to the negative control treatment (isotype control antibody + 0.9% saline), but there were no significant differences between the test article treatments.

[0489] Tumor growth from the first inoculation was successfully eliminated in one animal in the group treated with the combination of BNT411 and anti-PD-L1-mIgG1e3, see Figure 6B. Secondary inoculation of this tumor-free animal with the same tumor entity induced initial CT26 tumor growth followed by rapid elimination of the CT26 tumor, although the animal remained untreated following re-inoculation.

[0490] In conclusion, BNT411 in combination with a murine PD-L1 antibody demonstrated tumor growth retardation and survival benefits. Tumor clearance in one animal in the combination treatment group (BNT411 and anti-PD-L1-mIgG1e3) and subsequent immunity to tumor rechallenge suggest the formation of anti-tumor immune memory during treatment. Throughout treatment, both BNT411 and anti-PD-L1-mIgG1e3, as well as the combination of both, were well tolerated. There were no treatment-related adverse clinical effects, higher toxicity, or weight loss. EXAMPLES

[0491] This experiment was carried out to assess whether the beneficial effects seen in mice could also be achieved in humans.

[0492] Human whole blood was obtained from healthy donors and treated in vitro with BNT411 (concentration range: 0.1 nM to 10 μM). After 24 h of stimulation, the secretion of several cytokines, including IFNα, IP-10, IL-6 and TNFα, was analyzed by multiplexed CBA. The results of the CBA measurements are shown in Figure 7.

[0493] As can be seen in Figure 7, at very low doses (120k = 0.012 μM), BNT411 induced significant IFNα release. Importantly, proinflammatory cytokines such as IL-6 and TNFα, as well as regulatory cytokines such as IL-10, were only induced at higher concentrations (well above the concentrations that maximally induce IFNα), starting at approximately 0.06 μM.

[0494] In conclusion, IFNα secretion was induced at concentrations 5-25 times lower than those required for induction of proinflammatory and regulatory cytokines such as IL-6, TNFα and IL-10. Furthermore, the BNT411 concentrations for maximal induction of IFNα were 25-100 times lower than those required for maximal induction of IL-6, TNFα and IL-10. This further confirms a sufficiently wide therapeutic window to separate the intended secretion of IFNa from the secretion of proinflammatory cytokines. EXAMPLES

[0495] This experiment was performed to assess whether the beneficial effects seen in mice in vivo and in humans in vitro could also be achieved in human patients.

[0496] For this purpose, a study was designed to evaluate the safety profile of BNT411 in monotherapy and in combination with atezolizumab, etoposide and carboplatin (atezo / EC) and to determine the maximum tolerated dose / recommended phase 2 dose (MTD / RP2D). The study included two parts (1A and 1B) with dose escalation, where patients in part 1A received BNT411 monotherapy and patients in part 1B received BNT411 with atezolizumab, etoposide and carboplatin. Patients had solid tumors (preferably ES-SCLC in part 1B) and received the drug according to the following dosing schedule (until disease progression, unacceptable toxicity, or death): Part 1A: 3-week cycles of BNT411 ivQ1W for 4 cycles, then Q3W Part 1B: 3-week cycles, BNT411 ivQ1W for 4 cycles, then Q3W; atezo / EC Q3W The eight escalating dose levels (DL1-DL8) for BNT411 are shown in Table 4: [Table 4]

[0497] DL1 to DL3 in Part 1A were single-patient cohorts, and all other dose levels were 3+3 cohorts.

[0498] Efficacy was assessed by CT / MRI imaging per RECIST 1.1 and iRECIST every 6 weeks for 48 weeks and then every 12 weeks. Safety was assessed by physical examination, vital signs, electrocardiogram, clinical laboratory evaluations, eye examination, ECOG, pregnancy test, and ECHO / MUGA. Biomarker assessments included tumor biopsies and blood draws for cytokine analysis, immunophenotyping, tumor mutation burden, and TCR profiling.

[0499] As of August 26, 2021, patients were located in seven study centers (UK, USA, Spain, Germany). Twenty-five patients were screened (Part 1A: 22 patients; Part 1B: 3 patients), with seven failing screening (both in Part 1A). Eighteen patients were enrolled (Part 1A: 15 patients; Part 1B: 3 patients), with 15 patients evaluable (Part 1A: 12 patients; Part 1B: 3 patients). Two Part 1A patients were replaced (DL1 due to incorrect dosing, and DL5 due to PD before DLT evaluation was completed). One Part 1A patient dropped out of the study before receiving treatment. The demographic and clinical characteristics of these patients are shown in Table 5. Treatment-emergent adverse events (TEAEs) associated with BNT411 monotherapy and combination therapy are shown in Tables 6 and 7, respectively. [Table 5] [Table 6] [Table 7]

[0500] As can be seen in Tables 6 and 7, BNT411 has a tolerable safety profile at all doses tested as of August 26, 2021 (through DL6). The most frequent adverse events (AEs) associated with BNT411 monotherapy were fever (n=3 patients [20%] grades 1 and 2, Part 1A dose levels (DL) 1*, 2, and 6), chills (n=2 patients [13%], grade 1, Part 1A DL1 and DL6), and anemia (n=2 patients [13%], grades 1 and 3, Part 1A DL4 and DL5). Affected patients (marked with *) were enrolled in DL1 but received 22 times the dose (closer to DL4). There were no dose-limiting toxicities (DLTs) or relevant grade 4-5 AEs in either Part 1A or Part 1B. The two serious adverse events possibly related to BNT411 monotherapy were two cases of infusion-related reactions (grades 1 and 2, occurring in the same patient in part 1A DL6). The one serious adverse event possibly related to BNT411+atezo / EC was pneumonia (grade 3, part 1B DL4). This event resolved with antibiotic treatment and the cause of this event was thought to be multifactorial and could be either the underlying disease or immune activation caused by either BNT411 or atezo / EC.

[0501] Results of cytokine measurements in patients treated with BNT411 monotherapy are shown in Figure 8, where the mean maximum fold change (+SD) calculated from the highest cytokine values ​​observed on day 1 of cycle 1 compared to baseline is shown. IFNa and IL-6 peaked 4-8 hours after treatment, while IP-10 and TNFa peaked 2.5-8 hours after treatment. No significant cytokine changes were observed in DL1A, DL2A or DL3A.

[0502] As can be seen from FIG. 8, there was a dose-dependent cytokine release in the 10 patients in Part 1A: DL4A (3 patients), DL5A (4 patients), and DL6A (3 patients). Substantial induction of IFNa, IP-10, and other mode of action related cytokines was observed in DL6A. Importantly, TNFa induction levels remained unchanged, and some increase in IL-6 induction was observed in DL6A. Thus, these data demonstrate that administration of BNT411 to human patients was well tolerated at all doses tested, and results in a type I interferon-dominant cytokine profile consistent with the predicted mode of action of BNT411 as a selective TLR7 agonist.

[0503] Considering the above, it can be concluded that BNT411 has an acceptable safety profile at all doses up to DL6. Furthermore, at DL6A, BNT411 induces a substantial cytokine response dominated by type I interferons, consistent with the predicted mode of action of BNT411 as a selective TLR7 agonist, while IL-6 and TNFa levels remain relatively low. The pharmacodynamic responses resulting from administration of BNT411 at the dose levels tested warrant further evaluation of BNT411 in various cancer indications, both as monotherapy and in combination with atezo / EC and other immunotherapy-based regimens.

[0504] Part 1A Data Update – October 2022 The study population consists of patients with histologically confirmed solid tumors with metastatic or unresectable disease for whom there is no available standard therapy likely to confer clinical benefit or who are not candidates for such available therapies.

[0505] BNT411 appears to have a tolerable overall safety profile up to DL6.

[0506] As of the data cutoff date (October 13, 2022), one patient initiated BNT411 at DL4, and the dose was escalated to DL5 on C8D1 and further to DL6 on C12D1. The patient had stable disease (per RECIST 1.1) through study day 449. The second patient is taking BNT411 at an intermediate dose level between DL6 and DL7. On study day 86, there was a -26.2% change in the sum of target lesion diameters compared to baseline. As of day 420, the patient has stable disease (per RECIST 1.1) and remains on treatment. The third patient is taking BNT411 at DL7, and this patient had a partial response (per RECIST 1.1) on study day 251 and remains on study treatment with a partial response. These sustained tumor responses following BNT411 treatment are encouraging early indications of possible efficacy of BNT411 in treating a variety of solid tumors.

[0507] In view of the above, it appears that BNT411 may potentially have an acceptable overall safety profile at therapeutically relevant dose levels. Promising indications of efficacy were observed in patients across a variety of tumor types. Tumor responses and disease stability were supported by pharmacodynamic activity defined by induction of IFN-a and IP-10, which increased following BNT411 administration from DL5 onwards and is substantially observed from DL6 onwards. Furthermore, at DL6, BNT411 induces a substantial cytokine response dominated by type I IFN, consistent with BNT411's predicted mode of action as a selective TLR7 agonist, but acceptable levels of IL-6 and low levels of TNFα induction are observed. The preliminary safety profile, indications of efficacy, and pharmacodynamic responses resulting from administration of BNT411 warrant further investigation of BNT411 in various cancer indications.

Claims

1. 2. For use in a method for reducing or preventing the progression of a tumor or treating cancer in a subject, a compound having the formula 【Chemistry 1】 or a pharma- ceutically acceptable solvate or salt thereof, wherein said method comprises administering to said subject an appropriate amount of said compound.

2. The compound for use according to claim 1, wherein said appropriate amount of said compound is a therapeutically effective and safe amount.

3. The suitable amount of the compounds is from about 0.1 μg / kg to about 50 μg / kg body weight, or from about 8 μg to about 4000 μg in total, and / or from about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18 x 10 -9 mol ~ approx. 9100x10 -9 mol. The compound for use according to any one of the preceding claims.

4. The suitable amount of the compounds is from about 0.5 μg / kg to about 20 μg / kg body weight, or from about 40 μg to about 1600 μg in total, and / or from about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight, or about 91 x 10 -9 mol ~ approx. 3640x10 -9 mol. The compound for use according to any one of the preceding claims.

5. The suitable amount of the compounds is from about 2 μg / kg to about 10 μg / kg body weight, or from about 160 μg to about 800 μg in total, and / or from about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364 x 10 -9 mol ~ approx. 1820x10 -9 mol. The compound for use according to any one of the preceding claims.

6. The suitable amount of the compounds is from about 2.4 μg / kg to about 9.6 μg / kg body weight, or from about 192 μg to about 768 μg in total, and / or from about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 437 x 10 -9 mol ~ approx. 1747x10 -9 6. The compound for use according to any one of claims 1 to 5, wherein the compound is mol.

7. The suitable amount of the compounds is about 4.8 μg / kg to about 9.6 μg / kg body weight, or about 384 μg to about 768 μg in total, and / or about 10.9×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 873 x 10 -9 mol ~ approx. 1747x10 -9 6. The compound for use according to any one of claims 1 to 5, wherein the compound is mol.

8. The suitable amount of the compounds is about 4.8 μg / kg body weight, or about 384 μg in total, and / or about 10.9×10 -9 mol / kg body weight, or about 874 x 10 -9 6. The compound for use according to any one of claims 1 to 5, wherein the compound is mol.

9. 2. The compound for use according to any one of the preceding claims, which is a solvate.

10. 10. The compound for use according to claim 9, wherein the solvate is selected from the group consisting of a hydrate and a dimethylsulfoxide solvate.

11. The compound for use according to any one of claims 1 to 8, wherein the compound is anhydrous.

12. The compound for use according to any one of claims 1 to 11, wherein said compound is administered systemically, preferably intravenously.

13. 2. The compound for use according to any one of the preceding claims, wherein the subject is a human subject.

14. 2. The compound for use according to any one of the preceding claims, wherein the tumor or cancer is a solid tumor or cancer.

15. 20. The compound for use according to any one of the preceding claims, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor and mesothelioma.

16. The compound for use according to any one of the preceding claims, wherein the tumor or cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer and pancreatic cancer.

17. The compound for use according to any one of the preceding claims, wherein the tumour or cancer is small cell lung cancer (SCLC), such as extensive stage small cell lung cancer (ES-SCLC).

18. 2. The compound for use according to any one of the preceding claims, wherein the subject is chemotherapy naive.

19. 2. The compound for use according to any one of the preceding claims, wherein the compound is administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days).

20. 2. The compound for use according to any one of the preceding claims, wherein one dose of the compound is administered once a week (Q1W) for at least one treatment cycle.

21. 2. The compound for use according to any one of the preceding claims, wherein one dose of said compound is administered Q1W and then once every three weeks (Q3W) for at least four treatment cycles.

22. 20. The compound for use according to any one of the preceding claims, wherein each dose of the compound is infused over a period of at least 10 minutes, such as at least 15 minutes, at least 20 minutes, at least 25 minutes or at least 30 minutes.

23. 2. The compound for use according to any one of the preceding claims, wherein the method further comprises administering to the subject one or more additional therapeutic agents.

24. 24. The compound for use according to claim 23, wherein said one or more additional therapeutic agents are selected from the group consisting of checkpoint inhibitors (CPIs), platinum-based chemotherapeutic agents, topoisomerase inhibitors and combinations thereof.

25. 25. The compound for use according to claim 23 or 24, wherein the one or more additional therapeutic agents are selected from the group consisting of atezolizumab, carboplatin, etoposide and combinations thereof.

26. The compound for use according to any one of claims 23 to 25, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide.

27. The compound for use according to any one of claims 23 to 26, wherein said one or more further therapeutic agents are administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days) duration.

28. 28. The compound for use according to any one of claims 23 to 27, wherein one dose of each of said one or more further therapeutic agents is administered at least Q3W for at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

29. 29. The compound for use according to any one of claims 23 to 28, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide, wherein one dose of atezolizumab is administered Q3W (preferably on day 1 of a treatment cycle), one dose of carboplatin is administered Q3W (preferably on day 1 of a treatment cycle) for 4 treatment cycles, and one dose of etoposide is administered 3 times in week 1 of a treatment cycle (preferably on days 1, 2 and 3 of a treatment cycle) for 4 treatment cycles, each treatment cycle being 3 weeks (21 days).

30. 30. The compound for use according to claim 29, wherein one dose of the compound is administered Q1W (preferably on days 2, 8 and 15 of a treatment cycle) and then Q3W (preferably on day 2 of treatment cycle 5 and each subsequent treatment cycle) for four treatment cycles.

31. A compound having the formula 【Chemistry 2】 or a pharma- ceutically acceptable solvate or salt thereof, wherein the amount of said compound in said composition is from about 8 μg to 4000 μg, or from about 18×10 -9 mol ~ approx. 9100x10 -9 mol.

32. About 40 μg to about 1600 μg, or about 91×10 -9 mol ~ approx. 3640x10 -9 mol of said compound, preferably about 160 μg to about 800 μg, or about 364×10 -9 mol ~ approx. 1820x10 -9 32. The composition of claim 31 , comprising mol of said compound.

33. About 192 μg to about 768 μg, or about 437×10 -9 mol ~ approx. 1747x10 -9 33. The composition of claim 31 or 32, comprising mol of said compound.

34. About 384 μg to about 768 μg, or about 873×10 -9 mol ~ approx. 1747x10 -9 33. The composition of claim 31 or 32, comprising mol of said compound.

35. About 384 μg, or about 874×10 -9 33. The composition of claim 31 or 32, comprising mol of said compound.

36. The composition of any one of claims 31 to 35, wherein the composition is for systemic administration.

37. The composition according to any one of claims 31 to 36, wherein the composition is for injection or infusion, such as intravenous injection or infusion.

38. A composition according to any one of claims 31 to 37, wherein the compound is in an aqueous solution, such as 0.9% NaCl (saline), in a volume of from 1 to 500 ml, such as from 5 to 250 ml.

39. The composition of any one of claims 31 to 38, wherein the composition is in dosage unit form.

40. 40. The composition of any one of claims 31 to 39 for use in a method for reducing or preventing the progression of a tumor or treating cancer in a subject.

41. The composition may comprise from about 0.1 μg / kg to about 50 μg / kg of body weight of the compound, or from about 8 μg to about 4000 μg of the compound in total, and / or from about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight of said compound, or about 18×10 -9 mol ~ approx. 9100x10 -9 41. The composition for use according to claim 40, wherein the composition is administered to the subject in an amount to provide mol of the compound.

42. The composition may comprise from about 0.5 μg / kg to about 20 μg / kg of body weight of the compound, or from about 40 μg to about 1600 μg of the compound in total, and / or from about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight of said compound, or a total of about 91×10 -9 mol ~ approx. 3640x10 -9 42. The compound for use according to claim 40 or 41, administered to the subject in an amount to provide mol of said compound.

43. The composition may comprise from about 2 μg / kg to about 10 μg / kg of body weight of the compound, or from about 160 μg to about 800 μg of the compound in total, and / or from about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight of said compound, or a total of about 364×10 -9 mol ~ approx. 1820x10 -9 43. The compound for use according to any one of claims 40 to 42, administered to said subject in an amount to provide mol of said compound.

44. The composition contains from about 2.4 μg / kg to about 9.6 μg / kg of body weight of the compound, or from about 192 μg to about 768 μg of the compound in total, and / or from about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight of said compound, or a total of about 437×10 -9 mol ~ approx. 1747x10 -9 44. The compound for use according to any one of claims 40 to 43, administered to said subject in an amount to provide mol of said compound.

45. The composition may comprise from about 4.8 μg / kg to about 9.6 μg / kg of body weight of the compound, or from about 384 μg to about 768 μg of the compound in total, and / or from about 10.9×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight of said compound, or about 873×10 -9 mol ~ approx. 1747x10 -9 44. The compound for use according to any one of claims 40 to 43, administered to said subject in an amount to provide mol of said compound.

46. The composition may contain about 4.8 μg / kg of the compound, or about 384 μg of the compound in total, and / or about 10.9×10 -9 mol / kg body weight of said compound, or about 874×10 -9 44. The compound for use according to any one of claims 40 to 43, administered to said subject in an amount to provide mol of said compound.

47. The composition for use according to any one of claims 40 to 46, wherein the subject is a human subject.

48. The composition for use according to any one of claims 40 to 47, wherein the tumor or cancer is a solid tumor or cancer.

49. 49. The composition for use according to any one of claims 40 to 48, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor and mesothelioma.

50. 50. The composition for use according to any one of claims 40 to 49, wherein the tumor or cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer and pancreatic cancer.

51. The composition for use according to any one of claims 40 to 50, wherein the tumour or cancer is small cell lung cancer (SCLC), such as extensive stage small cell lung cancer (ES-SCLC).

52. The composition for use according to any one of claims 40 to 51, wherein the subject is chemotherapy naive.

53. The composition for use according to any one of claims 40 to 52, wherein said composition is administered in at least one treatment cycle, each treatment cycle lasting 3 weeks (21 days).

54. The composition for use according to any one of claims 40 to 53, wherein one dose of the composition is administered once a week (Q1W) for at least one treatment cycle.

55. The composition for use according to any one of claims 40 to 54, wherein one dose of the composition is administered Q1W and then once every three weeks (Q3W) for at least four treatment cycles.

56. The composition for use according to any one of claims 40 to 55, wherein the composition is infused over a period of at least 10 minutes, such as at least 15 minutes, at least 20 minutes, at least 25 minutes or at least 30 minutes.

57. 57. The composition for use according to any one of claims 40 to 56, wherein the method further comprises administering to the subject one or more additional therapeutic agents.

58. 58. The composition for use of claim 57, wherein the one or more additional therapeutic agents are selected from the group consisting of checkpoint inhibitors (CPIs), platinum-based chemotherapeutic agents, topoisomerase inhibitors, and combinations thereof.

59. 59. The composition for use of claim 57 or 58, wherein the one or more additional therapeutic agents are selected from the group consisting of atezolizumab, carboplatin, etoposide, and combinations thereof.

60. 60. The composition for use according to any one of claims 57 to 59, wherein the one or more additional therapeutic agents is a combination of atezolizumab, carboplatin and etoposide.

61. 61. The composition for use according to any one of claims 57 to 60, wherein said one or more further therapeutic agents are administered in at least one treatment cycle, each treatment cycle being of three weeks (21 days) duration.

62. 62. The composition for use according to any one of claims 57-61, wherein one dose of each of said one or more further therapeutic agents is administered at least Q3W for at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

63. 63. The composition for use according to any one of claims 57-62, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide, wherein one dose of atezolizumab is administered Q3W (preferably on day 1 of a treatment cycle), one dose of carboplatin is administered Q3W (preferably on day 1 of a treatment cycle) for four treatment cycles, and one dose of etoposide is administered three times in week 1 of a treatment cycle (preferably on days 1, 2 and 3 of a treatment cycle) for four treatment cycles, each treatment cycle being three weeks (21 days).

64. 64. The composition for use according to claim 63, wherein one dose of the composition is administered Q1W (preferably on days 2, 8 and 15 of a treatment cycle) and then Q3W (preferably on day 2 of treatment cycle 5 and each subsequent treatment cycle).

65. (i) a compound having the formula: 【Chemistry 3】 or a pharma- ceutically acceptable solvate or salt thereof; and (ii) one or more additional therapeutic agents selected from the group consisting of a checkpoint inhibitor (CPI), a platinum-based chemotherapeutic agent, a topoisomerase inhibitor, and combinations thereof.

66. 66. The kit of claim 65, wherein the one or more additional therapeutic agents are selected from the group consisting of atezolizumab, carboplatin, etoposide, and combinations thereof.

67. 67. The kit of claim 65 or 66, wherein the compound and the one or more further therapeutic agents are for systemic administration, in particular injection or infusion, such as intravenous injection or infusion.

68. 68. The kit of any one of claims 65 to 67 for use in a method for reducing or preventing the progression of a tumor or treating cancer in a subject.

69. The compounds are administered at about 0.1 μg / kg to about 50 μg / kg body weight, or at about 8 μg to about 4000 μg in total, and / or at about 0.23×10 -9 mol / kg weight ~ approx. 114x10 -9 mol / kg body weight, or about 18 x 10 -9 mol ~ approx. 9100x10 -9 69. The kit for use according to claim 68, wherein the kit is administered to the subject in an amount of 100 mol.

70. The compounds are administered at about 0.5 μg / kg to about 20 μg / kg body weight, or at about 40 μg to about 1600 μg in total, and / or at about 1.14×10 -9 mol / kg weight ~ approx. 45.5x10 -9 mol / kg body weight, or about 91 x 10 -9 mol ~ approx. 3640x10 -9 70. The kit for use according to claim 68 or 69, wherein the kit is administered to the subject in an amount of 100 mol.

71. The compounds are administered at about 2 μg / kg to about 10 μg / kg body weight, or at about 160 μg to about 800 μg in total, and / or at about 4.55×10 -9 mol / kg weight ~ approx. 22.8x10 -9 mol / kg body weight, or about 364 x 10 -9 mol ~ approx. 1820x10 -9 The kit for use according to any one of claims 68 to 70, wherein the kit is administered to the subject in an amount of 100 mol.

72. The compound is administered at a dose of about 2.4 μg / kg to about 9.6 μg / kg body weight, or at a dose of about 192 μg to about 768 μg in total, and / or at a dose of about 5.46×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 437 x 10 -9 mol ~ approx. 1747x10 -9 The kit for use according to any one of claims 68 to 71, wherein the kit is administered to the subject in an amount of 100 mol.

73. The compound is administered at about 4.8 μg / kg to about 9.6 μg / kg body weight, or at about 384 μg to about 768 μg in total, and / or at about 10.9×10 -9 mol / kg weight ~ approx. 21.8x10 -9 mol / kg body weight, or about 873 x 10 -9 mol ~ approx. 1747x10 -9 The kit for use according to any one of claims 68 to 71, wherein the kit is administered to the subject in an amount of 100 mol.

74. The compound is administered at about 4.8 μg / kg body weight, or at about 384 μg in total, and / or at about 10.9×10 -9 mol / kg body weight, or about 874 x 10 -9 The kit for use according to any one of claims 68 to 71, wherein the kit is administered to the subject in an amount of 100 mol.

75. The kit for use according to any one of claims 68 to 74, wherein the subject is a human subject.

76. The kit for use according to any one of claims 68 to 75, wherein the tumor or cancer is a solid tumor or cancer.

77. 77. The kit for use according to any one of claims 68 to 76, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), colon cancer, rectal cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, prostate cancer, pancreatic cancer, liver cancer, thymoma and thymic cancer, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, ovarian cancer, endometrial cancer, ureteral cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma, malignant solitary fibrous tumor and mesothelioma.

78. 78. The kit for use according to any one of claims 68 to 77, wherein the tumor or cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), melanoma, colon cancer, rectal cancer, cervical cancer, ovarian cancer, liver cancer, malignant solitary fibrous tumor, prostate cancer, ureteral cancer and pancreatic cancer.

79. The kit for use according to any one of claims 68 to 78, wherein the tumor or cancer is small cell lung cancer (SCLC), such as extensive-stage small cell lung cancer (ES-SCLC).

80. The kit for use according to any one of claims 68 to 79, wherein the subject is chemotherapy naive.

81. 81. The kit for use according to any one of claims 68 to 80, wherein the compound is administered in at least one treatment cycle, each treatment cycle being of 3 weeks (21 days).

82. 82. The kit for use according to any one of claims 68 to 81, wherein one dose of the compound is administered once a week (Q1W) for at least one treatment cycle.

83. 83. The kit for use according to any one of claims 68 to 82, wherein a dose of the compound is administered Q1W, then once every three weeks (Q3W) for at least four treatment cycles.

84. 84. The kit for use according to any one of claims 68 to 83, wherein each dose of the compound is infused over a minimum of 10 minutes, such as a minimum of 15 minutes, a minimum of 20 minutes, a minimum of 25 minutes or a minimum of 30 minutes.

85. 85. The kit for use according to any one of claims 68 to 84, wherein the one or more further therapeutic agents are administered in at least one treatment cycle, each treatment cycle being of three weeks (21 days) duration.

86. 86. The kit for use according to any one of claims 68-85, wherein one dose of each of the one or more additional therapeutic agents is administered at least Q3W for at least one treatment cycle, each treatment cycle being 3 weeks (21 days).

87. 87. The kit for use of any one of claims 68-86, wherein the one or more further therapeutic agents is a combination of atezolizumab, carboplatin and etoposide, wherein one dose of atezolizumab is administered Q3W (preferably on day 1 of a treatment cycle), one dose of carboplatin is administered Q3W (preferably on day 1 of a treatment cycle) for 4 treatment cycles, and one dose of etoposide is administered 3 times in week 1 of a treatment cycle (preferably on days 1, 2 and 3 of a treatment cycle) for 4 treatment cycles, each treatment cycle being 3 weeks (21 days).

88. 88. The kit for use of claim 87, wherein one dose of the compound is administered Q1W (preferably on days 2, 8, and 15 of a treatment cycle) and then Q3W (preferably on day 2 of treatment cycle 5 and each subsequent treatment cycle) for four treatment cycles.

Citation Information

Patent Citations

  • Substituted imidazoquinolines

    JP2020532570A

  • Combination drug including TLR7 agonist

    WO2019124500A1

  • Process for the preparation of a substituted imidazoquinoline

    WO2020178434A1

  • PT.2017